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BIOCHEMICAL AND PHARMACOLOGICAL CHARACTERIZATION OF THE ATG8 
CONJUGATION SYSTEM IN TOXOPLASMA GONDII 
 
 Toxoplasma gondii is an important human pathogen that infects millions of 
people worldwide and causing severe and potentially lethal disease in 
immunocompromised individuals. Recently, a homologue for the autophagy protein Atg8 
(TgAtg8) was identified in Toxoplasma that is required for both canonical and non-
canonical processes essential for parasite viability. Importantly, TgAtg8 functionality 
requires its conjugation to phosphatidylethanolamine through the activity of the Atg8 
conjugation system. In this thesis, we characterized the proteins that interact with 
TgAtg8 and TgAtg3, a component of the Atg8 conjugation system, to further define their 
functions in Toxoplasma and identify opportunities for targeted inhibition of Atg8-related 
processes. 
We previously identified that TgAtg8 is acetylated at lysine 23 (K23) and 
assessed the role of this modification in this thesis. Using mutagenesis, we showed that 
K23 acetylation did not modulate the interaction with TgAtg3, but appeared to promote 
TgAtg8 protein stability. Additionally, endogenous mutation of K23 to the non-
acetylatable amino acid arginine resulted in severe impairment of parasite replication 
and spontaneous differentiation into bradyzoites.  
To gain insight into the role of TgAtg8 in Toxoplasma biology, we next 
characterized TgAtg8 and TgAtg3 interacting proteins using affinity purification and mass 
spectrometry. We identified a novel group of interacting proteins that are unique to 
Toxoplasma, including the dynamin-related protein DrpC. Functional characterization of 
DrpC identified a potential role of TgAtg8 in trafficking of membrane from the Golgi to the 
nascent daughter parasites during replication.  
Lastly, we examined a group of small molecules recently identified as Atg3-Atg8 
inhibitors in Plasmodium falciparum and assessed their activity against Toxoplasma. 
Although the compounds effectively inhibited Toxoplasma replication, they did so 
through novel mechanisms of action unrelated to the disruption of the TgAtg3-Atg8 
interaction. Together, this work provides insight into the function of the Atg8 conjugation 
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system in Toxoplasma that will help guide the future development of novel therapeutics 
targeting Atg8-related processes. 
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Chapter 1: Introduction 
1.1 Toxoplasma gondii, a model apicomplexan 
 Toxoplasma gondii is an obligate, intracellular protozoan pathogen, and a 
member of the phylum Apicomplexa. This group contains over 6000 known species that 
collectively parasitize virtually all known animals [1]. Felids are the definitive host for 
Toxoplasma, and the parasite can only undergo sexual reproduction in the endothelial 
cells lining the cat small intestine. However, among the apicomplexans, Toxoplasma 
gondii exhibits a uniquely broad range of intermediate hosts due to its ability to infect any 
nucleated cell in all warm-blooded animals [2]. As a result, Toxoplasma is considered by 
many to be the world’s most successful parasite, and is of significant veterinary and 
medical importance for the disease it causes (toxoplasmosis) in its intermediate hosts. In 
addition to Toxoplasma, the phylum Apicomplexa contains other notable human 
parasites including Plasmodium spp., Cryptosporidium spp., and Babesia spp., the 
causative agents of malaria, cryptosporidiosis, and babesiosis, respectively. Together, 
the apicomplexans represent a group of extremely successful pathogens with significant 
impacts on global economics and human health.  
 As a single cell, eukaryotic organism, Toxoplasma contains a full collection of 
standard eukaryotic organelles, including a nucleus, endoplasmic reticulum, Golgi 
apparatus and a single mitochondrion (Figure 1). In addition to these standard 
eukaryotic features, the apicomplexans all share a characteristic structure called the 
apical complex, from which the phylum derives its name. This complex includes 
cytoskeletal structures, such as the conoid and apical polar rings, as well as secretory 
organelles that facilitate host cell attachment and invasion, including the micronemes, 
rhoptries and dense granules [3,4]. Other parasite specific organelles include the plant-
like vacuole (PLV), acidocalcisomes, and a non-photosynthetic plastid organelle, termed 
the apicoplast. The apicoplast is thought to be a vestigial plastid of green algae origin 
acquired by endosymbiosis and is found in all apicomplexans, with the notable exception 
of Cryptosporidium spp. [5,6]. It contains its own 35-kb circular genome that encodes for 
transfer RNAs and ribosomal genes, allowing for translation of protein-coding gene 
present in the apicoplast genome. The apicoplast is also the site of important metabolic 
processes, and is essential for parasite viability [7,8]. 
 In addition to these organelles, Toxoplasma has unique cytoskeletal features that 
collectively form a structure known as the pellicle. Like other alveolates, Toxoplasma 
contains a collection of alveolar sacs, which are flattened vesicles derived from the 
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ER/Golgi compartment [9]. In Toxoplasma, these vesicles are referred to as the Inner 
Membrane Complex (IMC), and are located between the parasite plasma membrane 
and the cortical microtubules (also referred to as the subpellicular microtubules). This set 
of 22 cortical microtubules emanates from the apical polar ring and are tethered to the 
IMC in a highly ordered fashion, providing structural support to maintain the 
characteristic crescent shape and apically polarized cell morphology [10]. Unlike other 
eukaryotes, the cortical microtubules in Toxoplasma are non-dynamic, and remain 
attached to the IMC throughout interphase.  
 Toxoplasma gondii was first described in two papers published in 1908; one by 
Alfonso Splendore, who discovered the parasite while working with rabbits in Brazil [11], 
and  another by Charles Nicolle and Louis Manceaux [12], who were conducting 
research on leishmaniasis in the North African rodent Ctenodactylus gundi [13]. Both 
groups initially mistook the parasite for Leishmania, however Nicolle and Manceaux 
realized soon after that they had discovered a new species of protozoan, which they 
named Toxoplasma gondii, in reference to the parasite’s crescent-shaped morphology 
(modified from the Latin word for arc or bow, toxon) and the host it was found in (gundi) 
[14]. In the following decades, numerous species of Toxoplasma were named according 
to the host species in which they were identified. However, advancements in biological 
and immunological techniques soon provided evidence that all of the various isolates 
collected from humans and animals were actually Toxoplasma gondii [2]. Currently, 
Toxoplasma gondii is thought to be the only species of the genus Toxoplasma, with most 
strains falling into one of three dominant clonal subtypes, referred to as types I, II and III 
[15–17]. This unique clonal structure is attributed to a genetic bottleneck event that 
occurred approximately 10,000 years ago, in which a single genetic cross was followed 
by a rapid expansion that produced the three clonal lineages observed today [18,19]. 
 Most cases of human toxoplasmosis are caused by infection with strains of the 
type II genotype. This is particularly true in Europe and North America, where 80-90% of 
human infections have been attributed to type II strains [17,20]. It is important to note 
that additional subtypes that do not fall into the traditional three clonal lineages have 
been reported in other continents, including South America, Africa and Asia [21–23]. 
These atypical strains display a wide range of virulence, however some have been 
shown to be hypervirulent and capable of causing lethal acute infections in 
immunocompetent individuals [24]. 
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  In addition to these differences in human toxoplasmosis, the three major 
subtypes display dramatic differences in virulence in laboratory mice (type I LD100 ~ 1 
parasite, type II LD100 ≥ 103, type III LD100 ≥ 105) [25], which has been attributed to 
variability of gene loci that encode two kinases secreted by the parasite into the host cell 
[26,27]. Another major difference between the three lineages is that the commonly-
studied type I RH strain parasites have lost the ability to form orally infective bradyzoite 
tissue cysts [28,29].  Additionally, type I parasites have a short doubling time, can be 
maintained indefinitely in tissue culture, and can be genetically manipulated using a 
variety of techniques [30].This is in contrast to technical challenges observed for many 
fellow apicomplexans with regards to culture maintenance and genetic tractability 
[31,32]. As a result, Toxoplasma type I strains have been established as a model 
organism for dissecting the molecular mechanisms behind many processes of zoite-
stage apicomplexan biology, including attachment, invasion, egress and motility [33]. 
 
Figure 1: Toxoplasma tachyzoite organelles. 
Adapted from Blader et al., Annu Rev Microbiol, 2015. Schematic representation of a 
Toxoplasma gondii tachyzoite. EC, endosomal compartment, ER, endoplasmic 
reticulum, IMC, inner membrane complex, PLV, plant-like vacuole. 
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1.2 Toxoplasma life cycle and modes of transmission 
 Throughout its complex life cycle, Toxoplasma differentiates between numerous 
stages (Figure 2) [34,35]. Of these different stages, three are infective, including the 
tachyzoite stage, the bradyzoite stage, and the sporozoite stage shed by cats in the form 
of oocysts. Within the intermediate host, Toxoplasma persists as highly proliferative 
tachyzoites that are responsible for acute toxoplasmosis and bradyzoites that form latent 
tissue cysts that persist during chronic toxoplasmosis.  Upon invasion of the host cell, 
Toxoplasma establishes residence within the parasitophorous vacuole (PV), a 
membrane structure formed during the invasion process that is devoid of host 
membrane proteins and is protected from fusion with host lysosomes [36]. Within the 
PV, Toxoplasma replicates through a form of asexual reproduction known as 
endodyogeny, in which two daughter parasites form within the growing mother parasite 
[37]. In endodyogeny, the mother parasite divides using closed mitosis, in which the 
nuclear envelope remains intact. During this process, some organelles are partitioned 
into each nascent daughter parasite (nucleus, Golgi, ER, mitochondrion, apicoplast), 
while some are formed de novo (rhoptries and micronemes [38]). Additionally, the IMC 
and cytoskeleton are formed de novo in each daughter parasite, while the plasma 
membrane is derived from the mother plasma membrane material. Multiple rounds of 
division continue until the PV contains 64-128 parasites, at which point the parasites 
actively egress from the vacuole, resulting in lysis of the host cell [39]. 
 Tachyzoite replication is thought to be responsible for the initial expansion and 
dissemination of parasites throughout the host following primary infection [40]. After 
establishing infection in an intermediate host, the fast-replicating tachyzoites undergo 
differentiation into the slow-growing bradyzoite form, mediated at least in part by the 
elevated production of interferon gamma as part of the host immune response [41]. 
These bradyzoites form latent tissue cysts that are most commonly found in striated 
muscle fibers of the heart and in the central nervous system. Importantly, tissue cysts 
persist throughout the life of the infected host, and can reactivate back to tachyzoites in 
the absence of immune pressure. In addition to their role in establishing chronic 
infection, bradyzoite tissue cysts play a central role in the Toxoplasma transmission, as 
they can establish infection in both intermediate and definitive hosts upon ingestion of 
cysts present in tissues from infected animals. 
 Toxoplasma can only enter its sexual stage of replication in the small intestine of 
its definitive host, the cat [42]. Felids can become infected by Toxoplasma either by 
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direct ingestion of infectious oocysts deposited into the environment by other cats, or by 
ingesting tissue cysts from chronically infected intermediate hosts. After an unknown 
number of rounds of asexual replication in the enterocytes lining the small intestine, 
Toxoplasma undergoes differentiation into gametocytes, termed microgametocytes 
(male) and macrogametocytes (female). These in turn produce the micro- and 
macrogametes that ultimately fuse together during fertilization to form the oocyst. 
Following fertilization, the oocysts are released into the lumen of the small intestine and 
shed into the environment in the cat’s feces. Within 1-5 days of excretion, the oocyst 
undergoes sporulation and are only then considered infectious. After sporulation, 
infectious oocysts are highly stable and are resistant to many chemical and physical 
disinfectants [43–45]. Additionally, each infected cat sheds tens of millions of oocysts 
into the environment, which then persist in both soil and water for years while 
maintaining their infectivity [46,47]. Upon ingestion of sporulated oocysts by an 
intermediate or definitive host, the sporozoites undergo an excystation process that is 
stimulated by bile salts and digestive enzymes present in the host stomach. The 
released sporozoites can then infect the epithelium of the host and differentiate into 
tachyzoites (if infecting an intermediate host) or merozoites/shizonts (upon infection of 
the definitive host), thus restarting the cycles of asexual or sexual replication as 
described above. 
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Figure 2: Life cycle of Toxoplasma gondii. 
(Top) Schematic representation of the Toxoplasma life cycle in intermediate and 
definitive hosts (from Florence Robert-Gangneux, and Marie-Laure Dardé Clin. 
Microbiol. Rev. 2012;25:264-296). (Bottom) Ultrastructures of the three infectious stages 
of Toxoplasma. (left) Tissue cyst that was isolated from the brain of a chronically 
infected mouse. Hn, host nuclei, Cw, cyst wall, Bz, bradyzoite, Dz, dead zoite. (center) 
Transmission electron micrograph (TEM) of a single tachyzoite residing in the 
parasitophorous vacuole (Pv). Organelles are labeled, including the conoid (Co), dense 
granule (Dg), the Golgi apparatus (Go), micronemes (Mn), nucleus (Nu), nucleolus (No) 
Bradyzoites in Tissue Cyst Tachyzoites in Parasitophorous Vacuole Sporozoites in Oocyst
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and rhoptries (Rh). Also shown is a light microscopy image of a parasitophorous vacuole 
containing four tachyzoites. Scale bar = 3 µm. (right) Images of Toxoplasma oocysts.  
(A) Unsporulated oocyst; (B) Sporulated oocyst. Note four sporozoites (arrows) that are 
visible in the right sporocyst. (C) Transmission electron micrograph of a sporulated 
oocyst. The oocyst wall (large arrow) surrounds two sporocysts (arrowheads), each of 
which contain four sporozoites (small arrows). Images of bradyzoite tissue cysts, TEM of 
tachyzoite, and oocysts all used from J.P. Dubey, D.S. Lindsay, and C. A. Speer, Clin. 
Microbiol. Rev 1998; 11:267-299.  
    
 
1.3 Clinical toxoplasmosis: disease manifestations and current therapeutics 
 Toxoplasmosis is one of the most prevalent parasitic infections in humans, 
infecting an estimated 30 percent of the world’s population [2]. In the United States 
alone, more than 60 million people are infected with Toxoplasma, costing an estimated 
3.3 billion dollars annually for medical treatment and the economic impact caused by 
loss of productivity [48].  Additionally, toxoplasmosis is widespread in agricultural 
livestock used for meat production, particularly in sheep and pigs, costing an estimated 
445 million dollars annually in the US [49]. For all hosts, infection with Toxoplasma can 
occur in one of three ways: ingestion of infectious sporozoites shed by cats in the form of 
oocysts, ingestion of bradyzoite tissue cysts through carnivorism of infected animals, or 
congenital transmission from an infected mother to the developing fetus. All three routes 
of infection have been observed in both intermediate and definitive hosts, however, the 
exact contribution that each route plays epidemiologically is still a matter of investigation 
[50,51].  
 Postnatally acquired toxoplasmosis results in an acute infection that later 
resolves to chronic disease upon conversion of the parasite to bradyzoites and the 
formation of tissue cysts. In immunocompetent hosts, symptoms are typically mild and 
can include headache, fever, and swelling of the lymph nodes [52]. However, the 
reactivation of latent infections or primary infection of immunocompromised patients 
often leads to the development of severe toxoplasmic encephalitis and pulmonary 
disease. As an opportunistic pathogen, Toxoplasma causes severe encephalitis in an 
estimated 40% of AIDS patients, with 10-30% of cases resulting in fatality [53–55]. In 
addition to AIDS patients, patients receiving immunosuppressive therapy for organ 
transplantation or receiving antineoplastic chemotherapeutics are also at risk for 
developing severe toxoplasmosis [56–58]. 
 Congenitally acquired toxoplasmosis occurs following vertical transmission of the 
parasite from a pregnant mother to the fetus. This typically occurs if the woman is 
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infected for the first time during pregnancy, however cases of vertical transmission 
following reactivation of chronic infection have been reported [59]. Generally, the risk of 
vertical transmission and the severity of the effects on the fetus depends on the 
immunological competence of the mother, and the age of the fetus when transmission 
occurs. The most severe forms of congenital disease occur when transmission happens 
early during fetal development, often resulting in encephalomyelitis and causing 
neonatal death in approximately 10% of cases [60]. Infants that survive prenatal infection 
display a variety of symptoms, often including intracranial calcifications, hydrocephalus 
and retinochoroiditis. These can lead to development of mental retardation and 
neurological deficiencies that severely impair quality of life for those who survive past 
infancy. In cases when transmission occurs during the third trimester of pregnancy, the 
infants are often asymptomatic at birth. However, congenital toxoplasmosis often leads 
to the development of clinical symptoms later in life, the most common of which is 
retinochoroiditis caused by reactivation of latent infections in the eye [61]. Indeed, 
toxoplasmosis accounts for 30-55% of all cases of infectious posterior uveitis, resulting 
in loss of visual acuity and frequently leading to bilateral blindness [62,63].  
 Acute toxoplasmosis typically is treated by administration of a combination of 
pyrimethamine and sulfadiazine. These two compounds work to inhibit the enzymes 
dihydrofolate reductase (DHFR) and dihydropterate synthetase (DHPS), respectively, 
resulting in the inhibition of the folate synthesis pathway (Figure 3). This leads to a 
decreased availability of tetrahydrofolic acid, a cofactor that is required for the synthesis 
of thymidine and purines required for nucleic acid synthesis and for the synthesis of the 
amino acid methionine. Although humans do not have a homologue of the DHPS 
enzyme, a DHFR homologue does exist and also is inhibited by treatment with 
pyrimethamine. As a result, patients undergoing treatment with pyrimethamine often 
experience toxic side effects including bone marrow suppression. Accordingly, patients 
are often co-administered folinic acid (leucovorin), which can rescue bone marrow cells 
from the effects of pyrimethamine to prevent hemotoxicity. In patients who experience 
adverse side effects due to sulfa allergies, sulfadiazine can be replaced with the 
antibiotic clindamycin. In place of pyrimethamine and sulfadiazine, which can both cross 
the placental barrier, mothers infected with Toxoplasma during the first 18 weeks of 
pregnancy are treated with the macrolide antibiotic spiramycin [64,65]. The proposed 
mechanism of action for spiramycin and other antibiotics shown to have activity against 
Toxoplasma (clindamycin, azithromycin) is the inhibition of protein synthesis. This is 
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thought to result from the inhibition of bacterial-like ribosomes present at the apicoplast 
due to the endosymbiotic origin of this organelle [8,66,67].  Although drug treatments 
can clear the acute stage of toxoplasmosis, no therapies currently exist that are able to 
target the latent tissue cysts present in the chronic stage of infection. Additionally, the 
development of resistance to pyrimethamine-based treatments in Plasmodium 
falciparum highlights the need for the identification of novel drug targets to treat 
Toxoplasma and related parasitic infections [68]. 
 
 
Figure 3: Mechanism of action for antiparasitics targeting the folate synthesis 
pathway. 
Current first-line therapies to treat toxoplasmosis involve inhibition of folate synthesis by 
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a combination of pyrimethamine and sulfadiazine. These drugs target the dihydrofolate 
reductase (DHFR) and dihydropteroate syntehtase (DHPS) enzymes, respectively. This 
treatment often is poorly tolerated because of patient allergies to sulfa compounds and 
side effects caused by the inhibition of host DHFR. 
 
1.4 Autophagy in eukaryotes: molecular machinery and cellular functions 
 The identification of new and selective drug targets to treat toxoplasmosis and 
other parasitic infections relies on the identification of cellular processes that are either 
absent or sufficiently divergent from similar processes in the eukaryotic host to allow for 
specific targeting of the parasite. Identifying selective targets is complicated by the fact 
that many aspects of Toxoplasma biology rely on the function of standard eukaryotic 
organelles, including the Golgi apparatus, endoplasmic reticulum and mitochondrion. 
One approach to identify opportunities for therapeutic intervention is to target parasite-
specific proteins, biological processes or organelles. In the following section, we will 
introduce aspects of the eukaryotic autophagy pathway, for which a subset of 
homologues has recently been identified in Toxoplasma and other protozoan parasites. 
We will first outline the core components of the autophagy pathway and their canonical 
functions in higher eukaryotes. We will then identify aspects of these complexes that are 
absent or divergent in function in Toxoplasma and may represent possible targets for the 
development of new antiparasitics.  
 In eukaryotic cells, macroautophagy (referred to hereafter as autophagy) is a 
catabolic process in which components of the cytoplasm are engulfed by an elongating 
membrane structure called the phagophore. This vesicle matures into an enclosed, dual-
membrane vesicle termed the autophagosome and is trafficked to the lysosome/vacuole 
where the engulfed material is degraded [69]. This process is induced in response to 
nutrient starvation [70,71], but also plays a significant role in cellular development and 
differentiation [72], proteostasis [73], clearance of damaged organelles and as a defense 
mechanism against invading pathogens [74,75]. While over 30 autophagy-related (ATG) 
genes have been identified, a subset of these genes comprise the “core” autophagy 
machinery, representing the genes that are required for de novo autophagosome 
formation and are especially well conserved across eukaryotic organisms [76]. The core 
ATG proteins separate into functional subgroups as depicted in Table 1. 
 The first set of core ATG proteins is the Atg1/ULK1 kinase complex. In yeast, 
Atg1 activity is regulated by the formation of a complex containing Atg1, Atg13 and the 
scaffolding complex consisting of Atg17, Atg29 and Atg31 [77,78]. Atg1 is a 
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serine/threonine kinase, and its role in the initiation of autophagy lies downstream of the 
target of rapamycin kinase (TOR1). Under nutrient replete conditions, TOR 
phosphorylates Atg13 at multiple residues, reducing its affinity for Atg1 and preventing 
formation of the functional Atg1 complex [79]. Under starvation conditions, TOR kinase 
is inactivated, resulting in hypophosphorylation of Atg13. This allows for the formation of 
the pentameric Atg1 complex containing Atg1, Atg13, and the Atg17/29/31 complex [80]. 
Once formed, the active Atg1/ULK1 complex localizes to the preautophagosomal 
assembly site (PAS), where it serves as a docking site for vesicles containing the  
integral membrane protein Atg9 [81]. Recent studies have shown that in yeast, an 
average of three Atg9-containing vesicles coalesce at the PAS and initiate 
autophagosome biogenesis by facilitating the recruitment of ATG proteins Atg8 and 
Atg18 [78,81,82]. 
 The second core group comprises the PI3-Kinase complex, and includes the 
class-III PI3-kinase Vps34 and its associated proteins. The kinase activity of Vps34 is 
required for the production of phosphatidylinositol (3)-phosphate (PI3P) at the 
membrane of the PAS and is regulated by phosphorylation by Vps15 [83,84]. Atg14 is 
recruited to the PAS independently of Vps34, and is thought to be important for proper 
localization of Vps34 to the autophagosome membrane [83]. Additionally, Atg14 has 
been shown to stimulate the kinase activity of Vps34. Activation of Vps34 leads to 
increased production of PI3P and recruitment of PI3P-effector proteins, such as Atg18 
and Atg2, which are required for autophagosome formation [83,85]. The functional role 
of Atg6 in this complex is less defined, but it appears to be able to associate directly with 
the PAS membrane and regulate autophagosome size and number [86].  
 The third and fourth core autophagy groups are conjugation systems for the two 
ubiquitin-like proteins Atg12 and Atg8. The first system is responsible for conjugation of 
Atg12 to Atg5, via the activity of the E1-like enzyme Atg7 and the E2-like enzyme Atg10, 
and without the activity of an E3-like enzyme [87]. The Atg5-Atg12 complex then forms a 
hetrotrimeric complex with Atg16, which homodimerizes to generate the functional 
Atg16-complex. The second conjugation system facilitates the conjugation of the 
cytosolic ubiquitin-like protein Atg8 (LC3/GABARAP/GATE-16 in mammals) to 
phosphatidylethanolamine (PE) present in the phagophore membrane. At the 
membrane, Atg8 plays important roles in the elongation and fusion of the phagophore 
membrane, and can also bind with substrate and adapter proteins containing the Atg8-
interacting motif (AIM) to selectively recruit proteins to the autophagosome for 
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degradation [88,89]. Conjugation of Atg8 to PE is carried out via the E1-like enzyme 
Atg7 and the E2-like enzyme Atg3, with the oligomeric Atg5-Atg12-Atg16 complex 
providing E3-like enzymatic function to stimulate transfer of Atg8 from Atg3 to PE 
[90,91].  Additionally, the cysteine proteinase Atg4 is responsible for both the pre-
processing of Atg8 to expose the C-terminal glycine for lipidation. Atg4 is also required 
for the cleavage of the amide bond between Atg8 and PE to liberate Atg8 from the 
autophagosomal outer membrane during autophagosome maturation [90,92]. 
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Table 1: Conservation of core ATG proteins in Toxoplasma gondii 
 
*Genes in italics represent putative Toxoplasma homologues identified based on 
sequence homology but have not been functionally characterized 
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Conservation in Toxoplasma: 
Atg1/ULK complex – No components of the Atg1/ULK complex or their upstream 
regulator TOR have been functionally characterized in Toxoplasma. Bioinformatics 
searches for homologues of the Atg1/ULK complex members identify putative TOR and 
Atg1 proteins in Toxoplasma, (TgTOR, TGGT1_316430; TgAtg1, TGGT1_316150). 
Importantly, when compared to the human and yeast mTOR/TOR1 proteins, the putative 
TgTOR protein is missing a significant portion of the kinase domain and has a large (~3 
kb) N-terminal extension with no identifiable domains. This divergence could explain the 
reduced sensitivity of Toxoplasma to the TOR inhibitor rapamaycin [93,94]. Toxoplasma 
lacks all components of the Atg17/29/31 scaffolding complex required for recruitment of 
the Atg1 complex to the PAS in higher eukaryotes, as well as an Atg13 homologue. 
Homologues to Atg18 and Atg9 are present, however their role in autophagy remains 
unclear, and in the case of Atg18, have not been studied. Recent studies characterizing 
the function of TgAtg9 showed that parasites lacking this protein had a reduced ability to 
survive prolonged periods of extracellular stress and had attenuated virulence in mice 
[95]. 
PI3K Complex – The Toxoplasma genome encodes a single class-III PI3K, TgPI3K 
(TGGT1_215700), which shares strong sequence homology with Vps34 (47% identity, 
67% similarity). TgPI3K localizes to the parasite cytoplasm, and conditional knock-down 
results in significant enlargement and subsequent loss of the apicoplast, suggesting a 
role for this kinase in apicoplast homeostasis [96]. Visualization of the Vps34 product, 
PI3P, shows that this lipid is enriched in the plant-like vacuole, a lysosome-like vacuolar 
compartment that contains the cathepsin proteases TgCPB and TgCPL [97,98]. 
Toxoplasma also has putative homologues of the regulatory kinase Vps15 
(TGGT1_310190) and Atg6 (TGGT1_221360). However, the function of these proteins 
in parasite biology remains unexplored. No homologue for Atg14 is present in 
Toxoplasma. 
Ubiquitin-like Conjugation Systems – A clear homologue of Atg7, the E1 enzyme for 
both Atg12 and Atg8, is present in Toxoplasma (TGGT1_229690). Although its 
localization and biological function remains unknown in Toxoplasma, it has been shown 
to localize to the mitochondrion in Plasmodium falciparum, and is essential for P. 
falciparum viability [99]. A putative Atg12 homologue is identified based on sequence 
homology (TGGT1_321300), and although there is significant homology to human and 
yeast Atg12 proteins in the TgAtg12 C-terminus, the protein contains a large N-terminal 
  15 
extension of unknown function. This results in a predicted protein size of 681 amino 
acids, as compared to 186 amino acids in higher eukaryotes. Additionally, the predicted 
TgAtg12 protein lacks the C-terminal glycine residue that is required for the formation of 
the thioester bond between Atg12 and Atg7 [100]. The putative Toxoplasma homologue 
of Atg5 is even more divergent, containing a ~375 bp N-terminal extension and a ~350 
bp insertion that divides the conserved Atg5 domain into N-terminal and C-terminal 
fragments. Further, sequence alignments with human Atg5 show that the putative 
TgAtg5 lacks the conserved lysine residue that forms an isopeptide bond with Atg12 
[101]. Together, these differences suggest that Toxoplasma (and other apicomplexans) 
may lack a functional Atg5-12 complex, unlike other protozoans in which Atg5-12 activity 
appears conserved [102].  
 Unlike the Atg5-12 conjugation system, all components of the Atg8 conjugation 
system are conserved and functional in Toxoplasma [94,103,104]. Toxoplasma 
homologues of TgAtg4 and TgAtg3 have been shown to coordinate TgAtg8 lipidation in 
similar manner to higher eukaryotes. Like PfAtg7, Plasmodium Atg3 orthologues localize 
to the parasite mitochondrion, while Toxoplasma Atg3 resides in the cytoplasm [94,105]. 
Although TgAtg7 has not been characterized in Toxoplasma, both TgAtg3 and TgAtg4 
are essential for parasite viability [94,104]. Conditional knock-down of either gene 
resulted in fragmentation of the parasite mitochondrion, suggesting that the Atg8 
conjugation pathway may be required for maintenance of this organelle. Functional 
homologues of Atg8 have also been found in both Toxoplasma and Plasmodium, and 
localize to the outer membrane of the apicoplast. The ability for apicomplexan Atg8 
homologues to complement Saccharomyces cerevisiae Atg8 knock-outs varies across 
species: Plasmodium falciparum Atg8 could recue ScAtg8 knock-out strain function 
while Plasmodium berghei Atg8 was unable to do so [105,106]. These differences may 
be attributable to variations in the amino acid composition across apicomplexans in 
regions of Atg8 that coordinate protein-protein interactions [107].  
 Functional differences are also observed for apicomplexan Atg8 proteins as 
compared to yeast and mammalian systems. First, components of the Atg8 conjugation 
pathway appear to be essential for parasite viability under all conditions. This is in 
contrast to yeast, where ATG knock-outs are viable and can be maintained in the 
absence of autophagy-inducing stimuli [108]. This difference is likely attributed to the 
recently identified non-canonical functions that Atg8 proteins have in organelle 
maintenance and division in apicomplexans [103]. Additionally, in higher eukaryotes, 
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Atg8 is translated as a pro-peptide that must undergo C-terminal cleavage by Atg4 to 
expose the C-terminal glycine residue required for interaction with the Atg8 conjugation 
system machinery and ultimately for conjugation to PE. As a result, in the absence of 
autophagy inducing stresses, Atg8 exists predominantly in its unlipidated form. In 
contrast, apicomplexan Atg8 proteins lack the C-terminal extension and are therefore 
available to undergo lipidation without pre-processing by Atg4. Accordingly, a significant 
portion of Atg8 is found to be lipidated under basal conditions in both Plasmodium and 
Toxoplasma [94,106]. In addition to these differences, other unique aspects of the 
apicomplexan Atg8 conjugation system will be further discussed in Section 1.6, as this 
system is the major focus of the work presented in this thesis. 
1.5 The Atg8 family of proteins: autophagy and beyond 
 Among the core ATG proteins, the members of the Atg8 conjugation pathway are 
uniquely well conserved across eukaryotes. Interestingly, the number of Atg8 
orthologues present varies widely across species, ranging from a single Atg8 protein in 
yeast to 25 Atg8 orthologues in Leishmania major [109]. In mammals, there are at least 
six Atg8 proteins comprising three subfamilies: the Golgi-associated ATPase enhancer 
of 16 kDa (GATE-16), the gamma-aminobutyric acid receptor associated protein family 
(GABARAP), and the microtubule-associated protein 1 light chain 3 family (MAP1LC3, 
referred to hereafter as LC3). LC3B is the best studied human Atg8 protein with respect 
to canonical autophagy. In contrast, the biological functions of other Atg8 orthologues 
remains less clear and their potential contributions to both canonical and non-canonical 
processes are underappreciated. In the following section, we will discuss in detail 
members of each of the three Atg8 families of proteins in mammals, providing historical 
context and recent advancements that shed light on the various biological functions 
these proteins possess in higher eukaryotes. This information will be valuable as we 
examine the potential functions of Atg8 proteins in early-branching eukaryotes, including 
Toxoplasma and other protozoan pathogens. 
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Figure 4: Structures of Atg8 family proteins. 
Ribbon structure representations of ubiquitin, and the mammalian Atg8 family proteins 
GATE-16, GABARAP, and LC3B. Alpha helices are shown in pink, beta-strands are 
shown in cyan. From Noda N, Ohsumi Y, Inagaki F, Chem. Rev., 2009; 109:4:1587-
1598. 
 
Golgi-associated ATPase enhancer of 16 kDa (GATE-16) – GATE-16 was the first of 
the Atg8 proteins to be crystalized and its resolved structure is highly conserved across 
all Atg8 orthologues [110–113]. The GATE-16 protein consists of a ubiquitin-like core 
domain that is preceded by two N-terminal alpha-helices. The GATE-16 and GABARAP 
family proteins are both able to undergo conformational changes between an “open” and 
“closed” state, which can be mediated by protein interactions [114]. In the “open” state, 
the N-terminal helices adopt an extended position that enables penetration into 
membranes mediated by hydrophobic interactions between the N-terminal helices and 
the hydrophobic center of the lipid bilayer [89]. This contrasts with the mechanism of 
interaction between LC3 proteins and the membrane, which are facilitated by interaction 
with the lipid head groups. With regard to canonical autophagy, GATE-16 appears to 
have specific function in membrane fusion events required for late steps of 
autophagosome biogenesis [89,115]. 
 Whereas LC3 proteins are ubiquitously expressed, GATE-16 is predominantly 
expressed in the brain [116]. Prior to being implicated in autophagy, GATE-16 was 
originally identified as being involved in ER-to-Golgi and intra-Golgi vesicular transport 
processes. Purified GATE-16 (then called p16) from bovine brains was found to 
stimulate intra-Golgi trafficking in an in vitro system and its activity was dependent on the 
presence of N-ethylmaleimide-sensitive factor (NSF) and soluble NSF attachment 
(SNAP) proteins [117]. It was later determined that GATE-16 binds directly to NSF and 
stimulates its ATPase activity to promote the disassembly of SNARE complexes formed 
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upon completion of vesicle fusion [118]. NSF and GATE-16 have since been shown to 
function outside of intra-Golgi transportation where they are required for homotypic 
fusion events in the post-mitotic Golgi [119–121]. In contrast to their function in intra-
Golgi transport, the role of GATE-16 and NSF in post-mitotic fusion is independent of 
NSF ATPase activity [121,122].  
GABARAP Family – The two GABARAP family proteins, GABARAP and GABARAPL1, 
share many structural similarities to GATE-16, including containing acidic residues in the 
N-terminal alpha helices [114]. GABARAPL1 shares a similar expression profile as 
GATE-16, being highly expressed in the central nervous system, while GABARAP is 
predominantly expressed in the endocrine glands and in distinct sub-regions of the brain 
[116,123]. GABARAP was originally described in the intracellular transport of the GABA 
(A) receptor (GABAAR), and was later found to mediate the membrane expression of the 
human kappa opioid receptor and the transient receptor potential cation channel V 
member TRPV-1 [124–127]. GABARAP proteins bind to these receptors to ensure their 
sequestration from the Golgi network into the appropriate transport vesicles [124]. 
Additionally, GABARAP proteins located on the surface of the transport vesicles can 
interact directly with kinesin family proteins to facilitate the anterograde transport of the 
GABAAR-containing vesicles to the plasma membrane along microtubules [128,129]. 
Recent studies suggest that in addition to binding with kinesin proteins, all members of 
the LC3/GABARAP/GATE-16 family proteins can directly interact with the microtubules 
through their N-terminus [130,131]. Lastly, GABARAP can also interact with the 
endocytosis-associated protein clathrin, suggesting a role for GABARAP proteins in 
receptor internalization and recycling [127,132]. 
LC3 Family – LC3 was originally identified in rats as a component of the microtubule 
associated protein MAP1A and MAP1B complexes [133]. MAP1A/B are microtubule 
stabilizing proteins that associate with microtubule lattices and are predominantly 
expressed in the brain. The MAP1A/B complex is composed of heavy and light chain 
subunits which are translated as polypeptides and processed by proteolytic cleavage 
near the C-terminus to generate the heavy and light chains [134]. In contrast, LC3 is an 
accessory protein that is found in complex with MAP1A/B heavy and light chains in a 
ratio of 1:2:0.2, and is transcribed from its own gene [135].  The human genome 
encodes for four members of the LC3 family: LC3A (for which two isoforms exist due to 
alternative splicing), LC3B and LC3C [115,136].  
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 Structural studies have revealed that the C-terminal ubiquitin-like core is well 
conserved between LC3 and GABARAP/GATE-16 proteins, wherease variability is 
present in the N-terminal alpha-helices [112]. While these regions are acidic in 
GABARAP and GATE-16 proteins, they are highly basic in LC3 members. These 
differences have been proposed as a potential mechanism by which Atg8 orthologues 
interact with distinct subgroups of interacting proteins [137]. Most members of the LC3 
family are ubiquitously expressed, however the LC3C protein is present at much lower 
levels than other members, and is only highly expressed in the lungs [136]. Loss of LC3 
family proteins resulted in a specific impairment in the autophagosome biogenesis 
process, with cells producing significantly smaller autophagosomes [138]. The main 
function of LC3 members is in expansion and elongation of the phagophore membrane, 
while GABARAP and GATE-16 proteins are required at later stages to mediate 
autophagosome membrane hemifusion. 
 Of the LC3 family members, LC3B is the most studied and as a result more is 
known about its functional role in autophagy. It is the only member of the Atg8 proteins 
that can recruit p62/SQSTM1, an adapter protein that specifically targets 
polyubiquitinated proteins for degradation by autophagy. This interaction recruits 
p62/SQstm1 to the autophagosomal membrane [139] and is mediated by interaction of 
the LC3 Interacting Region (LIR) on p62/SQSTM with LC3B. This forms a bridge 
between membrane-bound, lipidated LC3 and the polyubiquitinated cargo proteins being 
targeted for degradation [140]. Although p62/SQSTM1 can interact with all Atg8 family 
proteins in their unlipidated state, p62/SQSTM1 is unable to interact with 
GABARAP/GATE-16 proteins following their lipidation [139]. LC3 proteins also interact 
with other cargo-recruiting proteins in a similar manner, including neighbor of Brca1 
(NBR1, [141]), the mitophagy-related proteins BNIP3 and Nix [142–144], and autophagy-
linked FYVE protein (Alfy) [145,146] . Thus, despite their overall similarity in structure to 
other Atg8 proteins, LC3 proteins have family-specific functionality in autophagosome 
biogenesis and cargo recruitment processes. 
1.6 The apicomplexan Atg8 conjugation system: conserved and unique 
features 
 Autophagy was originally discovered in mammalian cells, but much of the work 
identifying the genes involved in autophagy and their functions has been done in the 
budding yeast Saccharomyces cerevisae [79,92]. However, phylogenomic studies have 
since identified orthologues of many of the autophagy-related genes in a wide range of 
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species, including plants and protozoans [109,147]. Among the core autophagy proteins 
identified, Atg8 and the members of the Atg8 conjugation system appear to be the most 
highly conserved. Functional characterization of Atg8 homologues in multiple protozoan 
parasites has revealed that this protein is required for multiple aspects of parasite 
biology, including stage conversion and differentiation. Atg8 homologues are also 
important for surviving the various environmental stresses that the parasites encounter 
as they complete their complex life cycles. For example, in Trypanosoma cruzi (the 
causative agent of Chagas disease), Atg8 is implicated in the delivery of proteins to the 
reservosome, an endocytic compartment rich in enzymes associated with proteolysis 
and lipid metabolism [148]. This allows for their degradation in response to changes in 
nutrient availability during transition from the vertebrate to invertebrate host [149]. 
Similarly, in Trypanosoma brucei (African sleeping sickness), autophagy is involved in 
the degradation of glycosomes during the transition from the bloodstream to the midgut 
of the tsetse fly [150]. In Leishmania major (the causative agent of cutaneous 
leishmaniasis), autophagy is required for cellular remodeling that occurs during 
differentiation into infective metacyclics [151]. Many of these processes depend on the 
canonical function of Atg8 and related autophagy proteins in the degradation of cellular 
components by autophagy. However, characterization of Atg8 proteins in other parasitic 
species, including the apicomplexans, has revealed that Atg8 and the Atg8 conjugation 
machinery also have functions in non-canonical processes that are specific to parasite 
biology. 
 Characterization of Atg8 homologues in the apicomplexan parasites Plasmodium 
spp. and Toxoplasma gondii revealed that in both species Atg8 localizes to the outer 
membrane of the apicoplast [94,106,152], a non-photosynthetic plastid organelle that 
plays an essential role in fatty acid metabolism [153]. In Toxoplasma, TgAtg8 tethers the 
apicoplast to centrosomes, either directly or indirectly, to ensure proper division of this 
organelle during parasite replication [103]. Conditional knock-down of TgAtg8 resulted in 
the failure of apicoplasts to be properly segregated into daughter parasites during 
replication and subsequent loss of parasite viability. The localization of TgAtg8 to the 
apicoplast is dependent on its conjugation to PE, which is facilitated by Toxoplasma 
homologues of Atg3 and Atg4. Both of these proteins, which localize to the parasite 
cytoplasm, are essential for parasite viability [94,104]. Conditional knock-down of either 
TgAtg3 or TgAtg4 resulted in fragmentation of the mitochondrion, suggesting that a 
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functional Atg8 conjugation pathway may be required for the maintenance of both 
apicoplast and mitochondrion organelles.  
 Two important structural features have been identified in apicomplexan Atg8 
proteins that differentiate them from homologues found in higher eukaryotes. First, 
apicomplexan Atg8 proteins contain a nine amino acid insertion that forms an 
apicomplexan-specific loop structure. Studies in Plasmodium falciparum have shown 
that this loop is critically important for the interaction between PfAtg8 and PfAtg3 [107]. 
Although the role of this structure has not yet been explored for TgAtg8, it is likely to play 
a similar role in regulating protein-protein interactions in Toxoplasma. Second, 
apicomplexan Atg8 proteins lack the C-terminal extension present in mammalian Atg8 
proteins that requires pre-processing by Atg4 to expose the C-terminal glycine residue 
for conjugation to PE. As a result, Atg8 proteins in Toxoplasma and Plasmodium are 
able to undergo constitutive lipidation, whereas yeast and mammalian Atg8 proteins are 
only lipidated upon induction of autophagy. However, it is worth noting that a portion of 
Atg8 is observed in the non-lipidated state under basal conditions. This suggests that 
despite not requiring pre-processing by Atg4, TgAtg8 lipidation does appear to be under 
some form of regulation that is currently unidentified. 
 Despite basal levels of Atg8 lipidation in Toxoplasma, Atg8 lipidation is induced 
in response to starvation or drug treatment. This can be visualized by the formation of 
Atg8-containing double membrane vesicles and/or GFP-TgAtg8 punctae that resemble 
putative autophagosomes [94,154]. It is possible that this apparent induction of 
autophagy may represent a cytoprotective mechanism that allows the parasite to 
mitigate the effects of cytotoxic stimuli. However prolonged exposure to autophagy-
inducing stressors results in a loss of parasite viability with features resembling 
autophagic cell death [93,154]. Interestingly, mutations in putative ATG proteins were 
shown to contribute to the development of chloroquine resistance in Plasmodium 
falciparum, lending further support for an autophagic cell death pathway in 
apicomplexans [155]. 
 In higher eukaryotes, the induction of autophagy and Atg8 lipidation is regulated 
through the posttranslational modification of ATG proteins [156,157]. For example, 
acetylation of Atg1/Ulk1 increases its kinase activity and promotes autophagy induction, 
while acetylation of Atg3 by p300 promotes its interaction with Atg8 and induces Atg8 
lipidation [158,159].  Additionally, acetylation of LC3B at K49 and K51 regulates its 
subcellular localization, requiring deacetylation by SIRT1 to translocate from the nucleus 
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to the cytoplasm for incorporation into nascent autophagosomes [160]. Interestingly, 
TgAtg8 was found to be acetylated in extracellular parasites [161], however the role of 
this modification in regulating TgAtg8 function remains unknown. The signaling 
pathways and enzymes that add or remove these PTMs to control autophagy have been 
well characterized in yeast and humans. In contrast, the analogous regulatory pathways 
remain largely undefined in Toxoplasma. Toxoplasma appears to have homologues to 
some of the kinases known to regulate autophagy in other systems (Atg1, TOR, PI3K), 
however these proteins remain poorly characterized in the parasite. Attempts to 
manipulate these pathways pharmacologically with compounds known to induce or 
inhibit autophagy in higher eukaryotes have been largely ineffective in Toxoplasma 
[93,94]. These findings illustrate the need to characterize the pathways that regulate the 
Toxoplasma autophagy pathway to allow for the future development of novel compounds 
to disrupt these pathways for therapeutic benefit. 
 Recent structural characterization of the P. falciparum Atg8 W- and L-site binding 
pockets identified differences in the electrostatic surface potential and amino acid 
composition between PfAtg8 and human Atg8 homologues LC3 and GATE-16 [107]. 
These differences were significant enough to result in a ~30-fold preference for the 
binding of small molecule inhibitors to PfAtg8 as compared to human LC3 [162]. 
Moreover, high-throughput screens have identified numerous compounds that bind 
within the PfAtg8 W- and L-site pockets and inhibit the interaction between recombinant 
PfAtg3 and PfAtg8 in vitro. These include multiple compounds from the Medicines for 
Malaria Venture “Malaria Box” that have anti-malarial activity in tissue culture [107,162]. 
An additional group of small molecules has been identified that bind to the PfAtg8 
apicomplexan loop and prevent its interaction with PfAtg3 [163]. Although these 
compounds have not yet been tested in other apicomplexans, they have been proposed 
as novel compounds with potential broad-spectrum use therapeutically, and as tools to 
study the autophagy pathway in these parasites [164]  
1.7 Summary and Aims 
 As introduced in the preceding sections, Toxoplasma and related apicomplexan 
parasites are important pathogens for which novel therapeutics are needed. These 
parasites contain a functional Atg8 conjugation system that is structurally unique from 
human Atg8 proteins and is essential for parasite-specific biological processes. 
Therefore, this pathway may be an ideal new target for the development of novel 
therapeutics to treat these parasitic infections. Further, the identification of specific Atg3-
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Atg8 inhibitors in Plasmodium falciparum provides proof-of-concept for the development 
of new anti-parasitic compounds that target Atg8 protein-protein interactions. However, 
our current understanding of how TgAtg8 coordinates both canonical and non-canonical 
processes in apicomplexan biology is limited do to the lack of understanding regarding 
which proteins TgAtg8 interacts with, and how these interactions are regulated. 
 With the work presented in this thesis, we sought to characterize the proteins that 
interact with members of the Toxoplasma Atg8 conjugation system to identify novel 
interactions that could be targeted pharmacologically. We hypothesized that in addition 
to interacting with homologues of the canonical eukaryotic Atg8 conjugation machinery, 
TgAtg8 interacts with novel proteins to facilitate its functions in parasite-specific 
processes. Additionally, we hypothesized that these protein interactions were subject to 
regulation by post-translational modifications, and that they could be pharmacologically 
disrupted by the recently identified PfAtg3-Atg8 interaction inhibitors. We addressed 
these hypotheses with the following three aims: 1) Determine the functional 
consequences of TgAtg8 lysine-23 acetylation on the TgAtg3-TgAtg8 interaction; 2) 
Characterize the TgAtg8 interactome to identify novel TgAtg8 interacting proteins, and 3) 
Determine whether TgAtg8 lipidation could be pharmacologically inhibited by treatment 
with Atg3-Atg8 interaction inhibitors recently identified in Plasmodium. 
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Chapter 2: Materials and Methods 
2.1 Tissue culture 
 Parasites were maintained in culture by continuous passage through human 
foreskin fibroblasts (HFFs). HFFs were grown to confluency in Dulbecco’s Modified 
Eagle Medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum 
(FBS), 1% PenStrep (100 U/mL Penicillin and 100 µg/mL streptomycin) and 2 mM L-
glutamine, in a humidified incubator at 37°C and 5% CO2. Confluent HFF monolayers 
were inoculated with parasites and maintained until the parasites had completed 
sufficient rounds of replication to completely lyse the HFF monolayer, at which point the 
parasites were transferred to a new flask of confluent HFFs. 
 The parasites used in this study were all generated in a modified type I RH 
background in which the hypoxanthine-xanthine-guanine phosphoribosyl transferase 
(HXGPRT) gene has been knocked-out [165]. This strain allows for drug selection with 
mycophenolic acid (details of drug selection described in Section 2.3), and will be 
referred to as RH∆hxgprt.  Additionally, a derivative of the RH∆hxgprt strain in which the 
DNA-repair enzyme ku80 has also been disrupted (RH∆hxgprt∆ku80) was used for 
tagging of genes at their endogenous locus, as the lack of ku80 greatly improves the 
efficiency of integration of transfected plasmid DNA by homologous recombination [166].  
2.2 Molecular cloning techniques 
 For the isolation of genomic DNA, freshly lysed parasites were passed through a 
3 µm polycarbonate filter to remove host cell material, and were centrifuged for 10 
minutes at 1000 relative centrifugal force (rcf). The parasite pellet was washed once with 
PBS and centrifuged as before. Genomic DNA was isolated using the DNeasy Blood 
and Tissue kit (Qiagen), and the recovered DNA was used as template for PCR. 
Amplification of DNA sequences by polymerase chain reaction (PCR) was done using 
the Phusion® High Fidelity DNA polymerase (Thermo Scientific) according to 
manufacturers’ guidelines. All PCR primers used in my studies are listed in Appendix 1. 
 For generation of constructs using coding sequences (CDS), parasite cDNA was 
prepared as follows and was used as template for PCR. First, parasites were harvested 
as described before, and total RNA was isolated from the pellet using the RNeasy kit 
(Qiagen) according to the manufacturers’ protocol. The collected RNA was analyzed on 
the NanoDrop One spectrophotometer (Thermo Scientific) to determine RNA 
concentration, and 2 µg of total RNA was reverse-transcribed (RT) into cDNA using the 
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Omniscript RT kit (Qiagen). The resulting cDNA was then used as template for PCR or 
was stored at -20°C for later use. 
 Unless otherwise specified, all amplicons were cloned into their respective 
vectors using the In-Fusion® HD Cloning Kit (Clontech). This approach utilizes a 
proprietary DNA recombinase to seamlessly insert amplicons into linearized vectors in a 
single, 15-minute reaction. To allow for insertion, 15-bp sequences are included in the 
sense and anti-sense primers used for the initial PCR amplification that are homologous 
to the sequence 15-bp up- and down-stream of the intended insertion site in the vector. 
In-Fusion® cloning reaction products were transformed into Stellar™ competent cells 
(Clontech) according to manufacturers’ protocol, plated on LB-agar plates containing 
100 µg/mL ampicillin and incubated at 37°C overnight. Single bacterial colonies were 
picked and used to inoculate 3 mL cultures grown overnight at 37°C, 250 RPM. One-
third of the culture was pelleted by centrifugation at 10,000 rcf for 1 minute, and plasmid 
DNA was isolated using the QuickLyse Miniprep Kit (Qiagen). All plasmids were 
confirmed by sequencing prior to further use in downstream applications.  
 Endogenous C-terminal epitope tagging of genes of interest was performed using 
the cloning approach and pLIC-3xHA-DHFR tagging construct described in [167]. Briefly, 
a fragment of the 3’ end of the gene of interest was amplified by PCR from genomic 
DNA and inserted into PacI-digested pLIC-3xHA-DHFR using Infusion cloning. The 
Infusion reaction was transformed into Stellar™ competent cells and plasmid DNA from 
recovered bacterial colonies was collected as described above. Presence of the insert 
was first confirmed by restriction digestion with PacI and visualization of the digestion 
products by electrophoresis on a 1% agarose/TBE gel containing 1:40,000 GelRed DNA 
stain (Biotium). Plasmids found to contain bands corresponding to the insert were further 
analyzed by sequencing to confirm that the insert was in frame with downstream epitope 
tags. Modified versions of the plasmid described in [167] containing various C-terminal 
epitope tags (cMyc, Strep-TY, 2xHA-DD) were used with a similar cloning approach to 
introduce various epitope tags at genomic loci in these studies.  
2.3 Transfection, drug selection, and isolation of clones 
 The plasmid DNA to be used for transfection was first linearized by restriction 
digestion overnight, and purified by phenol:chloroform extraction [168]. The purified DNA 
was isolated by ethanol precipitation [169], and was collected by centrifugation for 10 
minutes at 4°C at 10,000 rcf. The pelleted DNA was left uncapped in the tissue culture 
hood for at least 1 hour to air dry, and was then dissolved in 400 µL of Cytomix buffer 
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(10 mM KPO4, 120 mM KCl, 150 µM CaCl2, 5 mM MgCl2, 25mM Hepes, 2mM EDTA). To 
prepare parasites for transfection, freshly lysed parasites were pelleted by centrifugation 
for 10 minutes at 1000 rcf, washed with 10 mL of Cytomix buffer, and pelleted with an 
additional 10-minute spin at 1000 rcf. Parasites were then resuspended in Cytomix 
buffer to yield 3x107 parasites in 400 µL of buffer. The resuspended parasites and DNA 
were combined and transferred to a 4 mm gap BTX disposable electroporation cuvette, 
and electroporated at 1500 V, 25 Ω. Transfected parasites were then transferred to 
tissue culture flasks with confluent HFF monolayer, incubated overnight, and the next 
day media was replaced with media containing drug for selection.  
 Two drug selection approaches were used to generate stable parasite strains. 
Parasites lacking the HXGPRT rely on the function of inosine-monophosphate 
dehydrogenase (IMPDH) to generate guanosine monophosphate (GMP) required for 
purine biosynthesis. Therefore, inhibition of IMPDH by mycophenolic acid (MPA) kills 
parasites lacking HXGPRT. This allows for positive selection for parasites that have 
integrated plasmids containing the HXGPRT minigene cassette by treatment with 25 
µg/mL MPA and 25 µg/mL xanthine [170]. Parasites containing the HXGPRT gene are 
able to survive MPA treatment when supplemented with xanthine, which can be used to 
generate GMP through the activities of HXGPRT and GMP synthestase. A second 
selection approach utilizes a mutated dihydrofolate reductase-thymidlate synthase 
selection (DHFR-TS) cassette that produces a DHFR-TS enzyme that is resistant to the 
drug pyrimethamine [171].  Parasites transfected with plasmids containing the mutant 
DHFR-TS minigene were therefore selected by treatment with 1µM pyrimethamine.  
 Regardless of selection approach, parasites were maintained under drug for at 
least 3 passages, and were then cloned into 96-well plates by limiting dilution to isolate 
single parasite clones. Recovered parasite clones were screened for proper integration 
by PCR, immunofluorescence microscopy (IFA) and immunoblotting to confirm 
expression of tagged protein. 
2.4 Immunoblotting 
 Parasites that had been harvested intracellularly by syringe lysis, or that were 
freshly egressed, were pelleted by centrifugation for 10 minutes at 1000 rcf. The 
collected parasite pellet was then washed once with cold PBS, and pelleted by 
centrifugation as before. The pellet was lysed in ice-cold radio immunoprecipitation 
assay (RIPA) buffer for 30 minutes at 4°C with gentle mixing. The lysate was then 
centrifuged for 10 minutes at 13,000 rcf at 4°C to pellet insoluble debris, and the cleared 
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supernatant was transferred to a new Eppendorf tube. A 1:10 dilution of cleared lysate in 
water was prepared and used to quantitate total protein concentration using a 
bicinchoninic acid (BCA) assay (Pierce) according to manufacturers’ protocol. An equal 
amount of total protein for each strain or condition was separated by SDS-PAGE, with 
total protein loadings between 20 and 100 µg, depending on the experimental 
conditions. Alternatively, parasite lysates were normalized to parasite number by 
counting using a haemocytometer and resuspending the pellet in a volume of RIPA to 
yield 106 parasites per µL. 
 Unless otherwise specified, all SDS-PAGE assays were performed using 4-20% 
gradient gels (Bio-Rad, Mini-PROTEAN® TGX™) in a Tris/Glycine/SDS running buffer 
(25mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3), and were electrophoresed at 100 V for 
1 hour and 35 minutes. Gels were then electrotransferred to a nitrocellulose membrane 
in a Tris/Glycine/methanol buffer (25 mM Tris, 192 mM glycine, 20% methanol) for 1 
hour at 100 V, or for 12-16 hours at 24 V, 4°C. Nitrocellulose membranes were rinsed 
once with water and the transfer was visually inspected for air bubbles or irregularities by 
staining with Ponceau S Staining Solution (1 mg/mL Ponceau S, 5% acetic acid) for 5 
minutes. The blot was then washed with Tris buffered saline with 0.1% Tween-20 
(TBST) for 30 minutes to remove Ponceau S Stain, and was blocked for 30 minutes in 
and 5% (w/v) dry milk in TBST. Primary antibodies diluted in milk/TBST were incubated 
for 1.5 hours at room temperature, or overnight at 4°C on a rocker. Primary antibodies 
used in these studies are listed in Appendix 2. Blots were washed three times for 10 
minutes with TBST, and incubated with horseradish peroxidase (HRP)-conjugated 
secondary antibodies for 45 minutes at room temperature in milk/TBST. The membrane 
was then washed three times with TBST for 10 minutes, and proteins were detected with 
SuperSignal West Femto substrate (Thermo Fisher) and visualized with a FluorChem R 
imager (Bio-Techne). 
2.5 Immunofluorescence assays 
 For immunofluorescence (IFA) assays of intracellular parasites, parasites were 
inoculated into a confluent HFF monolayer grown on a glass coverslip in a 12-well tissue 
culture plate and incubated at 37°C, 5% CO2. The infected monolayer was then fixed for 
15 minutes with 4% paraformaldehyde in phosphate buffered saline (PBS). The fixed 
coverslips were washed twice with PBS, blocked in PBS with 3% bovine serum albumin 
(BSA) for 15 minutes, and permeablized with 3% BSA/PBS with 0.2% Triton X-100 for 
30 minutes. Primary antibodies were incubated in 3% BSA/PBS + Triton X-100 for 1.5 
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hours at room temperature, or overnight at 4°C. Coverslips were then washed three 
times for 15 minutes with PBS, and incubated with 3% BSA/PBS containing fluorophore-
conjugated secondary antibodies for 45 minutes at room temperature. After an additional 
three 15 minute PBS washes, coverslips were stained with DAPI in PBS for 5 minutes, 
followed by three 5 minute washes, and were mounted onto slides using Vecta Shield 
mounting media. Primary antibodies used for IFA in this study are listed in Appendix 2. 
 For extracellular IFAs, coverslips were placed in a 12-well plate and were 
incubated in a 0.01% Poly-L-lysine solution for 30 minutes in the tissue culture hood. 
Coated coverslips were then washed three times with PBS, and were allowed to air dry 
for at least 1 hour prior to use. Extracellular parasites, either freshly lysed or syringe 
lysed and filtered, were washed as described previously, added to the Poly-L-lysine-
coated coverslips and were placed in a 4°C refrigerator for 15-30 minutes to allow 
parasites to settle and attach to the coverslip. The coverslips were then processed for 
IFA as described above for intracellular IFA analyses. 
2.6 Doubling Assays 
 Intracellular parasites were manually released from host cells by passage 
through a 27-gauge needle, and were filtered through a 3 µm filter to remove host cell 
debris. Filtered parasites were then pelleted by centrifugation for 10 minutes at 1000 rcf, 
and were resuspended in media for counting using a haemocytometer. A total of 
100,000 parasites were used to infect a confluent HFF monolayer in a 12-well plate. 
Two-hours after infection, the monolayers were washed three times with media to 
remove any parasites that remained extracellular, and the media was replaced and 
stored in an incubator at 37°C, 5% CO2. At either 24 or 48 hours post infection, cells 
were fixed with ice-cold methanol for 30 seconds, allowed to dry, and stained using 
Differential Quik Stain kit (Polysciences, Inc.). At least 100 vacuoles for each well were 
scored for the number of parasites per vacuole, and the raw counts were converted to 
percentages. Graphs represent the average of three independent experiments unless 
otherwise specified. 
2.7 Plaque assays 
 Intracellular parasites were harvested as described in Section 2.6, and 500 
parasites were used to infect a confluent HFF monolayer in 12-well plates. Infected 
plates were incubated at 37°C, 5% CO2 and were left undisturbed for 5 days. The 
monolayer was then fixed with cold methanol, allowed to air dry, and stained with Crystal 
Violet dye solution (Sigma Aldrich). After rinsing with PBS, stained plates were allowed 
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to dry and were imaged on a FluorChem R imager (Bio-Techne). Plaque number was 
scored by manually counting the number of plaques in each well, while calculation of 
area of host cell lysis was done using the ColonyArea plug-in in ImageJ [172]. 
2.8 Egress assays 
 Freshly lysed parasites were used to inoculate confluent HFF monolayers in 12-
well plates and incubated for 24-30 hours at 37°C, 5% CO2. Media was then aspirated 
and monolayers were washed twice with HBSS pre-warmed to 37°C. Following the 
second wash, the HBSS was replaced with HBSS containing drug or vehicle, and plates 
were incubated for 2 minutes at 37°C, 5% CO2. The monolayers were then fixed with 
methanol, stained with Differential Quik Stain, and a minimum of 100 vacuoles per 
condition were scored as intracellular or egressed to determine percent egress. 
 Egress was also quantitatively assessed using the CytoTox-ONE™ Homogenous 
Membrane Integrity Assay (Promega) to measure lactate dehydrogenase (LDH) 
released from host cells as a result of parasite egress as described in [173]. Confluent 
HFF monolayers were infected with 5 x 104 RHΔhxgprt parasites per well in 96-well 
format. Twenty-four hours post infection, the monolayers were washed with DMEM 
supplemented with 1% FBS, and were incubated in the same media with drug in a two-
fold serial dilution, or vehicle, with each treatment done in technical triplicate. After a 15-
minute incubation at 37°C, 50 µL of CytoxONE Assay Buffer with substrate was added 
to each well and incubated 5 minutes at 25°C. The reaction was stopped by addition of 
25 µL stop solution to each well, and plates were read on a plate reader at 560nm 
excitation and 590nm emission. 
2.9 Co-immunoprecipitation assays 
 Co-immunoprecipitation (co-IP) assays in which the precipitated protein was 
visualized by immunoblotting used approximately 5 x 107 freshly egressed parasites. To 
identify interacting proteins by mass spectrometry, approximately 109 freshly egressed 
parasites were used. For both approaches, the extracellular parasites were collected by 
centrifugation for 10 minutes at 1000 rcf and 4°C, and the pellet was washed once with 
cold PBS. The pellet was then re-suspended in 150 µL (small-scale co-IP) or 500 µL (co-
IP for mass spectrometry) of ice-cold Pierce Co-IP Lysis Buffer supplemented with 
protease and phosphatase inhibitor cocktail (CST). The pellet was lysed for 30 minutes 
at 4°C with gentle mixing, and was sonicated for 10 seconds using a microtip sonicator. 
The lysates were centrifuged for 10 minutes at 13,000 rcf and 4°C to remove insoluble 
debris, and the soluble fraction was transferred to a new 1.5 mL microfuge tube. Lysates 
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were first incubated for 30 minutes at 4°C with mouse IgG-conjugated magnetic beads 
(CST) to remove proteins that bound non-specifically to the beads. Following this 
incubation, the beads were collected on a magnet, and the pre-cleared lysate was 
transferred to a new 1.5 mL microfuge tube and incubated for 1 hour at 4°C with 
magnetic beads pre-conjugated with antibodies against the epitope tag on the target 
protein (either HA or cMyc). The beads were then collected on a magnet and washed 
three times with Co-IP Lysis Buffer, and twice with PBS. For detection of 
immunoprecipitated proteins by immunoblotting, the precipitated proteins were eluted off 
of the magnetic beads by the addition of 30 µL 2xSDS-PAGE buffer containing 5% β -
mercaptoethanol and boiled for 5 minutes at 95°C.  
 Alternatively, the washed beads were submitted to the Indiana University School 
of Medicine Proteomics Core facility for protein identification by mass spectrometry. The 
on-bead samples were first dentatured in 8M urea, reduced with 5 mM (tris(2-
carboxyethyl)phosphine), and alkylated with 10 mM chloroacetamide. Alkylated samples 
were then digested with 0.3 µg endoproteinase LysC (sequencing grade, Roche 
Diagnostics) overnight at 37°C. The samples were then diluted to a final concentration of 
2M urea using 100 mM Tris-HCl, pH 8.5, and digested with 0.5 µg trypsin (Promega 
Gold) overnight at 37°C. Digested peptides were injected onto a 15 cm C18 column 
(PepMap, 3µm) on a Thermo Dionex UltiMate 3000 RSLCnano chromatography system, 
and eluted with a linear gradient from 3 to 40% acetonitrile (in water with 0.1% formic 
acid) over 120 min room temperature at a flow rate of 700 nL/min. Effluent was 
electrosprayed into a Orbitrap Velos Pro (Thermo-Fisher Scientific) mass spectrometer 
for analysis. Data analysis was performed using SEQUEST HT within Proteome 
Discoverer 2.1 (Thermo) and searched against the Toxoplasma gondii database 
(www.toxodb.org, TgondiiGT1_AnnotatedProteins version 29) with common 
contaminants using SEQUEST HT with an FDR of ≤1%.  Results were imported into 
Scaffold 4 Q+ (Proteome Software) for additional analysis. 
2.10 Bioinformatics: sequence alignments, structural modeling and virtual 
docking 
 Databases used for the retrieval and analysis of gene and protein sequences 
include the Toxoplasma database (ToxoDB, www.toxodb.org) [174], the National Center 
for Biotechnology Information database (www.ncbi.nlm.nih.gov) [175–177], and the 
Eukaryotic Pathogens database (EupathDB, www.eupathdb.org) [178]. Alignment of 
amino acid sequences and generation of phylogenetic trees was performed using 
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Clustal Omega [179]. Phylogenetic analyses were done using the PhyML 3.0 webserver 
(http://www.atgc-montpellier.fr/phyml/) using all default settings and with bootstrapping 
set at 100 [180]. The I-TASSER server [181] was used to generate the predicted TgAtg8 
protein structure, supplying the full TgAtg8 protein sequence as input and without any 
modifications to default settings. Docking simulations were done using the SwissDock 
server [182] providing the solved PfAtg8 (PDB code 4EOY, [107]) structure or the output 
of the I-TASSER TgAtg8 model as input for the target, and the ZINC accession numbers 
for the MMV compounds as input for the ligands. All docking was done using the 
default/accurate specifications and without defining a region of interest. Docking results 
were visualized and screened using the ViewDock tool in UCSF Chimera [183,184]. 
Modeling of the K23 mutations and their effect on surface potential was done using 
SwissPDB Viewer [185]. 
2.14 Quantitative real-time PCR 
 Quantitative assessment of mRNA transcript levels was done using the Fast 
SYBR® Green Master Mix kit (ThermoFisher) according to the protocol provided by the 
manufacturer. These reactions were performed using cDNA prepared as described in 
section 2.2. Relative quantification of transcript levels was performed using the 2-ΔΔCt 
methodology as described in [186], using alpha-tubulin (TUBA1) as the reference gene 
for normalization. Primers for qPCR were designed using the online software tool 
Primer3 (v. 0.4.0) [187] that selects for primer pairs with optimal thermodynamic 
properties to avoid hairpin formation and primer dimerization, and are listed in Appendix 
1. 
2.15 Expression and purification of recombinant TgAtg8 
 Recombinant, N-terminally 6xHis tagged TgAtg8 was generated by cloning the 
TgAtg8 coding sequence into NdeI/BamHI linearized pET19b expression plasmid using 
the In-Fusion® HD Cloning Kit (Clontech). The final construct was confirmed by 
sequencing and was transformed into Rosetta™ competent cells (Novagen), a derivative 
of BL21 DE3 pLysS cells that allows for expression of eukaryotic proteins containing 
codons rarely used in E. coli by supplying additional tRNAs on a secondary plasmid. 
Large (250 mL) bacterial cultures were grown in LB containing 100 µg/mL ampicillin at 
250 rpm, 37°C, and the growth was monitored by measurement of OD600 using a 
NanoDrop One spectrophotometer. When the cultures reached an optical density of 0.6 
– 0.8, protein expression was induced by addition of IPTG to a final concentration of 1 
mM. Induction of 6xHis TgAtg8 was confirmed by SDS-PAGE analysis of bacterial 
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lysates before and after IPTG induction as shown by Coomassie or silver staining. After 
a 2 hour incubation following induction, bacterial pellets were collected by centrifugation 
at 4000 rcf for 20 minutes at 4°C, and the pellets were processed for purification using 
the TALON Metal Affinity Resin kit (Clontech) according to the manufacturer’s protocol. 
Eluted proteins were concentrated using Vivaspin columns (GE Life Sciences) with a 
molecular weight cut-off of 3 kDa. Protein concentrations were determined using a 
NanoDrop One spectrophotometer and were further confirmed by BCA assay (Pierce). 
The purified TgAtg8 protein was analyzed by SDS-PAGE and silver staining, and was 
found to be >90% pure as determined by densitometry analysis using ImageJ [188,189]. 
2.16 Acetyl-TgAtg8-K23 antibody production and analysis 
 In an attempt to generate an Atg8 K23-acetyl specific antibody, two rabbits were 
immunized with a peptide corresponding to amino acids 18-32 of TgAtg8, containing 
acetylated-K23 [HRIRA-K(Acetyl)-YPNRIPVIC]. Four immunizations with the acetyl-K23 
peptide were given over 13-weeks, and at the conclusion the sera were collected from 
both animals and were pooled for affinity purification. The serum was first purified over a 
column containing the non-acetyl-K23 peptide to remove any antibodies that recognized 
TgAtg8 independently of its acetylation status. The flow through was then purified over 
an affinity column containing the acetyl-K23 peptide. Pacific Immunology Corporation 
(Ramona, CA) performed all steps of the antibody production, including peptide 
synthesis, and confirmed the specificity of the affinity purified acetyl-K23 antibody by 
ELISA. 
 Upon the receipt of the affinity-purified antibodies, both antibodies were tested for 
their reactivity to additional peptides containing K23 mutants used in our studies (K23R, 
K23A, K23Q). To this end, 20 µg of each peptide was spotted onto a nitrocellulose 
membrane and allowed to air dry for 1.5 hours. The membrane was then blocked for 1hr 
in 5% milk/TBST, and was probed with both affinity purified antibodies diluted 1:1000 in 
milk/TBST for 1.5 hours. The membranes were then washed for 30 minutes in TBST, 
and probed with HRP-conjugated goat anti-rabbit secondary antibodies for 45 minutes. 
The membrane was washed for an additional 30 minutes and detected using 
SuperSignal West Femto substrate and visualized with a FluorChem R imager. 
2.17 Methods of autophagy induction 
 The two previously established methods used to induce autophagy in these 
studies were treatment of intracellular parasites with the ionophore monensin [154], and 
starvation of extracellular parasites by incubation in HBSS [94]. For monensin treatment, 
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confluent monolayers of HFFs in tissue culture flasks (immunoblotting) or grown on 
glass coverslips in 12-well plates (IFA) were infected with freshly lysed parasites. For 
IFA experiments, the infected monolayers were washed twice with 1% FBS media 24 
hours after infection, and was incubated in media supplemented with monensin at 1 
ng/mL or vehicle (ethanol) for 6-24 hours. In some experiments, the autophagy inhibitor 
3-methyladenine was included during monensin treatment at a final concentration of 10 
mM. For monitoring of TgAtg8 lipidation following monensin treatment, 75 cm2 tissue 
culture flasks containing confluent HFFs were infected with 107 freshly lysed parasites. 
After a 36-hour incubation, the monolayer was washed twice with 1% FBS media, and 
incubated in media containing monensin or vehicle for 6 hours. The monolayer was then 
processed for immunoblotting as described in section 2.4. 
 Alternatively, intracellular parasites were syringe lysed from the host cells, 
centrifuged for 10 minutes at 1000 rcf, and washed twice with HBSS. The pellet was 
then resuspended in HBSS and incubated in 15 mL polypropylene tubes, loosely 
capped, for 8 hours in a 37°C, 5% CO2 tissue culture incubator. For visualization of GFP-
Atg8 punctae following HBSS starvation, parasites were processed for extracellular IFA 
as described in section 2.5. Alternatively, parasites were pelleted by centrifugation for 10 
minutes at 1000 rcf and processed to visualize TgAtg8 lipidation status by immoblotting 
as described in section 2.4. 
2.18 CPRG assay for generation of growth inhibition curves 
 To generate growth inhibition curves to determine EC50 values for various 
compounds, HFF monolayers in 96-well plates were inoculated with 100 manually 
released β-galactosidase expressing parasites [190]. Four days after inoculation, 
chlorophenol red-β-D-galactopyranoside (CPRG) was added to each well at a final 
concentration of 100 µM. Plates were read 24 hours after addition of CPRG on a 
Synergy H1 (BioTek) plate reader at 570 nm excitation and 630 nm emission. Averages 
from three biological replicates were used to generate growth inhibition curves using 
Prism (GraphPad v 7.0a), normalizing to uninfected HFF (100% inhibition) and 
dimethylsulfoxide (DMSO) vehicle (0% inhibition) wells. Results from three independent 
replicates were plotted in Prism, and curves were fit to the log-transformed (x-axis) data 
by non-linear regression, using the four-parameter, variable slope settings. 
2.19 Differential Scanning Fluorimetry 
 Differential scanning fluorimetry analyses (also referred to as thermal shift 
assays) were preformed to assess the effects of TgAtg8 K23 mutations on intrinsic 
  34 
protein stability and interaction with the TgAtg3 AIM peptide. This assay measures the 
fluorescence of a SYPRO Orange thermofluor that binds nonspecifically to hydrophobic 
surfaces exposed during protein unfolding [191].  Assays were conducted in a 96-well 
plate in 100 mM HEPES (pH 7.0) buffer containing 150 mM NaCl and 5x SYPRO orange 
dye (Invitrogen) at a final volume of 20 µl per well. Each reaction mixture contained 
purified recombinant Atg8 at a final concentration of 8 µM, in the presence or absence of 
TgAtg3 AIM peptide (corresponding to residues 160-176) or cMyc control peptide. All 
reactions were heated from 25°C to 95°C at a ramp rate of 1°C/min on a StepOne Plus 
RT-PCR machine. SYPRO Orange fluorescence was measured at each temperature 
(StepOne Plus Filter 4; 488 nm/610 nm excitation and emission wavelengths), and the 
obtained values were plotted against temperature. The melting temperature (Tm) was 
obtained by taking the first derivative of this graph using Prism, and Tm values from 
triplicate experiments were used to calculate the Tm for each condition. Raw 
fluorescence values were normalized using Prism (minimum value set to 0%, maximum 
value set to 100%) and plotted as “Percent Unfolded”.  
2.20 Cytosolic Ca2+ Measurements 
 Freshly egressed parasites were passed through a 3 µm filter to remove host cell 
debris, and were washed once with Intracellular Buffer (IB) (5 mm NaCl, 144 mm KCl, 
5.6 mm D-glucose, 1 mm MgCl2, 2 mm EGTA, 25 mm HEPES, pH 7.4). The parasites 
were then loaded with 2.5 µM Fluo-4 AM calcium indicator dye (ThermoFisher) in IB for 
1 hour at room temperature. Following a 30-minute wash with IB to remove extracellular 
dye, the parasites were resuspended in IB to a final concentration of 107 parasites per 
mL, and 100 µL were transferred to each well in a 96-well plate. A Synergy H1 (BioTek) 
plate reader was used to monitor Fluo-4 AM fluorescence at 488 nm excitation and 524 
nm emission wavelengths. Each treatment condition was performed in triplicate, with 
measurements taken every 5 seconds. After a 1 minute period to establish baseline 
fluorescence levels, 10 µL of Hanks’ Balanced Salt Solution (calcium and magnesium-
free) containing DMSO vehicle, A23187, or MMV1 was added to each well using the 
Synergy H1 injectors and measurements were taken every 5 seconds for 10 minutes. 
Data were analyzed using Prism, with graphs representing the Fluo4-AM fluorescence 
intensities after DMSO subtraction. 
2.21 Statistical Analyses 
 All statistical analysis performed in this study were conducted using Prism 
(GraphPad v 7.0a). All normalization and linear or non-linear regression techniques used 
  35 
are described in their respective Methods sections. All graphs containing asterisks to 
denote significance contain information regarding p-value cut-off and statistical test used 
to determin significance in the respective figure legends. Statistical analysis of mass 
spectrometry results for TgAtg8 and TgAtg3 interactomes were conducted using the 
SAINTExpress [192,193] program with default settings (www.crapome.org). Raw total 
spectrum counts were supplied in list or matrix format according to guidelines. Proteins 
were considered significant if they were present in at least 2 out of 3 IPs, and had a fold-
change (FC-B) value greater than 2.0 and SAINT Probability (SP) score ≥ 0.75. 
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Chapter 3: Results 
Aim 1: Determine the functional consequences of TgAtg8 lysine-23 acetylation on 
the TgAtg3-TgAtg8 interaction 
 Acetylation of autophagy proteins is emerging as a major mechanism by which 
the autophagy pathway is regulated in eukaryotes. In particular, acetylation has been 
shown to regulate the Atg3-Atg8 interaction, and the subcellular localization of Atg8 
family proteins. We had previously identified that autophagy was induced in response to 
drug treatment [154]. Additionally, we discovered that TgAtg8 was acetylated at lysine-
23 [161]. Therefore, we sought to determine whether acetylation of TgAtg8 at lysine-23 
regulated TgAtg8 localization or function. Our studies focused primarily on the effects of 
this modification on the interaction of TgAtg8 with TgAtg3, because this was the only 
proposed TgAtg8 interacting protein identified in Toxoplasma at the time. Using a 
combination of genetic and biochemical approaches, we determined that TgAtg8 
acetylation is not likely to alter the TgAtg3-TgAtg8 interaction. However, our results 
suggest that this modification may affect TgAtg8 protein stability, potentially through 
regulation of TgAtg8 protein-protein interactions. 
3.1 Toxoplasma Atg8 acetylation occurs on a conserved lysine residue near 
the TgAtg8 W-site binding pocket 
 Characterization of global protein acetylation in Toxoplasma tachyzoites 
identified that the parasite Atg8 homologue is acetylated at lysine 23 (K23) [161]. K23 
acetylation on TgAtg8 was found only in extracellular parasites, leading us to 
hypothesize that this PTM might be involved in regulating TgAtg8 function in response to 
extracellular stress. Bioinformatics analyses showed that lysine-23 was conserved in 
numerous Atg8 homologues in higher eukaryotes, including P. falciparum Atg8, and 4 of 
the 6 human Atg8 proteins (Figure 5). Importantly, the analogous lysine residue (K24) in 
the human Atg8 homologue HsGABARAPL2 (also known as GATE-16) was identified as 
acetylated by two different proteomics studies looking at global protein acetylation 
[194,195]. Although the conservation of this PTM across eukaryotes is intriguing and 
may represent a conserved functional role of this modification, the biological significance 
of GABARAPL2/GATE-16 K24 acetylation remains unknown. 
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Figure 5: Amino acid sequence alignment of eukaryotic Atg8 homologues. 
ClustalOmega was used to align the amino acid sequences of Atg8 proteins from 
Toxoplasma (TgAtg8), Plasmodium falciparum (PfAtg8), Saccharomyces cerevisiae 
(ScAtg8), and the six human Atg8 homologues LC3A/B/C, GABARAP, and 
GABARAPL1/2. 
 
 Acetylation of lysine residues can alter many aspects of protein function, 
including protein stability, subcellular localization, protein-protein interactions, and 
enzymatic activity [195–197]. Additionally, the acetylation status of the human Atg8 
protein LC3B regulates its localization by modulating its interaction with the protein DOR 
[160]. While acetylated, LC3B resides in the nucleus. However, upon deacetylation by 
Sirt1 LC3B interacts with DOR and translocates to the cytoplasm where it is utilized for 
autophagosome biogenesis. To gain insight into how acetylation of TgAtg8 at K23 might 
affect TgAtg8 function, we performed structural modeling using the I-TASSER server to 
develop a predicted model of TgAtg8 and determine where K23 localized within the 
TgAtg8 structure (Figure 6A). This modeling revealed that K23 localizes on the second 
alpha-helix in the N-terminus of TgAtg8 (Figure 6B). Additionally, this residue was 
localized adjacent to the W- and L-site binding pockets that facilitate protein-protein 
interactions between Atg8 and proteins that contain the consensus WXXL Atg8 
Interacting Motif (AIM), also referred to as LC3 Interacting Motif (LIR) [198,199]. We 
therefore hypothesized that acetylation of TgAtg8 at K23 can reversibly neutralize the 
positive charge on K23, and in doing so, alter TgAtg8 protein-protein interactions.  
A
B
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Figure 6: Structural modeling of TgAtg8.  
The TgAtg8 amino acid sequence was submitted to the I-TASSER server to predict the 
three-dimensional protein structure. The predicted model is shown in (A) and is colored 
according to secondary structure (alpha helices in red, coils in grey, and beta sheets in 
purple). B) Visualization of the TgAtg8 W-site (blue) and L-site (red) binding pockets that 
are the sites of interaction with AIM motifs on Atg8 interacting proteins, with relation to 
the acetylated lysine residue K23, highlighted in green 
 
 The functional significance of specific acetylation events is typically determined 
using site-directed mutagenesis to mutate the acetylated lysine residue to arginine (R) 
that retains the charge of an unmodified lysine residue while preventing acetylation, 
glutamine (Q), which is routinely used as an acetyl-lysine mimic and can functionally 
mimic acetylated lysine residues in a variety of proteins, or alanine (A) to neutralize 
charge and prevent acetylation [200–203]. We therefore used these established 
methods to attempt to characterize the effects of K23 acetylation on TgAtg8 function. 
The effects of these mutations on the TgAtg8 electrostatic surface potential were 
visualized using the SwissPDB Viewer software program to model the K23R, K23Q, and 
K23A mutations to the predicted TgAtg8 protein structure. As shown in Figure 7, the 
K23R mutation maintains the positive charge of the alpha-2 helix on which K23 resides, 
while mutation to glutamine and alanine neutralizes this charge. 
α1
α2
W-site
L-site
K23
A B
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Figure 7: Modeling of K23 mutations and effects on surface potential. 
(top) Chemical structures of lysine, acetylated lysine, and amino acids used to mimic 
acetylated and non-acetylated lysine by mutagenesis. Blue box illustrates positively 
charged side-chains, while gray box represents neutral side-chains. (bottom) Modeling 
of predicted TgAtg8 structure to visualize the effects of each K23 mutation on 
electrostatic surface potential.  
 
3.2 Ectopic expression of K23 mutants does not affect parasite fitness 
 We next performed site-directed mutagenesis to introduce the K23R, K23Q, and 
K23A mutations into an expression plasmid containing a GFP-TgAtg8 fusion protein that 
was previously developed for use in monitoring TgAtg8 localization in Toxoplasma [94]. 
Each of these constructs was transfected into RH∆hxgprt parasites and single-parasite 
clones for each were obtained. The expression of each GFP-TgAtg8 K23 mutant protein 
was confirmed by immunofluorescence assay and immunoblotting. Interestingly, both 
methods revealed differences in total protein levels, with K23R and K23A mutant 
proteins showing slightly lower expression, while K23Q mutant GFP-TgAtg8 was slightly 
higher as compared to wild-type K23K controls (Figure 8A-B). Importantly, a similar 
trend was observed in parasites obtained from multiple, independent transfections, 
suggesting that the observed differences were not likely due to differences in the 
genomic location of plasmid integration or number of integrations. Despite these 
differences in protein levels, the ectopic expression of GFP-Atg8 K23 mutants had no 
  40 
observable impact on parasite fitness as demonstrated by equivalent rates of replication 
(Figure 8C). 
 
Figure 8: Ectopic expression of GFP-TgAtg8 K23 mutants does not impair parasite 
viability. 
A) Representative IFA images of parasites expressing wild-type K23K or K23 mutant 
proteins, as visualizes using the GFP epitope tag. All proteins were found to localize 
predominantly to the cytosol, with additional signal enrichment at the parasite apicoplast. 
Scale bar represents 3 µm. B) Representative immunoblot of GFP-TgAtg8 proteins 
stained for anti-GFP or anti-SAG1 (loading control). Values below lanes represent 
densitometry values for this representative blot as calculated using ImageJ, and are 
normalized to K23K. C) Doubling assays of parasites ectopically expressing wild-type 
(K23K) or mutant GFP-Atg8 proteins. Parasites were allowed to replicate for 24 hours, at 
which point the number of parasites per vacuole was enumerated. Expression of K23 
mutant proteins did not alter parasite replication rate (n=3, ± SEM).  
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3.3 GFP-TgAtg8 WT and K23 mutants localize to the daughter parasite pellicle 
during division 
 Previous studies characterizing GFP-TgAtg8 showed that this protein localizes 
predominantly in the cytoplasm, and is occasionally found to localize to bright punctae 
that co-localize with the apicoplast [94]. Further studies showed that this localization to 
the apicoplast increases during parasite division [103]. While characterizing our GFP-
TgAtg8 K23 mutant, we observed that in addition to the apicoplast, GFP-TgAtg8 was 
also enriched at the daughter parasite pellicle during mitosis (Figure 9). We confirmed 
that this localization was TgAtg8 dependent by monitoring the localization of cytosolic 
GFP (not fused to TgAtg8). Immunofluorescence analyses of parasites expressing 
cytosolic GFP showed that this protein failed to localize to the daughter pellicle during 
mitosis (Figure 10). As Atg8 is known to interact with membranes through hydrophobic 
interactions with its N-terminal helices, we tested whether the alteration of charge by 
mutation of K23 affected the ability of GFP-TgAtg8 to localize to the daughter buds. 
Mutation of K23 to non-acetylated lysine mimic (K23R) or acetylated-lysine mimic 
(K23Q) residues did not prevent localization of GFP-TgAtg8 to daughter parasite 
pellicles during mitosis (Figure 10). These studies suggest that TgAtg8 localizes to the 
daughter parasite pellicle during division independently of its acetylation status. 
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Figure 9: GFP-TgAtg8 is enriched at daughter parasite pellicle during mitosis. 
A) IFA analysis of GFP-TgAtg8 during replication revealed that TgAtg8 localizes to the 
daughter parasite early during division and remains enriched at the daughter pellicle 
through completion of cytokinesis. GFP-TgAtg8 visualized in green, DAPI staining to 
visualize nuclei are shown in blue.  
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Figure 10: Localization of GFP-TgAtg8 to dividing parasites is not altered by 
mutation of K23. 
A) Parasites expressing cytosolic GFP (green) failed to show enrichment of GFP at the 
daughter parasites during division. Daughter parasites were visualized by co-staining 
with acetyl-tubulin (red) to delineate daughter parasite cytoskeleton. B) IFA of GFP-
TgAtg8 K23 mutant parasites, showing that all three K23 mutants were found to localize 
to the daughter parasites during division. 
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 We next attempted to resolve whether mutation of K23 altered the ability of GFP-
TgAtg8 proteins to undergo lipidation. Previous studies characterizing GFP-Atg8 in 
Toxoplasma showed that lipidation of the fusion protein is only visible by immunoblotting 
following extracellular starvation treatment [94]. Therefore, we conducted extracellular 
starvation assays in HBSS for each of the GFP-TgAtg8 K23 mutant proteins and sought 
to determine whether each of these proteins was lipidated. We were unable to resolve 
the two bands corresponding to GFP-TgAtg8 and GFP-TgAtg8-PE by SDS-PAGE using 
4-20% gradient gels followed by immunoblotting for GFP (Figure 11A). For endogenous 
Atg8, resolution of the lipidated and unlipidated band is often improved by SDS-PAGE 
using gels containing 6 M Urea [204]. We also attempted to assess GFP-Atg8 lipidation 
status using this approach, but were once again unable to resolve the two bands (Figure 
11B). Therefore, we were unable to assess the effect of TgAtg8 K23 acetylation on 
lipidation using the GFP-TgAtg8 strains. 
 
Figure 11: Assessment of GFP-Atg8 K23 mutant lipidation. 
A) Immunoblot of GFP-TgAtg8 proteins attempting to visualize GFP-TgAtg8 lipidation 
after 8 hours of extracellular starvation (HBSS). Proteins were resolved using standard 
4-20% Tris/Glycine SDS-PAGE gels, and transferred proteins were visualized with 
antibodies against GFP (TgAtg8) or Toxoplasma beta-tubulin as a loading control. B) 
Immunoblot of the same samples shown in (A) resolved by SDS-PAGE using a 13.5% 
separating gel containing 6M urea. 
 
3.4 Generation of endogenously-tagged cMyc-Atg8 K23K and K23R parasite 
strains 
 Although parasite fitness did not appear to be altered when GFP-TgAtg8 K23 
mutant proteins were ectopically expressed, we hypothesized that the lack of phenotype 
could be due to the presence of the endogenous TgAtg8 protein in these parasites. We 
therefore attempted to introduce these K23 mutations at the endogenous TgAtg8 locus 
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using double-homologous recombination to replace the TgAtg8 genomic sequence with 
a cDNA copy of TgAtg8 containing wild-type K23K or K23R, A or Q mutations (Figure 
12A). A cMyc-epitope tag was also introduced at the N-terminus of each of these 
constructs to allow for subcellular localization by IFA and to assess protein expression, 
stability and lipidation competence for the K23 mutant proteins. 
 Viable transfectants were recovered following transfection with the wild-type 
cMyc-TgAtg8-K23K control plasmid, and proper integration was confirmed by PCR of the 
TgAtg8 locus (Figure 12). The endogenously tagged cMyc-TgAtg8-K23K protein 
resolved as two bands by SDS-PAGE and immunoblotting, representing unlipidated 
TgAtg8 and lipidated TgAtg8 (Atg8-PE). Additionally, cMyc-TgAtg8-K23K correctly 
localized to the parasite apicoplast, suggesting that the endogenously tagged cMyc-
TgAtg8 retained all functionality previously reported for TgAtg8 and GFP-TgAtg8 fusion 
proteins. Although we easily obtained K23K wild-type cMyc-TgAtg8 parasites, we were 
unable to recover K23Q or K23A mutant parasites despite numerous attempts, 
suggesting that these mutations have deleterious effects on tachyzoite viability. We 
were, however, successful in recovering K23R mutants in one out of six independent 
transfections, and confirmed the proper integration by PCR (Figure 13A). 
 We next sought to determine the effects of ablation of K23 acetylation on TgAtg8 
localization and lipidation by comparing the cMyc-Atg8-K23K and cMyc-Atg8-K23R 
parasites. Immunofluorescence assays showed that like K23K, the K23R mutant protein 
predominantly localized to the apicoplast (Figure 13B). This was further confirmed by 
immunoblotting which revealed that the cMyc-Atg8-K23R mutant protein migrated as two 
bands, representing unlipidated and lipidated TgAtg8 (Figure 13C). Interestingly, we 
observed that the endogenous K23R mutant protein also displayed lower levels of total 
protein as compared to K23K wild-type, similar to our observations with ectopic GFP-
Atg8 K23K and K23R proteins. 
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Figure 12: Generation of endogenous cMyc-Atg8 K23K parasites. 
A) Diagram of the construct used to target the TgAtg8 genomic locus for replacement 
with a cMyc-epitope tagged TgAtg8 cDNA sequence. Arrows indicate primer pairs 
used to confirm proper integration at the endogenous TgAtg8 locus. The blue primer 
pair amplifies a fragment unique to parental strain, the red pair amplifies unique 
fragment in recombined strain, and the black pair amplifies a 1791 bp fragment in 
parental strain and a 372 bp fragment in recombined strain. Asterisks indicates site of 
K23 mutations. B) PCR products from genomic DNA isolated from cMyc-TgAtg8 and 
parental (RH∆hx∆ku80) parasites. Blue, red and black arrows refer to the primer pairs 
described in (A). C) Western blot of lysates from freshly egressed parental 
RHΔhxgprtΔku80 and cMyc-TgAtg8 parasites, probed with antibodies recognizing the 
cMyc epitope, and Toxoplasma β-tubulin as a loading control. Two bands are 
observed for cMyc-TgAtg8, representing unmodified (Atg8) and lipidated (Atg8-PE) 
forms of TgAtg8. D) IFA of cMyc-TgAtg8 parasites stained with DAPI (blue), and for 
cMyc (red), showing that cMyc-TgAtg8 localizes predominantly to the apicoplast. 
Scale bar = 3µm. 
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Figure 13: Endogenous K23R mutation does not alter localization to apicoplast or 
prevent lipidation. 
A) PCR of the genomic Atg8 locus in RH∆hxgprt∆ku80 parental, wild-type cMyc-Atg8 
K23K, or cMyc-Atg8 K23R mutant parasites. Black arrows designate primer pair with 
forward primer upstream of 5’ homology region used for recombination, and reverse 
primer that binds to 3’ end of TgAtg8 CDS. This primer set produces a 3.3 kb amplicon 
in parental, and a 1.9 kb amplicon in recombined parasites. PCR using a forward primer 
that binds to the 5’ of the TgAtg8 CDS (red) with the reverse TgAtg8 CDS primer (black) 
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generates a 400 bp amplicon in the recombined TgAtg8 locus. B) IFA analysis staining 
for cMyc revealed that both K23K and K23R proteins correctly localize to the apicoplast, 
visualized as the bright foci oriented immediately apical of DAPI-stained nuclei. C) 
Immunoblot with anti-cMyc showed that both K23K and K23R are present as unlipidated 
(top band in cMyc blot) and lipidated (bottom band in cMyc blot) forms. The Toxoplasma 
surface antigen SAG1 was used as a loading control. 
 
3.5 Endogenous mutation of K23 to arginine impairs parasite replication and 
promotes spontaneous differentiation to bradyzoites 
 While characterizing the localization and lipidation status of cMyc-TgAtg8 K23R, 
we noticed that the K23R mutant parasites grew significantly slower than the parental 
and K23K wild-type control parasites. To assess their growth defects, we performed 
plaque assays to monitor parasite growth over a 5-day period. This assay showed that 
while the K23K parasites grew similarly to the parental strain, K23R mutants had a 
severe growth defect, as shown by the reduction in both number and area of plaques 
that represent destruction of the host cell monolayer as the result of parasite propagation 
and egress (Figure 14). The reduction in the size of plaques observed in the K23R 
mutant parasites suggested that the rate of intracellular replication was significantly 
slower than that of K23K and parental parasites. To test this, we performed a doubling 
assay to determine the number of rounds of division that parasites underwent in a 24-
hour period. After allowing the parasites to replicate for 24 hours, the cells were fixed 
and the number of parasites per vacuole were counted. For both parental and K23K 
parasites, over half of the vacuoles contained 8 or 16 parasites, indicating that parasites 
had undergone 3 or 4 rounds of replication (Figure 14). In contrast, over 80 percent of 
the vacuoles for K23R parasites contained 4 or fewer parasites. This data shows that the 
endogenous mutation of Atg8K23 to arginine significantly impairs tachyzoite replication. 
 While assessing the growth defects in the K23R mutant parasite strain, we 
observed that these parasites remained intracellular for over 7 days, forming large, 
rounded vacuoles with features resembling bradyzoite tissue cysts formed in vitro. To 
determine whether the K23R parasites were undergoing differentiation into bradyzoites, 
we preformed immunofluorescence assays at 7 days post-infection to visualize two 
established markers of bradyzoite cysts: staining of the cyst wall glycoproteins using 
fluorophore-conjugated Dolichos biflorus lectin [205], and reactivity with antibodies 
against the bradyzoite-specific protein BAG1 [206]. Indeed, these analyses revealed at 
day 7 post infection, over 80% of the vacuoles stained positive with both markers of 
bradyzoite cysts (Figure 15A-B). This was specific to the K23R mutant parasites, as no 
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vacuoles stained positive for either marker in parental or K23K parasite strains. This 
observation was further confirmed by performing qPCR for genes specifically expressed 
during tachyzoite (SAG1) or bradyzoite (BAG1, ENO1, LDH2) stages, which showed that 
K23R parasites showed a down-regulation of tachyzoite gene markers and significantly 
higher expression level for bradyzoite specific genes (Figure 15C). The ability of the 
K23R parasites to differentiate into bradyzoites was remarkable, as they were generated 
in the Type I RH∆hxgprt∆ku80 background strain that has a significantly lower ability to 
differentiate to bradyzoites. Additionally, bradyzoite differentiation in vitro in HFFs 
typically requires exogenous stress, usually in the form of altering pH stress [207,208]; 
however, the K23R parasites differentiated under normal tissue culture conditions 
without any such additional stress.  
 While attempting to further characterize this phenotype, we observed that the 
K23R mutant parasites lost both their replication defect and bradyzoite differentiation 
phenotype over the course of 3-4 months in culture. These phenotypes were retained in 
freshly-thawed stocks of the original parasite clone, but were subsequently and 
repeatedly lost following 4-5 passages. This adaptation prevented us from conducting 
complementation assays to determine whether the growth phenotypes could be 
corrected by complementation with a wild-type copy of TgAtg8, as the cloning procedure 
requires multiple rounds of passage over the course of multiple weeks. We also 
attempted to confirm the K23R mutant phenotype by isolating parasite clones from 
independent transfections, however these attempts were unsuccessful. 
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Figure 14: Parasite replication is significantly impaired in K23R endogenous 
mutant parasites. 
A) Representative plaque assay of parental RH∆hxgprt∆ku80, cMyc-Atg8 K23K and 
cMyc-Atg8 K23R parasites. K23R mutant parasites showed a significant reduction in 
plaque number and area of host cell lysis indicating impairment of progression through 
the lytic cycle. B) Doubling assays of parental, K23K and K23R parasites assessing the 
number of parasites per vacuole at 24 hours post infection. While the majority of parental 
and K23K vacuoles contained 8 or more parasites, most K23R vacuoles contained 4 or 
fewer, indicating impairment of parasite replication. 
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Figure 15: K23R mutant parasites undergo spontaneous differentiation into 
bradyzoites and form cysts in vitro. 
A) Representative IFAs of RH∆hxgprt∆ku80 parental strain, cMyc-TgAtg8 K23K and 
K23R parasites, stained with DAPI (blue), bradyzoite-specific chaperone protein BAG1 
(green) and rhodamine-conjugated Dolichos biflorus lectin (red), which binds to 
glycoproteins in the bradyzoite tissue cyst wall. Parental and K23K vacuoles were 
imaged at 66 hours post infection, when vacuoles contained >32 parasites and prior to 
lysis of the host cell monolayer. K23R vacuoles were imaged Day 7 post-infection. B) 
Quantitation of percentage of K23R vacuoles that stained positive for BAG1 and lectin 
(n=3, ± SEM). C) Representative qPCR analysis of tachyzoite specific transcripts 
(SAG1) and bradyzoite-specific transcripts (BAG1, ENO1, LDH2). Values represent log2 
fold-change in K23R parasites relative to K23K parasites (normalized to alpha-tubulin). 
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3.6 Attempt to generate a TgAtg8 K23-acetyl specific antibody 
 To overcome the difficulties encountered in dissecting the role of TgAtg8 K23-
acetylation using a mutagenesis-based approach, we attempted to generate an antibody 
that specifically recognized the acetylated form of TgAtg8 to allow us to characterize 
TgAtg8 K23-acetylation under various conditions and treatments. To this end, two 
rabbits were immunized with a synthetic peptide containing acetylated K23. The sera 
from the two rabbits were pooled and affinity purified to isolate an antibody that 
specifically recognized K23-acetylated TgAtg8. We assessed the specificity of the affinity 
purified antibody by preforming dot blots with the acetylated K23 peptide, an 
unacetylated K23 peptide, and peptides containing each of the mutations used in our 
previous studies (K23R/A/Q). As shown in Figure 16, the acetyl-K23 specific antibody 
showed strong specificity in this assay, and recognized only the acetylated peptide. We 
next attempted to use this reagent to visualize TgAtg8 K23 acetylation by 
immunoblotting on parasite lysates. As a control, we included lysates from the GFP-
TgAtg8 K23 mutant strains. We expected that given the specificity of the acetyl-K23 
antibody as seen by dot blot, this antibody should not be able to bind to the K23 mutant 
proteins. However, while the antibody was specific for the acetylated peptide, we 
observed equivalent reactivity against K23K and K23 mutant proteins (Figure 16C). Due 
to a lack of specificity of this antibody at the protein level, we were unable to use this 
reagent for further characterization of TgAtg8 K23 acetylation in the parasite. 
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Figure 16: Acetyl-K23 non-specifically recognizes TgAtg8 K23 mutant proteins. 
A) Dot blot of K23-acetyl and K23-non-acetyl peptides (20µg each), probed with anti-
K23-Acetyl antibody and non-acetyl specific antibodies. Water was used as a negative 
control. B) Dot blot of K23-acetyl and peptides containing each of the K23 mutations 
used in our study, probed with anti-K23-Acetyl antibody. C) Immunoblot of lysates from 
K23K, K23Q and K23R parasites probed with anti-K23-Acetyl antibody, showing that the 
antibody lacks specificity at the protein level. 
 
3.7 Atg8 K23 mutations do not prevent binding with Atg3 AIM or alter protein 
thermal stability  
 In Plasmodium falciparum, structural characterization of the PfAtg3-Atg8 
interaction showed that PfAtg3 contained a consensus AIM (Atg8 Interacting Motif) that 
binds within the W- and L-site pockets on PfAtg8 [107]. As the TgAtg8 acetylated lysine 
residue (K23) is located near these binding pockets, we hypothesized that this 
modification (and the mutations used to mimic this modification) may alter interaction 
between TgAtg8 and AIM-containing proteins, including TgAtg3. Although TgAtg3 and 
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TgAtg8 are assumed to interact in a similar manner as observed in other systems, this 
interaction has never been confirmed, and no AIM in TgAtg3 had been proposed or 
validated. Based on the identified PfAtg3 AIM sequence, we identified a similar putative 
AIM sequence in TgAtg3 (Figure 18). We therefore sought to confirm the ability of this 
predicted AIM sequence to bind to TgAtg8 and determine whether mutation of K23 
altered this interaction.  
 As previously described, we encountered many difficulties in directly assessing 
the lipidation of the GFP-Atg8 proteins and were unable to generate an endogenous 
K23Q mutant parasite strain mimicking K23 acetylation. Therefore, we chose to examine 
the TgAtg3 AIM-TgAtg8 interaction using thermal shift assays. This assay measures the 
ability for a ligand to bind to a target protein by quantifying the resulting shift in melting 
temperature (Tm, the temperature at which half of the target protein is denatured) caused 
by ligand binding [209,210]. To conduct these assays, we expressed recombinant 6xHis-
tagged TgAtg8 K23K, K23R, K23A and K23Q proteins in E. coli, which were purified 
using TALON cobalt affinity resins (Figure 17). Additionally, we synthesized a peptide 
corresponding to TgAtg3 amino acids 160-176 that contains the putative AIM sequence 
(VGHDVEGGWMLPLLNDE). These reagents were then used to perform thermal shift 
assays in the presence of the thermofluor dye SYPRO Orange, that fluoresces upon 
binding to hydrophobic surfaces exposed following protein denaturation [209,211]. 
Thermal unfolding curves were obtained for each TgAtg8 K23 mutant protein, and the Tm 
was determined (Figure 18). We observed a concentration-dependent increase in Tm in 
the presence of the TgAtg3 AIM peptide (Figure 18A). No increase in Tm was observed 
with equal concentrations of a control cMyc peptide, suggesting that the increased 
thermal stability was due to the interaction between the TgAtg3 AIM peptide and TgAtg8 
(Figure 18B). Importantly, all K23 mutant proteins showed a similar increase in Tm in the 
presence of TgAtg3 AIM peptide, suggesting that none of the TgAtg8 K23 mutations 
altered the interaction between the TgAtg3 AIM peptide and TgAtg8. 
 In addition to being used to monitor protein-ligand interactions, thermal shift 
assays can be used to assess the effect of point mutations on protein thermal stability, 
with single mutations being able to alter thermal stability by as much as 10°C [212]. To 
determine whether the apparent effects of K23 mutations on protein stability were the 
result of alterations in the intrinsic protein stability, we preformed thermal shift assays in 
the absence of peptide ligands. We observed a similar trend in protein thermal stability 
as we saw with protein levels in the parasite, with K23R and K23A mutations having 
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decreased Tm values, and K23Q having a slightly increased Tm (Figure 19). However, 
these changes in Tm were less than 2°C as compared to K23K, suggesting that the 
observed differences in protein levels in the parasite are unlikely solely due to effects of 
these mutations on intrinsic protein stability.  
 The interaction between TgAtg3 and TgAtg8 was further confirmed by tagging 
the endogenous TgAtg3 locus with a C-terminal 3xHA epitope tag in the cMyc-TgAtg8-
K23K and K23R background strains (Figure 20). This allowed for direct assessment of 
the interaction between full-length TgAtg3 and TgAtg8 proteins by co-
immunoprecipitation and immunoblotting. We observed that TgAtg3 localized to the 
cytoplasm, and that the tagged protein resolved as two bands, correspond to the two 
previously reported splice variants observed for TgAtg3 [94]. In agreement with our 
previous findings, both K23K and K23R proteins were co-precipitated by 
immunoprecipitation of TgAtg3 using HA affinity resin (Figure 20). Reciprocal co-
immunoprecipitations using anti-cMyc conjugated magnetic beads further demonstrated 
that both K23K and K23R proteins interact with TgAtg3 (Figure 20). These results show 
that mutation of Atg8 K23 to arginine (K23R) does not prevent interaction with the AIM 
motif present in TgAtg3. 
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Figure 17: Purification of recombinant TgAtg8 K23 WT and mutant proteins. 
A) Silver stained SDS-PAGE gel of recombinant 6xHIS-Atg8 K23K, K23R, K23A, and 
K23Q proteins. Proteins were purified using TALON Cobalt resin and the flow-through 
lysate (unbound) and recovered purified proteins (elutions) were subjected to SDS-
PAGE. All Atg8 K23 proteins were found to be >90% purity as determined by 
densitometry analysis using ImageJ. B) Immunoblot of samples in (A) probing with an 
anti-HIS tag antibody.  
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Figure 18: Mutation of K23 does not alter ability to bind to putative TgAtg3 AIM 
peptide. 
A) (top) Representative plot for Atg8-K23K showing rightward-shift of melting 
temperature in response to increasing concentrations of TgAtg3 AIM peptide (sequence 
of TgAtg3 AIM aligned with PfAtg3 AIM shown above graph). (bottom) Melting 
temperature increases in presence of Atg3 AIM peptide for all K23 mutant proteins. B) 
Representative plot for TgAtg8-K23K in presence of cMyc control peptide that fails to 
alter melting temperature.  
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Figure 19: Mutation of K23 does not alter intrinsic protein thermal stability. 
Representative plot of Atg8-K23K and K23 mutant proteins, in the absence of peptide 
ligands. Quantitation of melting temperature for Atg8-K23K and K23 mutant proteins 
revealed minimal effects of K23 mutation on protein thermal stability, n=5, ± SEM. 
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Figure 20: Endogenously-tagged TgAtg3-HA co-immunoprecipitates with both 
K23K and K23R proteins. 
A) Schematic of cloning approach used to introduce a 3xHA epitope tag at the C-
terminus of the endogenous TgAtg3 gene. Prior to transfection, the plasmid used for 
tagging was linearized by digestion with BstBI to allow for integration at the endogenous 
TgAtg3 locus. B) Representative IFA and immunoblotting analyses of recovered TgAtg3-
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HA parasites. TgAtg3 (green) localizes to the cytoplasm and resolved as two bands, 
corresponding to two forms that arise by processing of the TgAtg3 N-terminus. C) 
Representative immunoblots (IB) probing for Atg3-HA and cMyc-Atg8 following 
immunoprecipitation (IP) with anti-HA (top) or anti-cMyc (bottom) resin. Both K23K and 
K23R proteins co-precipitate with TgAtg3, suggesting that acetylation of K23 is not 
required for their interaction. 
 
Summary Aim 1:  
 To address our first aim, we used a combination of bioinformatics, structural 
modeling, mutational analyses and biophysical approaches to assess the effect of K23 
acetylation TgAtg8 localization, interaction with TgAtg3 and on parasite fitness. We 
presented evidence that this modification may regulate TgAtg8 protein stability, 
potentially through altering TgAtg8 protein-protein interactions, as these mutations did 
not alter intrinsic protein thermal stability. Ablation of this modification at the endogenous 
gene locus is not well-tolerated; it impairs parasite replication and promotes 
spontaneous differentiation from tachyzoites to bradyzoite tissue cysts. However, our 
data collectively suggest that these observed phenotypes are not due to alterations of 
the interaction between TgAtg8 and TgAtg3. Our characterization of the endogenous 
K23R mutant parasites also suggests that this mutation is unlikely to prevent TgAtg8 
interaction with other components of the Atg8 conjugation system (TgAtg7 and TgAtg4), 
as TgAtg8 lipidation and localization to the apicoplast was not affected in these mutants. 
This suggests that the phenotypes observed are likely due to altered TgAtg8 functions 
outside of its established role in autophagy and apicoplast maintenance. However, these 
potential alternative functions remain unknown, in large part due to our lack of 
understanding regarding which proteins TgAtg8 interacts with in Toxoplasma. 
Accordingly, in our second aim we sought to characterize the TgAtg8 interactome to 
identify novel interacting proteins and shed light on potential new functional roles for 
TgAg8 in parasite biology.  
 
Aim 2: Characterization of the TgAtg8 interactome to identify TgAtg8 interacting 
proteins 
 The function of Atg8 in Toxoplasma has largely focused on its role in canonical 
autophagy-related processes in response to drug treatment or starvation. However, it is 
now apparent that TgAtg8 also exhibits non-canonical functions including but not limited 
to coordinating apicoplast division by tethering this organelle to the centrosomes [103]. 
The mechanism by which TgAtg8 exerts this function is unclear as is whether TgAtg8 
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directly tethers the apicoplast to the centrosome or indirectly through protein-protein 
interactions. Additionally, Atg8 proteins have diverse functions in higher eukaryotes, 
including in protein sorting, vesicle trafficking, and targeted degradation of organelles 
and proteins. Importantly, all of these processes rely on interactions between Atg8 and 
other proteins, and have not been explored in Toxoplasma. We hypothesized that 
TgAtg8 was also involved in diverse biological processes in Toxoplasma that are 
important for parasite viability. Further, we proposed that these unexplored functions 
may be identified by characterization of TgAtg8 interacting proteins. With our second 
aim, we used affinity purification and mass spectrometry to identify proteins that interact 
with TgAtg8 in tachyzoites. We present evidence supporting a functional role of TgAtg8 
in trafficking of vesicles throughout the Golgi network, and characterize a novel dynamin-
related protein identified in the TgAtg8 interactome. These results expand our 
understanding of the function of TgAtg8 in Toxoplasma biology and identify potential 
interactions that could be further explored as novel pharmacological targets. 
3.8 Identification of TgAtg8 interacting proteins by affinity purification and 
mass spectrometry 
 Our results from the mutagenesis-based studies to assess K23 acetylation 
suggest that this modification does not alter the interaction between TgAtg8 and TgAtg3. 
However, Atg8 proteins interact with numerous proteins outside of the Atg8 conjugation 
machinery, and many of these interactions are dependent upon the electrostatic 
interactions with the Atg8 N-terminal helices where K23 acetylation is predicted to occur. 
We therefore hypothesized that the effects on protein stability and the phenotypes 
observed in the endogenous cMyc-Atg8 K23R parasites were due to alterations in the 
interaction of TgAtg8 with other AIM-containing proteins. We used a proteomics 
approach to identify proteins that interact with TgAtg8 by immunoprecipitation of TgAtg8 
from the cMyc-Atg8 K23K parasite strain previously described (Figure 12). We 
hypothesized that the identification of TgAtg8 interacting proteins would inform future 
studies assessing the role of K23 acetylation on TgAtg8 protein-protein interactions, and 
provide insight into the potential mechanisms underlying the non-canonical functions of 
TgAtg8 in parasite biology. 
 Initially, we hoped to characterize the TgAtg8 interacting proteins from 
intracellular and extracellular tachyzoites, as well as following induction of autophagy. 
However, while preforming these assays, we observed that TgAtg8 protein levels were 
significantly lower in intracellular parasites than in extracellular parasites (Figure 21). As 
  62 
a result, the TgAtg8 protein levels were often below the limit of detection by 
immunoblotting in lysates from intracellular parasites. The difference in TgAtg8 
expression was also seen by qPCR from intracellular and extracellular parasites, which 
showed a ~2.5-fold increase in mRNA levels in freshly lysed parasites (Figure 21). 
Additionally, although we were able to immunoprecipitate TgAtg8 from extracellular 
parasites, induction of autophagy by extracellular HBSS starvation resulted in the 
retention of TgAtg8 in an insoluble fraction, thus preventing its immunoprecipitation 
(Figure 21). Therefore, we were only able to characterize the TgAtg8 interactome from 
freshly egressed, extracellular parasites. 
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Figure 21: TgAtg8 expression increases in extracellular and remains insoluble 
upon HBSS starvation. 
A) Quantitative RT-PCR of transcript levels for putative Toxoplasma ATG genes from 
intracellular and freshly egressed, extracellular parasites. Members of the Atg8 
conjugation system, including TgAtg3, TgAtg4, and TgAtg8 show significantly increased 
expression levels in extracellular parasites. B) Representative immunoblot from cMyc-
TgAtg8 parasite lysates harvested from intracellular and extracellular parasites. Blots 
were probed with anti-cMyc and with SAG1 as a loading control. Values below lanes 
indicate values of TgAtg8/SAG1 protein levels for each condition, as determined by 
densitometry using ImageJ. C) Representative immunoblot of lysates prepared for 
immunoprecipitation of cMyc-TgAtg8 from freshly egressed parasites. Pellets were lysed 
in RIPA buffer, and cMyc-TgAtg8 was found predominantly in the soluble lysate (Input) 
with minimal protein remaining in the insoluble pellet (pellet). Immunoprecipitation with 
anti-cMyc magnetic beads shows ability to IP both lipidated and unlipidated forms of 
cMyc-TgAtg8. D) Immunoblot of lysates prepared as described in (C) prior to and 
following 8 hours of extracellular HBSS starvation. Starvation prevents the liberation of 
cMyc-TgAtg8 from the insoluble fraction. 
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 To identify TgAtg8 interacting proteins, we incubated lysate from 109 freshly 
egressed cMyc-Atg8 parasites with magnetic beads conjugated with non-specific mouse 
IgG (negative control) or with anti-cMyc antibodies. Mass spectrometry from three 
independent biological replicates identified proteins that were specifically enriched by 
immunoprecipitation with the anti-cMyc beads, likely representing TgAtg8 interacting 
proteins. The raw spectral counts from each biological replicate were used for statistical 
analysis using SAINT (Significance Analysis of INTeractome) to assign probability 
scores to each interaction (Table 2, Appendix 3). This analysis returned a list of twelve 
proteins with high-confidence enrichment values (SAINT Probability > 0.75), including 
the E1-like component of the Atg8 conjugation system TgAtg7 (Table 2). Many of the 
identified interacting proteins were also found to contain putative AIM sequences that 
could facilitate their interaction with TgAtg8, and have been implicated as important for 
tachyzoite viability based on a genome-wide CRISPR knockout study [213]. 
 In addition to identifying homologues of Atg8 conjugation machinery, we 
identified homologues to the mammalian NSF and SNAP proteins (Sec18p and Sec17p 
in yeast), which are known interacting proteins of the Atg8 family protein GATE-16. We 
also found a significant enrichment of components of the branched chain 
ketodehydrogenase complex (BCKDH). In Toxoplasma, the primary function of this 
complex is the conversion of pyruvate to acetyl-CoA in the mitochondrion, as the 
Toxoplasma pyruvate dehydrogenase complex localizes to the apicoplast [7,214]. The 
BCKDH is a multi-subunit complex consisting of E1 alpha, E1 beta, E2, and E3 subunits, 
three of which were identified in our TgAtg8 interactome (Table 2). We also identified a 
putative thiamine pyrophosphokinase (TPP), which localizes to the mitochondrial matrix 
in higher eukaryotes and phosphorylates thiamine to generate TPP, an essential co-
factor for the E1 subunits of 2-oxo acid dehydrogenase complexes including PDH and 
BCKDH [215,216].  
 A number of parasite-specific proteins of unknown function, annotated as 
“hypothetical proteins”, were also enriched in our dataset. Although these proteins lack 
conserved domains as identified by amino acid sequence, some insight on potential 
protein function was provided by analysis with HHpred [217], which identifies proteins 
with similar predicted tertiary structure. One of the identified hypothetical proteins, 
TGGT1_ 268430 had a predicted Golgi-localized gamma adaptin ear-containing, ARF-
binding (GGA1) domain, found in clathrin adapter proteins involved in protein trafficking 
from the trans-Golgi network and from the Golgi to the lysosome [218]. Additionally, the 
  65 
second hypothetical protein, TGGT1_ 247300, contained structural similarities to the 
Armadillo repeat proteins beta-catenin and kinesin-associated protein 3. Beta-catenin is 
a multifunctional protein implicated in cell-cell adhesion and the Wnt signaling pathway. 
However, it also plays a critical role in promoting mitotic progression, where it localizes 
to the centrosomes to coordinate formation of the mitotic spindle and regulate 
centrosome separation during mitosis [219]. Kinesin-associate protein 3 (KAP3) is also a 
multifunctional protein that localizes to motor protein complexes that transport cargo 
along microtubules in interphase cells, and relocalizes to the mitotic spindle during cell 
division. Disruption of the KAP3/kinesin complex in HeLa cells resulted in abnormal 
numbers of centrosomes and formation of multiple mitotic spindles that resulted in 
aneuploidy, highlighting the importance of this protein in progression through mitosis 
[220]. 
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Table 2: Identified TgAtg8 Interacting Proteins 
Protein Name Gene ID Fold Change SP AIM CRISPR Score 
Atg8 Conjugation System 
TgAtg7 TGGT1_229690 126.27 1 Yes -3.91 
TgAtg8 TGGT1_254120 20.12 1  -2.75 
Branched Chain Ketodehydrogenase (BCKDH) Complex 
TgBCKDH E2 TGGT1_319920 167.6 1  -1.92 
TgBCKDH E1b TGGT1_314400 21.82 1  -1.6 
TgTPPK TGGT1_215250 20.79 1  -3.28 
TgBCKDH E1a TGGT1_239490 21.95 0.85 Yes n/a 
Golgi vesicle trafficking  
TgDrpC TGGT1_270690 214.21 1 Yes -4.54 
TgNSF TGGT1_318510 76.11 1 Yes -4.36 
TgGAT TGGT1_268430 32.49 1 Yes -1.77 
TgSNAPb TGGT1_218760 15.98 1  -5.35 
TgARP TGGT1_247300 9.59 0.97  -0.08 
Others 
TgPUS2 TGGT1_306660 25.19 1 Yes -4.59 
TgMFS TGGT1_297245 8.9 0.97 Yes -5.71 
* For identified TgAtg8 interacting proteins that were previously uncharacterized or 
lacked clear homologues, gene names were assigned according to predicted function 
based on presence of functional domains or predicted structural homologues identified 
by HHpred. GAT, GGAs And TOM1; ARP, Armadillo Repeat containing Protein; PUS, 
Pseudouridine Synthetase; MFS, Major Facilitator Superfamily. 
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Figure 22: Proteins identified in TgAtg8 interactome. 
Twelve proteins were identified as being enriched in TgAtg8 IPs with high confidence 
(SAINT Probability score >0.75). The SAINTExpress stringent fold-change (FC-B) and 
SP values are plotted, displaying high confidence hits colored in red. Dashed line 
represents SP cutoff (0.75). 
 
 Interestingly, TgAtg3 was not detected as an interactor in this analysis, despite 
our previous data suggesting that these two proteins do interact (Figure 20). However, 
proteomics analysis performed to identify TgAtg3 interacting proteins using the 
endogenously tagged TgAtg3-HA (Figure 20) identified both TgAtg7 and TgAtg8 as the 
top two TgAtg3 interacting proteins (Table 3, Appendix 4) 
 
Table 3: Identified TgAtg3 interacting proteins 
Protein Description Gene ID Fold Change SP 
TgAtg7 TGGT1_229690 187.86 1 
TgAtg3 TGGT1_236110 42.94 1 
TgAtg8 TGGT1_254120 67.65 1 
hypothetical protein TGGT1_305270 86.21 1 
hypothetical protein TGGT1_311830 13.96 0.99 
hypothetical protein TGGT1_203280 16.16 0.97 
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3.9 Localization of TgAtg8 interacting proteins 
 In Toxoplasma, TgAtg8 localizes predominantly to the outer membrane of the 
apicoplast. As none of the proteins identified in our TgAtg8 interactor list had never been 
characterized or localized, we hypothesized that our immunoprecipitation may simply be 
enriching for proteins that localize to the apicoplast due to pulling down apicoplast 
membrane. To address this, we tagged five of the interacting proteins, including 
representatives of the Golgi trafficking-related proteins, as well as components of the 
BCKDH complex and the dynamin-like protein TgDrpC. For all genes, a 3xHA epitope 
tag was introduced at the endogenous locus of the gene of interest in the 
RHΔhxgprtΔku80 background. Each tagged protein was analyzed by SDS-PAGE and 
immunoblotting, and all proteins migrated near their predicted molecular weight, with the 
exception of TgTPPK (predicted MW = 89 kD, observed MW = ~60 kD) (Figure 23). 
Transcriptomics data for TgTPPK does not predict alternative splice forms for this gene, 
however analysis of the TgTPPK mRNA sequence using the ATGpr webserver [221] 
identifies a putative alternative translation start site (starting at mRNA base pair 664) that 
would produce a protein with a predicted molecular weight of 64 kD, and in frame with 
the 3xHA epitope tag. Importantly, the protein produced from this alternative translation 
start site would include the functional TPP kinase domain. 
 Next, we localized each of the tagged TgAtg8 interacting proteins by IFA using 
an anti-HA antibody (Figure 24). All components of the BCKDH complex localized to the 
parasite mitochondrion, as shown by their co-localization with the mitochondrial matrix 
protein F1β ATPase. This localization is in agreement with the previous report 
suggesting their function in acetyl-CoA production in the mitochondrial matrix [214]. The 
putative TgNSF protein co-localized with the Golgi-localized sortilin-like receptor 
TgSORTLR, while the dynamin-related protein TgDrpC was found to localize to bright, 
cytosolic punctae that occasionally localized near regions of mitochondrial constriction 
(Figure 25). However, this localization at the mitochondrion did not increase following 
monensin treatment (which induces mitochondrial fragmentation), so the functional 
consequences of TgDrpC localization near regions of mitochondrial constriction remains 
unclear. These results show that the identified TgAtg8 interacting proteins localize to 
numerous and distinct sub-cellular regions and our immunoprecipitation was not simply 
enriching for apicoplast-localized proteins. 
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Figure 23: Confirmation of endogenously-tagged TgAtg8 interacting proteins by 
immunoblotting. 
Immunoblots of TgAtg8 interacting proteins detected with anti-HA antibody. All proteins 
migrated near expected molecular weights, except for TgTPPK, which migrated at 
approximately 60 kD. 
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Figure 24: TgAtg8 interacting proteins localize to mitochondrion and Golgi 
organelles. 
Representative IFA staining for endogenously-tagged TgAtg8 interacting proteins, as 
visualized by staining with anti-HA (red). All three components of the BCKDH complex 
localize to the parasite mitochondrion, as shown by co-localization with the mitochondrial 
matrix protein F1β ATPase (green). The putative TgNSF protein localizes to the Golgi 
apparatus as shown by co-localization with sortilin receptor-like protein TgSORTLR 
(green). 
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Figure 25: TgDrpC localizes to cytosolic punctae near regions of mitochondrial 
membrane constriction. 
Representative IFA of TgDrpC (green), DAPI (blue) and F1β ATPase (red) showing 
partial co-localization of TgDrpC punctae with regions of mitochondrial membrane 
constriction (arrowheads). Scale bar = 3µm. Image by Robert Charvat. 
 
3.10 TgDrpC relocates from cytoplasm to daughter buds during parasite 
replication 
 Of the identified TgAtg8 interacting proteins, we were particularly interested in 
TgDrpC, as the functions of dynamin and dynamin-like proteins in organelle division and 
Golgi trafficking aligned with functions associated with TgAtg8 [222]. Two dynamin-like 
proteins, TgDrpA and TgDrpB, have previously been characterized in Toxoplasma and 
were required for apicoplast and secretory organelle biogenesis, respectively [223,224]. 
However, unlike TgDrpA and TgDrpB, TgDrpC lacks a conserved GTPase Effector 
Domain (GED) that is typically required for efficient formation of dynamin oligomers and 
for stimulation of the GTPase domain activity [225]. In mammals, dynamin-like protein 1 
C
Phase DrpC MergeF1β
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is required for mitochondrial fission, and dynamin-related proteins are required for 
mitochondrial division in Arabidopsis spp. and Trypanosoma brucei [226–228]. We 
therefore sought to functionally characterize TgDrpC to determine the biological function 
of this divergent dynamin-like protein and to explore its role in Atg8/autophagy related 
processes in Toxoplasma. 
 To characterize TgDrpC and its interaction with TgAtg8, we tagged the 
endogenous TgDrpC gene in the cMyc-TgAtg8 background parasites. 
Immunofluorescence analyses showed that TgDrpC punctae did not co-localize with 
TgAtg8 in intracellular parasites (Figure 26). In contrast, TgDrpC and TgAtg8 were 
frequently found to co-localize at regions near the apicoplast or Golgi in extracellular 
parasites (Figure 26). This co-localization was observed in approximately 30% of 
parasites, and the frequency of co-localization did not increase following prolonged 
extracellular treatment (data not shown). Therefore, the TgAtg8-TgDrpC co-localization 
and interaction appears to occur in a sub-set of parasites, perhaps in response to certain 
conditions; however, the potential conditions that promote the interaction remain 
unknown. We also preformed reciprocal co-immunoprecipitation of TgDrpC-HA and 
cMyc-TgAtg8 and confirmed that these proteins can interact in extracellular parasites 
(Figure 26C). 
 While characterizing TgDrpC localization, we frequently observed that TgDrpC 
formed ring structures that appeared to localize to the leading edge of the elongating 
daughter parasite pellicle during mitosis (Figure 27). To explore this localization, we 
conducted immunofluorescence assays for TgDrpC and co-stained with antibodies that 
recognize two proteins commonly used to visualize daughter bud formation, IMC3 and 
MORN1. IMC3 is a component of the inner membrane complex that localizes 
underneath the plasma membrane and is used to visualize the entire daughter pellicle 
[229]. MORN1 is recruited to the apical complex of the nascent daughter cells early 
during division, and migrates with the growing daughter IMC through cytokinesis. During 
its migration MORN1 forms a ring structure at the leading edge of the growing IMC, and 
this ring is required for constriction of the daughter IMC to complete cell division 
[230,231]. These experiments revealed that TgDrpC co-localizes to MORN1-positive 
structures early during daughter bud formation and migrates with the MORN1 ring during 
mitosis, remaining localized to this structure until the late stages of cytokinesis (Figure 
27). 
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Figure 26: Characterization of TgDrpC interaction with TgAtg8. 
A) Schematic diagram of mammalian dynamin-1 and dynamin-1 like proteins showing 
conservation of domains in Toxoplasma dynamin-related proteins. TgDrpA and TgDrpB 
both contain the GTPase, central domain, and GTPase Effector Domain (GED). In 
contrast, TgDrpC contains only the GTPase domain. Known functions of dynamin and 
dynamin-like proteins from Toxoplasma and mammalian systems are listed at right of 
domain diagram. B) Representative IFA images of TgDrpC-HA (red) and cMyc-TgAtg8 
(green) co-tagged parasites. TgDrpC punctae were not found to co-localize with TgAtg8 
in intracellular parasites, however co-localization was observed in ~30 percent of 
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extracellular parasites. C) Immunoblot showing reciprocal co-immunoprecipitation of 
TgAtg8 and TgDrpC from extracellular parasites. IN, soluble lysate input, IgG, IP with 
non-specific mouse IgG control, UB, unbound/flow-through, EL, elution in 2xSDS buffer. 
Scale bar = 3µm. 
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Figure 27: TgDrpC localizes to daughter buds during parasite replication. 
Representative IFA of TgDrpC-HA (red) showing localization of TgDrpC to ring 
structures during mitosis. Co-staining with IMC3 (green) to visualize daughter bud 
formation revealed that TgDrpC localizes throughout the cytoplasm during interphase, 
but is only found in cytoplasmic punctae apical of the leading edge of the nascent 
daughter parasite during mitosis. Scale bar = 3µm. 
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Figure 28: TgDrpC co-localizes with MORN1 structures during cell division. 
IFA analysis of TgDrpC-HA (red) co-stained for MORN1 (green). TgDrpC does not co-
localize with MORN1 at the basal complex during interphase, but is recruited to the 
daughter bud early during formation. TgDrpC co-migrates with MORN1 at the leading 
edge of the daughter parasite pellicle during mitosis until the final stages of cytokinesis. 
Scale bar = 3µm. 
 
3.11 Conditional knock-down of TgDrpC impairs parasite replication 
 Given the dynamic localization of TgDrpC, we hypothesized that this protein may 
be involved in trafficking of membrane material to the inner membrane complex of the 
daughter parasites, which is thought to be derived from the ER/Golgi compartments [9]. 
A
In
te
rp
ha
se
S
/M
M
ito
si
s
C
yt
ok
in
es
is
Phase DrpC-HA MORN1 Merged
Phase DAPI DrpC-HA Merged
Phase DrpC-HA IMC3 Merged
M
ito
si
s
In
te
rp
ha
se
B
  77 
We sought to determine the function of TgDrpC by assessing the effects of conditional 
TgDrpC knock-down on parasite replication and fitness. We used a conditional knock-
down approach becuase previous studies showed that TgDrpC is essential for parasite 
viability [213,232]. We employed a similar cloning strategy utilized to introduce the 3xHA 
epitope tag at the endogenous TgDrpC locus in the RHΔhxgprtΔku80 background but 
included a destabilization domain (DD) tag in the tagging construct. For this system, 
proteins fused to the DD tag are constitutively degraded in the absence of a synthetic 
stabilizing compound called Shield-1 [233]. This allows for the reversible regulation of 
protein levels in Toxoplasma and for the functional characterization of essential genes 
[234]. 
 Two independent TgDrpC-HA-DD parasite clones were isolated and the 
regulation of TgDrpC-HA-DD protein by Shield-1 was assessed. Plaque assays 
performed in the presence of a two-fold dilution series of Shield-1 showed a 
concentration-dependent reduction in the area of host cell lysis, suggesting that loss of 
TgDrpC impaired parasite replication (Figure 29). We next monitored the TgDrpC-HA-
DD protein levels by immunoblotting to assess the kinetics and efficiency of TgDrpC 
knock-out (Figure 30). No reduction in TgDrpC-HA-DD protein levels was observed 
following 24 hours of culture in the absence of Shield-1. However, after 48 hours without 
Shield-1 we observed a nearly complete loss of TgDrpC-HA-DD protein levels (88.5% 
reduction, ± 7.4%, n=3, SEM). No decrease in endogenously tagged TgDrpC protein 
levels was observed in the TgDrpC-HA parasite strain, illustrating the specific 
degradation of DD-tagged TgDrpC.  
 We next assessed the effects of loss of TgDrpC on parasite replication by 
conducting doubling assays in the presence or absence of Shield-1. In agreement with 
our immunoblotting results, we observed no difference in number of parasites per 
vacuole after 24 hours without Shield-1. After 48 hours, TgDrpC-HA and TgDrpC-HA-DD 
parasites maintained in Shield-1 appeared to have undergone egress and reinvasion, as 
most vacuoles contained 4 or fewer parasites (Figure 31). In contrast, we observed that 
the majority of vacuoles in the TgDrpC-HA-DD parasites contained 16 or more parasites, 
suggesting that the loss of TgDrpC blocks parasite replication and prevents progression 
through the lytic cycle. 
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Figure 29: Conditional knock-down of TgDrpC using destabilization domain (DD) 
reveals essential role in parasite viability. 
Plaque assay showing area of host cell lysis due to parasite replication over a five day 
period. Plaque size shows a positive correlation with concentration of Shield-1, indicating 
that stabilization of TgDrpC-HA-DD is required for parasite growth.  
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Figure 30: Assessment of TgDrpC-HA-DD regulation by Shield-1. 
Immunoblots staining for TgDrpC-HA and TgDrpC-HA-DD proteins in the presence 
and absence of 200 nM Shield-1. A reduction of TgDrpC-HA-DD protein levels is 
observed 48 hours after the removal of Shield-1. Quantitation showing densitometry 
analysis of three biological replicates shown on right (n=3, ±SEM). 
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Figure 31: Loss of TgDrpC impairs parasite replication and progression through 
lytic cycle. 
Doubling assays quantifying the number of parasites per vacuole following 24 and 48 
hours of growth in the presence or absence of Shield-1 (n=3, ±SEM). 
 
3.12 Conditional knock-down of TgDrpC impairs organelle maintenance and 
biogenesis 
 Having shown that TgDrpC is required for parasite replication, we next sought to 
determine whether the growth impairment was due to defects in organelle biogenesis or 
maintenance. We first assessed the effects of conditional TgDrpC knock-down on the 
inner membrane complex, which was visualized by IFA using antibodies against IMC3. 
The relocalization of TgDrpC to the daughter parasites during division suggested that 
TgDrpC may be involved in the trafficking of membrane or proteins to the newly forming 
daughter pellicle. In TgDrpC-HA-DD parasites maintained in the presence of Shield-1, 
we saw normal IMC3 staining delineating the entire parasite pellicle (Figure 32). Upon 
loss of TgDrpC by removal of Shield-1, parasites were highly vacuolarized with large, 
membranous blebs within the PV at the basal end of parasites (Figure 32, arrowheads). 
However, despite these irregularities in parasite morphology, staining for IMC3 showed 
that IMC3 was correctly localized and delineated each individual parasite pellicle. 
Additionally, we observed parasites undergoing mitosis with IMC3 recruited to the 
budding daughter parasites (Figure 32, arrows), suggesting that TgDrpC is not required 
for the formation of the inner membrane complex during division. 
 We next assessed the effects of TgDrpC knock-down on the mitochondrion and 
apicoplast organelles, which require TgAtg8 function for maintenance and division. 
D
rp
C
-H
A
-D
D
C
l. 
3C
C
l. 
2D
[Shield-1] nM 200 100 50 25 12.5 0
DrpC-HA DrpC-HA-DD
0
25
50
75
100
125
150
D
rp
C
/S
A
G
1
+ Shield
- Shield
200 0
0
25
50
75
100
125
%
 V
ac
uo
le
s
200 0
[Shield-1] nM
2
4
8
16
32
20
0 0
[Shield-1] nM
1
2
4
8
16
32
20
0 0
0
25
50
75
100
125
%
 V
ac
uo
le
s
DrpC-HA DrpC-HA DrpC-HA-DDDrpC-HA-DD
24 hrs 48 hrs
A
B
C
  81 
Conditional knock-down of TgDrpC resulted in mitochondrial fragmentation in 
approximately 35-45% of parasites (Figure 33). Additionally, we observed vacuoles 
containing parasites lacking a discernible apicoplast, which occurred at similar frequency 
as the observed mitochondrial phenotype (Figure 33). These phenotypes are similar to 
the ones observed following genetic manipulation of TgAtg8 and members of the TgAtg8 
conjugation pathway, suggesting that TgAtg8’s function in maintaining these organelles 
may be facilitated in part by its interaction with TgDrpC. 
 Given the enrichment of Golgi-trafficking related proteins identified in the TgATg8 
interactome, we determined the effects of TgDrpC knock-down on the Golgi apparatus. 
Upon maintaining TgDrpC-HA-DD parasites in the absence of Shield-1, we found a 
significant number of vacuoles containing Golgi that appeared completely disrupted, as 
visualized by staining for TgSORTLR (Figure 34). A similar phenotype is observed when 
tachyzoites are exposed to Brefeldin A, which inhibits the association of COP-I coat 
proteins with the Golgi and results in the collapse of the Golgi due to fusion with the ER 
(Figure 34) [235].   
 Previous studies showed that disruption of Golgi-trafficking by overexpression of 
a dominant-negative version of TgSORTLR blocked the formation of rhoptries and 
micronemes [236]. Additionally, disruption of the Golgi with Brefeldin A blocks secretion 
of proteins from the dense granules [235]. Further, the biogenesis of the rhoptries and 
micronemes is dependent upon the dynamin-related protein TgDrpB [223]. Therefore, 
we hypothesized that conditional knock-down of TgDrpC may similarly effect the 
formation or function of these secretory organelles. To test this hypothesis, we 
preformed immunofluorescence assays to visualize the rhoptries and dense granules 
under the presence and absence of Shield-1. These assays showed that conditional 
knock-down of TgDrpC led to an accumulation of the rhoptry protein ROP1 in small 
cytoplasmic vesicles, and resulted in the failure to form mature rhoptry organelles 
(Figure 35). IFA analysis of the micronemal protein MIC5 did not reveal significant 
alterations in MIC5 localization following loss of TgDrpC, suggesting that biogenesis of 
the micronemes may not be dependent on TgDrpC (data not shown). Additionally, we 
visualized GRA7, a protein that localizes to the dense granules found in the cytoplasm 
that are constitutively secreted into the PV following invasion of host cells. While 
TgDrpC-HA-DD parasites maintained in the presence of Shield-1 displayed an 
enrichment of GRA7 signal in the PV with few cytoplasmic punctae, parasites grown in 
the absence of Shield-1 contained a significantly higher number of cytoplasmic GRA7 
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vesicles (Figure 36). Together, these results suggest that TgDrpC is required for rhoptry 
organelle biogenesis and for trafficking of GRA7 vesicles for secretion into the PV. 
 
Figure 32: Loss of TgDrpC does not impair formation of IMC. 
Representative IFAs of TgDrpC-HA-DD parasites maintained in the presence of 200 nM 
Shield-1 (+ Shield-1) or in the absence of Shield-1 (- Shield-1). Cells were fixed for IFA 
analysis 48 hours after the removal of Shield-1, and stained with anti-IMC3 to visualize 
the inner membrane complex (IMC). Parasites grown in the absence of Shield-1 are 
vacuolarized, and display large, intravacuolar membranous blebs (arrowheads). 
However, IMC3 appears to correctly localize to the IMC following removal of Shield-1, 
and is seen at daughter parasites (arrows), indicating that its recruitment during division 
is not impaired by loss of TgDrpC. Scale bar = 3µm. 
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Figure 33: Loss of TgDrpC causes defects in mitochondrion and apicoplast 
organelles associated with TgAtg8 function. 
A) Representative IFAs (left) and quantitation (right) of mitochondrial fragmentation 
observed upon conditional knock-down of TgDrpC. Parasites growth in that absence of 
Shield-1 for 48 hours showed fragmentation of the parasite mitochondrion, as observed 
by staining with an antibody against the mitochondrial matrix protein F1β-ATPase. Scale 
bar = 3µm. B) Representative IFAs of parasites grown in the presence or absence of 
200 nM Shield-1 for 48 hours. Vacuoles containing parasites without apicoplasts or with 
disintegrated apicoplasts (highlighted with dashed line), were observed upon removal of 
Shield-1. Scale bar = 3µm. Quantitation for both A) and B) represent n=3, ± SEM, *** = p 
< 0.0001, one-way ANOVA with Sidak-corrected multiple comparisons. 
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Figure 34: Loss of TgDrpC results in disruption of the Golgi apparatus. 
A) Representative IFA of TgDrpC-HA-DD parasites grown in the presence or absence of 
200 nM Shield-1 for 48 hours. In the absence of Shield-1, vacuoles contained parasites 
with disrupted Golgi, as visualized with staining for TgSORTLR (green). Quantitation 
represents n=3, ± SEM, * = p < 0.05, one-way ANOVA with Sidak-corrected multiple 
comparisons. B) Representative IFA of parasites treated for 2 hours with DMSO (control) 
or 5 µg/mL Brefeldin A, showing the redistribution of TgSORTLR (green) following 
disruption of the Golgi. Scale bar = 3µm 
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Figure 35: Loss of TgDrpC inhibits the formation of rhoptry organelles. 
Representative IFAs of parasites maintained in the presence or absence of 200 nM 
Shield-1 for 48 hours. Staining for the rhoptry protein ROP1 (red) showing that in the 
absence of Shield-1, ROP1 is found to localize to small cytoplasmic vesicles rather than 
fully-formed, mature rhoptries. Scale bar = 3µm. 
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Figure 36: Loss of TgDrpC impairs secretion of the dense granules into the PV. 
Representative IFAs of parasites maintained in the presence or absence of 200 nM 
Shield-1 for 48 hours. Staining for the dense granule protein GRA7 (red) revealed an 
enrichment of GRA7 localization to vesicles in the parasite cytoplasm in the absence of 
Shield-1, suggesting an impairment of dense granule secretion upon loss of TgDrpC. 
Scale bar = 3µm. 
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are homologues of proteins that interact with the mammalian GATE-16 Atg8 family 
protein, which was originally identified for its role in Golgi trafficking. Our analysis of one 
of the identified TgAtg8 interacting proteins, TgDrpC, revealed that this divergent 
dynamin-like protein is essential for parasite viability. Conditional knock-down of TgDrpC 
indicates potential functional roles for TgDrpC in biogenesis of the rhoptry organelles 
and secretion of the dense granules. Additionally, loss of TgDrpC resulted in 
fragmentation of the parasite mitochondrion, disruption of the Golgi and loss of 
apicoplast. As these phenotypes are similar to those seen upon loss of TgAtg8, we 
believe that the interaction between TgAtg8 and TgDrpC may be required for the 
maintenance of these organelles, however the exact mechanism behind these 
phenotypes remains unresolved.   
 
Aim 3: Determine whether TgAtg8 lipidation could be pharmacologically inhibited 
by treatment with recently identified Plasmodium falciparum Atg3-Atg8 interaction 
inhibitors.  
 Recent work characterizing the Plasmodium falciparum Atg3-Atg8 interaction has 
identified a group of small molecule inhibitors that bind to PfAtg8 W- and L-site pockets 
and prevent its association with PfAtg3’s AIM region. Three inhibitor compounds were 
identified from the open-access Medicines for Malaria Venture box of Malaria 
compounds, and were effective against P. falciparum in culture. Importantly, these 
compounds also display activity against numerous other protozoan parasites, leading to 
the proposal that inhibition of parasitic Atg3-Atg8 interactions may be a conserved drug 
target for many protozoan pathogens. We hypothesized that these inhibitors would have 
utility in Toxoplasma as tools to study the function of the autophagy pathway in parasite 
biology and as potential new therapeutics. In our third aim we tested the hypothesis that 
these compounds would inhibit the Atg3-Atg8 interaction in Toxoplasma as they do in 
Plasmodium. In the following sections, we present data showing that although these 
compounds are effective at inhibiting Toxoplasma in vitro, these compounds do not 
prevent the TgAtg3-Atg8 interaction and instead display novel mechanisms of action 
relating to parasite replication and calcium-mediated egress. 
3.13 Virtual docking suggests MMV compounds are unable to bind within 
TgAtg8 W- and L-site pockets 
 To assess whether the three compounds from the Malaria Box identified as 
PfAtg3-Atg8 inhibitors (referred to hereafter as MMVs 1-3, Table 4) have similar effects 
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against Toxoplasma, we first sought to compare the amino acid conservation of the W- 
and L-site residues between PfAtg8 and TgAtg8, as these are the regions of the protein 
targeted by these compounds [162]. Alignment of the PfAtg8 and TgAtg8 amino acid 
sequences showed a high level of conservation (66% identity, 83% similarity). 
Importantly, 17 out of the 19 residues comprising the PfAtg8 W- and L-site binding 
pockets are conserved in TgAtg8 (Figure 37A). This high level of conservation between 
the P. falciparum and Toxoplasma Atg8 suggests that the MMV compounds identified as 
PfAtg3-Atg8 inhibitors may act similarly on TgAtg8.  
 To test this hypothesis, we used the I-TASSER predicted TgAtg8 protein 
structure for in silico docking analyses with MMVs 1-3 (Figure 37B). In parallel, we 
performed docking of all three compounds with the solved PfAtg8 crystal structure to 
confirm that the predictions generated by the docking program used in our studies 
(SwissDock) were in agreement with the previous docking studies that used the 
OpenEye docking program [162]. Interestingly, while all three compounds were 
predicted to bind within the W- and L-site pockets in PfAtg8, only MMV1 was predicted 
to bind to this region in TgAtg8. Further, no binding sites involving the TgAtg8 W- and L-
site pockets were found for MMV2 and 3 (Figure 37B) even though our docking studies 
successfully reproduced the previously reported binding predictions for these two 
compounds in PfAtg8. Together, these results suggest that the ability of the PfAtg3-Atg8 
inhibitors to bind within the TgAtg8 W- and L-site pockets may not be conserved, despite 
high levels of similarity between PfAtg8 and TgAtg8 in both amino acid sequence and 
predicted protein structure. 
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Table 4: Effects of Plasmodium falciparum Atg3-Atg8 inhibitors on protozoan 
pathogens 
 
 
Toxoplasma gondii
Plasmodium falciparum
Blood Stage, EC50 
Gametocytes, EC50
Leishmania
Trypanosoma
T. brucei rhodesiense, EC50
T. cruzi, EC50
Cryptosporidium parvum, EC50
L. infantum, EC50
L. donovani (axenic), 
% Inhibition at 5 µM
CHEMBLE ID
MMV Number
Compound
TABLE 1 Reported activity of PfAtg3-Atg8 inhibitors against protozoan pathogens
TS-4, EC50
RhΔhx, EC50
Plasmodium berghei
Liver Stage
% Inhibition at 5 µM
T. brucei brucei, EC50 
MMV1
CHEMBL470514
MMV007907
597 nM
82-2374 nM
>30 µM
231-2678 nM
91%
N/A
14814 nM
13423 nM
281 nM
5384 nM
98%
MMV2
CHEMBL591637
MMV001246
203 nM
1206-4375 nM
>30 µM
781-4651 nM
97%
1780 nM
272 nM
931 nM
250 nM
336 nM
96%
MMV3
CHEMBL591362
MMV665909
275 nM
1360-3741 nM
>30 µM
2019 nM
95%
3470 nM
376 nM
1037 nM
260 nM
1587 nM
85%
Reference
Van Voorhis et al., 2016
This publication
Boyom et al., 2014
Kaiser et al., 2015
Babesia
B. bovis, EC50 
B. bigemina, EC50
B. caballi, EC50
15190 nM
12900 nM
5620 nM
6600 nM
680 nM
3350 nM
4600 nM
1000 nM
1000 nM
Neospora caninum
% Inhibition at 1 µM
N/A >50% >50%
T S MER LR Van Voorhis et al., 2016T S MER LR T S MER LRLife Cycle Stages
a
Inhibition at 10µM 
No effect
NH
N
S
N
S
O NH
NS
N
Br
O NH
NS
N
Structure
ZINC190251 ZINC06823436 ZINC12547067ZINC ID
a ER, early ring, LR, late ring, T, trophozoite, S, schizont, M, merozoite
Van Voorhis et al., 2016
Van Voorhis et al., 2016
Van Voorhis et al., 2016
Van Voorhis et al., 2016
Van Voorhis et al., 2016
Van Voorhis et al., 2016
Kaiser et al., 2015
Kaiser et al., 2015
Kaiser et al., 2015
Duffy and Avery, 2013,
Van Voorhis et al., 2016
 Lucantoni et al., 2016,
Van Voorhis et al., 2016
  90 
 
Figure 37: P. falciparum Atg3-Atg8 inhibitors are not predicted to bind to TgAtg8 
despite conservation of residues comprising the W- and L-site pockets. 
A) Comparative analysis of the PfAtg8 and TgAtg8 amino acid sequences, highlighting 
the conservation of residues in the W-site (blue) L-site (red), and apicomplexan-specific 
loop (yellow). Two residues (F48/L49) contributing to both W- and L-sites are highlighted 
in purple. Numbers below sequence alignments indicate number of conserved residues 
in each region. B) The TgAtg8 protein structure was predicted using the I-TASSER 
server and was used for in silico docking studies for MMVs 1-3. Insets illustrate 
predicted binding sites for each of the MMV compounds. The residues located in the W- 
and L-site binding pockets, as well as the apicomplexan loop, are highlighted on the 
protein surface using the coloring scheme as described above. 
 
3.14 Plasmodium Atg8-Atg3 inhibitors impair Toxoplasma replication in vitro 
 Despite these potential differences in binding, we next sought to determine 
whether MMVs 1-3 inhibited Toxoplasma growth. Parasites were inoculated onto HFF 
monolayers and allowed to replicate for five days in the presence of either 10 µM drug or 
DMSO vehicle. Treatment with all three MMVs showed a significant reduction in the area 
of host cell lysis, suggesting that Toxoplasma progression through the lytic cycle was 
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impaired by drug treatment (Figure 38A).  This growth inhibition was further confirmed 
using an established colorimetric assay [190] that utilizes a Toxoplasma strain stably 
expressing the E. coli β-galactosidase enzyme to generate quantitative inhibition curves 
for MMVs 1-3 (Figure 38B). All three compounds exhibited sub-micromolar EC50 values, 
in agreement with the range of EC50 values reported for these compounds in P. 
falciparum and other protozoan parasites (Table 4) [237–241]. Together, our results 
show that all three PfAtg3-Atg8 interaction inhibitors are active against Toxoplasma in a 
dose-dependent manner, despite not being identified in a previous screen of the Malaria 
Box compounds against Toxoplasma [237]. 
 
Figure 38: PfAtg3-Atg8 inhibitors block Toxoplasma growth in vitro. 
A) Representative plaque assay showing impaired parasite growth over a five-day period 
in the presence of MMV compounds at 10 µM, as compared to DMSO vehicle treated 
controls. B) Growth inhibition curves were generated to determine of EC50 
concentrations for each of the three MMV compounds. Parasites expressing β-
galactosidase were cultured in the presence of drug or DMSO for 4 days. Parasite 
growth was assessed by colorimetric assay following a 24-hour incubation with the β-
galactosidase substrate CPRG. Percent inhibition was calculated by normalizing to 
uninfected HFFs (100% inhibition) and DMSO vehicle treated infected wells (0% 
inhibition). Curves represent the average of three independent experiments, and are 
plotted with error bars representing ± standard error of the mean (SEM). EC50 values 
were calculated by non-linear regression using Prism and are included for each 
compound below their respective curves. C) Treatment with MMVs 1-3 showed a 
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concentration-dependent decrease in the number of parasites per vacuole after 24 hours 
of treatment as compared to DMSO vehicle treated controls (n=3, ± SEM). 
 
3.15 Effects of MMV1-3 on Atg8-related organelles 
 Having identified that the MMV compounds could effectively inhibit Toxoplasma 
growth, we next sought to assess whether this inhibition was associated with their 
reported mechanism of action in inhibiting PfAtg3-Atg8 interaction and thus preventing 
Atg8 lipidation. Genetic manipulation of TgAtg8 lipidation by conditional knock-down of 
TgAtg3 [94] and TgAtg4 [104] resulted in defects in the maintenance of the 
mitochondrion and apicoplast organelles. We therefore hypothesized that treatment with 
the MMV compounds might similarly effect these organelles. Interestingly, while 
conducting these assays, we noted that treatment with MMV1 at concentrations greater 
than 1 µM caused parasite egress from the host cell. This effect was unique to MMV1, 
as MMV2 and MMV3 did not induce egress at any concentrations tested. Therefore, in 
the case of MMV1, our characterization of the effects of drug treatment on the 
mitochondrion and apicoplast was limited to concentrations below 1 µM. 
 Treatment with MMV1 at concentrations that did not induce parasite egress had 
no effect on apicoplast division or mitochondrial integrity (Figure 39 and Figure 40). 
However, upon treating intracellular parasites with 10 µM MMV2 and MMV3, we 
observed significant mitochondrial fragmentation within the first 6 hours of treatment 
(MMV2 = 65.0±13.0%, MMV3 = 84.7±8.2%, SEM, n=3), with nearly all vacuoles 
containing parasites with fragmented mitochondria after 24 hours of treatment (MMV2 = 
94.4±3.2%, MMV3 = 97.7±0.7%, SEM, n=3) (Figure 39). Unlike the mitochondrion, the 
apicoplast remained intact under all treatment conditions, although defects in positioning 
and segregation of this organelle into dividing parasites were frequently observed 
(Figure 40, arrowheads). 
 As MMV2 and MMV3 were found to inhibit Toxoplasma growth with sub-
micromolar EC50 values, we next assessed whether mitochondrial fragmentation also 
occurred at lower concentrations of drug treatment. Interestingly, no alterations in 
mitochondrial morphology were observed in parasites treated with 1 µM MMV2 or MMV3 
(Figure 41), a concentration at which both compounds significantly inhibit parasite 
growth (Figure 38B). Additionally, whereas the effects of monensin treatment and 
starvation on mitochondrial fragmentation were prevented by co-treatment with the 
autophagy inhibitor 3-methyladenine (3-MA) [93,154], no such protection was observed 
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upon co-treatment of MMV2 or MMV3 with 3-MA (Figure 41). These results suggest that 
the inhibition of parasite growth by MMV2 and MMV3 is independent of their ability to 
induce mitochondrial fragmentation at higher concentrations. 
 
Figure 39: Treatment with MMV2 and MMV3 causes fragmentation of the parasite 
mitochondrion. 
A) Representative IFA images following 6 and 24 hours of treatment with DMSO vehicle 
or MMVs, stained for F1β-ATPase (red) to visualize the mitochondrion. B) IFAs of DMSO 
or MMV treated parasites stained for ATrx1 (red) to visualize the apicoplast and DAPI 
(blue). The apicoplast remains intact during MMV treatment, however organelle-
positioning defects are observed at 24 hours (arrowheads), likely due to the observed 
defects in cytokinesis. Scale bar = 3µm. 
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Figure 40: MMV treatment does not result in loss of apicoplast. 
Representative IFAs of DMSO or MMV treated parasites stained for ATrx1 (red) to 
visualize the apicoplast and DAPI (blue). The apicoplast remains intact during MMV 
treatment, however organelle-positioning defects are observed at 24 hours 
(arrowheads), likely due to the observed defects in cytokinesis. 
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Figure 41: Mitochondrial fragmentation caused by MMV2 and MMV3 not protected 
by autophagy inhibitor 3-MA. 
Representative IFA images of parasites treated with DMSO, 10 mM 3-MA, or MMV2-3 
for 24 hours, stained for the mitochondrial matrix protein F1β-ATPase (red) and DAPI 
(blue). Mitochondrial fragmentation was observed with 5 and 10 µM treatment, and was 
not protected by co-treatment with 3-MA. Scale bar = 3µm. 
 
3.16 MMV1-3 do not prevent Atg8 lipidation 
 To further characterize the effects of MMV treatment on the autophagy pathway 
in Toxoplasma, we next sought to directly assess how these compounds altered TgAtg8 
lipidation status. In yeast and mammalian systems, Atg8 lipidation is routinely monitored 
by visualization of a GFP-Atg8 fusion protein, which relocalizes to cytosolic punctae 
representing autophagosomes following autophagy induction [242]. A similar approach 
has been used to monitor the induction of TgAtg8 lipidation in Toxoplasma in response 
to drug treatment and starvation [94,154]. However, TgAtg8 also localizes to the outer 
membrane of the apicoplast in a lipidation-dependent manner [104] . Given the predicted 
function of MMV1-3 as Atg3-Atg8 interaction inhibitors, we hypothesized that treatment 
of intracellular parasites with MMV1-3 would result in a loss of TgAtg8 localization to the 
apicoplast, as was observed in TgAtg8 mutants lacking the C-terminal glycine required 
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for lipidation [104]. However, we experienced difficulties in testing this hypothesis due to 
the high levels of GFP-TgAtg8 present in the cytosol as the result of its overexpression 
[94]. Thus, to facilitate the monitoring of TgAtg8 lipidation and localization in response to 
intracellular MMV treatment, we utilized the endogenously tagged cMyc-TgAtg8 
parasites described in Section 3.4 (Figure 12). 
 We hypothesized that treatment with the MMV compounds would result in a shift 
in TgAtg8 localization from the apicoplast to the cytosol. However, following 6 and 24 
hours of treatment with all three MMVs tested, TgAtg8 retained its punctate staining 
pattern and remained predominantly localized to the apicoplast (Figure 42A). Further, 
immunoblotting revealed that rather than inhibiting TgAtg8 lipidation, treatment with 10 
µM MMV2 and MMV3 for 6 hours resulted in an increase in the lipidated form of TgAtg8, 
similar to the effects of autophagy induction by starvation and monensin treatment on 
endogenous TgAtg8 (Figure 42B). 
 As before, the induction of egress by MMV1 treatment limited the concentrations 
of this compound that we were able to assess to concentrations well below those 
reported to effect Atg8 lipidation in Plasmodium falciparum [162]. Therefore, we could 
not determine whether MMV1 could block TgAtg8 lipidation in intracellular parasites. To 
overcome this limitation, we used established methods to monitor GFP-TgAtg8 lipidation 
following induction of autophagy by extracellular starvation and tested whether MMV1 
could prevent the lipidation-dependent relocalization from the cytosol to punctate 
structures [94]. As shown in Figure 42C, no reduction of GFP-TgAtg8 punctae formation 
was observed by co-treatment with either 1 or 10 µM MMV1. Together, these findings 
show that the MMV compounds do not inhibit Atg8 lipidation in Toxoplasma and are 
unlikely to act as TgAtg3-TgAtg8 interaction inhibitors as reported for Plasmodium. 
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Figure 42: Treatment with MMVs does not alter Atg8 localization at the apicoplast 
or prevent Atg8 lipidation. 
A) Representative IFAs of cMyc-TgAtg8 parasites after 6 and 24 hours of treatment with 
DMSO or MMVs, stained with DAPI (blue) and for cMyc (red). cMyc-TgAtg8 retains its 
apicoplast localization following MMV treatment. Scale bar = 3µm. B) Representative 
immunoblots of lysates from cMyc-Atg8 parasites treated for 6 hours with DMSO or 
MMVs. Treatment with 10 µM MMV2 and MMV3 increased the ratio of lipidated TgAtg8 
(Atg8-PE) to unlipidated TgAtg8 (Atg8). No change in lipidation state was observed by 
treatment with 500 nM MMV1. The increased levels of Atg8-PE were similar to the 
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Figure 5: Treat ent ith Vs does not alter Atg8 localization at the apico-
plast or prevent Atg8 lipidation. A) Representative IFAs of cMyc-TgAtg8 parasites 
after 6 and 24 hours of treatment with DMSO or MMVs, stained with DAPI (blue) and 
for cMyc (red). cMyc-TgAtg8 retains its apicoplast localization following MMV treat-
ment. Scale bar = 3µm. B) Representative immunoblots of lysates from cMyc-Atg8 
parasites treated for 6 hours with DMSO or MMVs. Treatment with 10 μM MMV2 and 
MMV3 increased the ratio of lipidated TgAtg8 (Atg8-PE) to unlipidated TgAtg8 
(Atg8). No change in lipidation state was observed by treatment with 500 nM MMV1. 
The increased levels of Atg8-PE were similar to the increase in endogenous TgAtg8 
lipidation in RHΔhxgprt parasites starved extracellularly (HBSS) or treated with 1 
ng/mL monensin for 6 hours, as compared to DMSO treated controls. Blots were 
probed with anti-cMyc or anti-TgAtg8, and with anti-SAG1 as a loading control. C) 
Representative IFA images of GFP-Atg8 parasites before (Control) or after 8 hours 
of extracellular starvation in HBSS. Co-treatment with MMV1 failed to reduce the 
number of parasites with GFP-Atg8 punctae, *** = p<0.001, + SEM. Scale bar = 
3µm.
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increase in endogenous TgAtg8 lipidation in RHΔhxgprt parasites starved extracellularly 
(HBSS) or treated with 1 ng/mL monensin for 6 hours, as compared to DMSO treated 
controls. Blots were probed with anti-cMyc or anti-TgAtg8, and with anti-SAG1 as a 
loading control. C) Representative IFA images of GFP-Atg8 parasites before (Control) or 
after 8 hours of extracellular starvation in HBSS. Co-treatment with MMV1 failed to 
reduce the number of parasites with GFP-Atg8 punctae, *** = p<0.001, + SEM. Scale 
bar = 3µm. 
 
3.17 MMV2 and MMV3 inhibit Toxoplasma cytokinesis 
 Our initial characterization of MMV1-3 showed that they blocked parasite growth, 
as shown by the decreased area of lysis of the host cell monolayer. However, a 
reduction in the area of host cell lysis can be attributed to impairment of one or more 
steps of the Toxoplasma lytic cycle, including parasite replication, egress, and host cell 
invasion [39]. We therefore sought to determine which step or steps of this cycle were 
affected by treatment with MMV1-3.  
 All three compounds were first assessed for their effects on parasite replication 
by quantifying the number of rounds of parasite replication during 24 hours of drug 
treatment. Despite the effects of MMV1 on parasite egress, we did observe a 
concentration-dependent delay in parasite growth at concentrations that did not induce 
egress (Figure 43A). Additionally, treatment with MMV2 or MMV3 at 2.5 µM completely 
blocked parasite replication, as all vacuoles contained two or fewer parasites after 24 
hours of treatment while ~50% of DMSO vehicle treated vacuoles contained 8 or more 
parasites (Figure 43A). 
  While characterizing the effects of the MMV compounds on parasite replication 
we observed that parasites treated with 2.5 µM or higher concentrations of MMV2 and 
MMV3 exhibited an abnormal, rounded morphology with a loss of uniform parasite size 
and shape (Figure 43 A-B). Immunofluorescence staining with DAPI to visualize the 
parasite nuclei revealed that parasites within these abnormal vacuoles appeared to have 
nuclei that had duplicated but failed to properly divide. Together, these changes 
suggested that parasite cytokinesis may be impaired by treatment with MMV2 and 
MMV3, as the phenotypes are similar to those observed in parasites with defects in the 
late stages of cell division [200,243].  
 Quantification of abnormal vacuoles showed that approximately 40% of vacuoles 
displayed these morphological abnormalities, and the percentage of abnormal vacuoles 
did not increase between 6 and 24 hours of treatment. These replication defects were 
further characterized by staining with an antibody against the protein inner membrane 
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complex 3 (IMC3), a component of the parasite cytoskeleton that together with the 
plasma membrane comprises the parasite pellicle [244]. While the nuclei in DMSO-
treated parasites appeared uniform in size and shape, and were correctly segregated 
into a single IMC3-stained pellicle, parasites treated with MMV2 and MMV3 contained 
duplicated nuclei surrounded by a single cytoskeleton, as well as IMC3 structures 
containing no nucleus or apicoplast (Figure 44). Together, these results suggest that the 
growth inhibitory effects of MMV2 and MMV3 are a result of a rapid block of Toxoplasma 
replication involving disruption of cell division due to impaired daughter bud formation 
and nuclear division. 
 
 
Figure 43: MMV2 and MMV3 block Toxoplasma replication and impair division. 
A) Treatment with MMVs 1-3 showed a concentration-dependent decrease in the 
number of parasites per vacuole after 24 hours of treatment as compared to DMSO 
vehicle treated controls (n=3, + SEM). B) IFAs of parasites treated with 10 µM MMV2 
and MMV3 for 6 hours showing representative images of normal vacuoles (DMSO) and 
abnormal vacuoles observed with MMV2 and MMV3 treatment. Visualization of the 
nuclei by staining with DAPI revealed that MMV2 and MMV3 treated parasites contained 
distorted parasites with apparent defects in nuclear division. The percentage of 
abnormal vacuoles does not increase between 6 and 24 hours of treatment, n=3, + 
SEM. Scale bar = 3µm. 
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Figure 6: MMV2 and MMV3 block Toxoplasma replication and impair cytokinesis. 
A) Treatment with MMVs 1-3 showed a concentration-dependent decrease in the 
number of parasites per vacuole after 24 hours of treatment as compared to DMSO 
vehicle treated controls (n=3, + SEM). B) IFAs of parasites treated with 10 µM MMV2 
and MMV3 for 6 hours showing representative images of normal vacuoles (DMSO) 
and abnormal vacuoles observed with MMV2 and MMV3 treatment. Visualization of 
the nuclei by staining with DAPI revealed that MMV2 and MMV3 treated parasites 
contained distorted parasites with apparent defects in nuclear division. The percentage 
of abnormal vacuoles does not increase between 6 and 24 hours of treatment, n=3, + 
SEM. C) Representative IFAs of normal (DMSO) and abnormal vacuoles (MMV2/3) 
stained for IMC3 (red), to visualized the inner membrane complex of daughter cells, 
and DAPI (blue). MMV treated parasites display nuclei that are not surrounded by an 
IMC3-positive cytoskeleton, and IMC3 structures that do not contain nuclei or apico-
plasts as observed by DAPI staining. Scale bar = 3µm.
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Figure 44: MMV2 and MMV3 impair cytokinesis. 
Representative IFAs of normal (DMSO) and abnormal vacuoles (MMV2/3) stained for 
IMC3 (red), to visualized the inner membrane complex of daughter cells, and DAPI 
(blue). MMV treated parasites display nuclei that are not surrounded by an IMC3-positive 
cytoskeleton, and IMC3 structures that do not contain nuclei or apicoplasts as observed 
by DAPI staining. Scale bar = 3µm. 
 
3.18 Assessing the role of calcium in MMV1 induced egress 
 We next sought to characterize the mechanism by which MMV1 induced parasite 
egress from the host cells. The induction of egress by MMV1 followed similar kinetics as 
those observed upon treatment with 1 µM calcium ionophore A23187, which induces 
nearly 100% egress within 2 minutes (Figure 45A). To quantitatively assess MMV1-
induced egress we utilized an established assay to measure the release of lactate 
dehydrogenase caused by lysis of the host cells upon parasite egress [173]. The 
induction of egress by MMV1 was concentration dependent, with an egress EC50 of 
~1150 nM (Figure 45B).   
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Figure 6: MMV2 and MMV3 block Toxoplasma replication and impair cytokinesis. 
A) Treatment with MMVs 1-3 showed a conc ntration-dependent decrease in the 
number of parasites per vacuole after 24 hours of treatment as compared to DMSO 
vehicle treated controls (n=3, + SEM). B) IFAs of parasites treated with 10 µM MMV2 
and MMV3 for 6 hours showing representative images of normal vacuoles (DMSO) 
and abnormal vacuoles observed with MMV2 and MMV3 treatment. Visualization of 
the nuclei by staining with DAPI revealed that MMV2 and MMV3 treated parasites 
contained distorted parasites with apparent defects in nuclear division. The percentage 
of abnormal vacuoles doe  not increase betw en 6 and 24 hours of treatment, n=3, + 
SEM. C) Representative IFAs of normal (DMSO) and abnormal vacuoles (MMV2/3) 
stained for IMC3 (red), to visualized the inner membrane complex of daughter cells, 
and DAPI (blue). MMV treated parasites display nuclei that are not surrounded by an 
IMC3-positive cytoskeleton, and IMC3 structures that do not contain nuclei or apico-
plasts as observed by DAPI staining. Scale bar = 3µm.
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 We next examined whether MMV1 induces egress by a similar mechanism as 
calcium ionophores, which depends on the calcium dependent protein kinase TgCDPK3 
[245,246]. Interestingly, MMV1 failed to induce egress in parasites lacking TgCDPK3 
(Figure 45C), indicating that MMV1 induces egress by a similar mechanism as calcium 
ionophores. We therefore hypothesized that treatment of extracellular parasites with 
MMV1 would result in the release of intracellular calcium as has been shown for 
ionophores [247]. To test this, freshly egressed parasites were loaded with the calcium 
indicator dye Fluo-4 AM and the fluorescence intensities were monitored prior to and 
immediately following treatment with MMV1, A23187, or DMSO vehicle. Treatment with 
MMV1 resulted in increased Fluo-4 AM fluorescence, with similar kinetics and peak 
intensities as treatment with A23187 (Figure 45D). Treatment with the cell-permeant 
calcium chelator BAPTA-AM completely blocked the increase in Fluo-4 AM fluorescence 
in response to MMV1 treatment (Figure 45E). Lastly, we assessed whether prolonged 
treatment with MMV1 recapitulates the loss of parasite viability observed with 
extracellular ionophore treatment, termed ionophore-induced death [248]. Indeed, 
treatment of extracellular parasites with MMV1 for 2 hours dramatically reduced parasite 
viability as illustrated by the reduction in growth compared to DMSO controls, as 
measured by plaque assay (Figure 45F). Together, our results suggest that MMV1-
induced egress involves the release of calcium from intracellular stores and activation of 
calcium-mediated signaling pathways that have previously been implicated in parasite 
egress. 
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Figure 45: MMV1 induces parasite egress by increasing intracellular calcium 
levels. 
A) Infected HFF monolayers were treated for two minutes with 10 µM MMVs, DMSO 
vehicle, or 1 µM calcium ionophore A23187. The percentage of egressed vacuoles was 
calculated by scoring at least 100 vacuoles as intracellular or egressed (n=3, + SEM). B) 
Induction of egress by MMV1 was quantitatively assessed to determine an egress EC50 
value by measuring the amount of lactate dehydrogenase (LDH) released from the host 
cells upon parasite egress. Percent egress was normalized to DMSO treated (0%) and 
10 µM MMV1 (100%) treated wells, n=3, + SEM. C) Parasites lacking the calcium 
dependent protein kinase TgCDPK3 fail to egress following two-minute treatment with 
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MMV1, n=3, + SEM, *** = p <0.0001. D) Kinetic traces of Fluo-4 AM fluorescence 
(relative fluorescence units, RFU) in response to A23187 or MMV1. Extracellular 
parasites were loaded with the calcium indicator dye Fluor-4 AM to measure changes in 
intracellular calcium concentrations following drug treatment. Baseline fluorescence was 
measured for 60 s, at which time compounds were injected into the wells (shown by 
arrow). Traces represent the average of three technical replicates with the shaded area 
representing the standard error of the mean. E) Change in fluorescence intensity 
between the final baseline RFU measurement (60 s) and the first measurement following 
injection of compounds (67 s). Parasites treated with the calcium chelator BAPTA-AM 
show no change in intracellular calcium levels following treatment with MMV1, n=3, + 
SEM.  F) Representative plaque assay used to assess parasite viability following 
treatment of extracellular parasites for 2 hours with DMSO or MMV1. Control parasites 
were added to HFF monolayer immediately following manual release from host cells and 
prior to 2-hour treatment. 
 
Summary Aim 3: 
 In our third aim we explored the conservation of activity and mechanism of action 
for three small molecules recently identified as Atg3-Atg8 interaction inhibitors in 
Plasmodium falciparum. Our results showed that all three compounds were active 
against Toxoplasma at sub-micromolar concentrations, despite not being identified in a 
high-throughput screen of MMV compounds against Toxoplasma. Two of these 
compounds blocked parasite replication by disrupting cytokinesis, and were found to 
induce mitochondrial fragmentation and TgAtg8 lipidation at high concentrations. The 
third compound was found to stimulate parasite egress from the host cells in a calcium-
signaling dependent manner. Additionally, none of the three compounds appeared to 
prevent the lipidation of TgAtg8 or its localization to the apicoplast. Together, these 
results show a lack of conservation for the mechanism of action for these three 
compounds between Plasmodium and Toxoplasma. Further, our studies provide 
important groundwork characterizing the effects of these compounds on Toxoplasma 
biology, and identified novel activities for these compounds in replication and egress. 
Further studies identifying specific drug targets for each of the compounds will be 
required and will inform the assessment of their potential for further optimization and 
development as novel broad-spectrum antiparasitics.  
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Chapter 4: Discussion 
Aim 1: Determine the functional consequences of TgAtg8 lysine-23 acetylation on 
the TgAtg3-TgAtg8 interaction 
 In our first aim, we examined the effects of TgAtg8 K23 acetylation on TgAtg3-
Atg8 interaction, TgAtg8 localization and function, and parasite fitness. As acetylation of 
mammalian Atg8 protein LC3B has recently been shown to regulate its localization and 
function, we hypothesized that K23 acetylation may act in a similar fashion to regulate 
TgAtg8 function. Structural modeling of the TgAtg8 protein revealed that this lysine 
residue localized to the second N-terminal alpha-helix, which is involved in coordinating 
interactions with proteins and membranes for Atg8 proteins in higher eukaryotes. 
Additionally, this residue was adjacent to the W- and L-site binding pockets that facilitate 
interactions between Atg8 proteins and interactors that contain the conserved WXXL 
Atg8 Interacting Motif (Figure 7). Based on these findings, we hypothesized that K23 
acetylation regulates the interaction between TgAtg8 and AIM containing proteins. We 
chose to test this hypothesis by examining the interaction between TgAtg8 and TgAtg3, 
which was, at the time, the only putative AIM-containing protein that had been proposed 
in Toxoplasma. 
 To address this hypothesis, we developed numerous parasite strains and 
reagents to utilize genetic, biochemical, and biophysical techniques to assess the effects 
of K23 acetylation on TgAtg8 function. We first attempted to ectopically express GFP-
TgAtg8 K23 mutant proteins containing amino acid substitutions routinely used to mimic 
lysine in its acetylated (K23Q) or non-acetylated (K23R) state. We hypothesized that if 
K23 acetylation was important for TgAtg8 function, overexpression of these mutant GFP 
fusion proteins may act in a dominant-negative manner by competing with endogenous 
TgAtg8 for interaction with components of the Atg8 conjugation system. However, 
parasites expressing GFP-TgAtg8 K23 mutant proteins did not display any defects in 
parasite replication or fitness (Figure 8). It is important to note that ectopic expression of 
a lipidation-deficient GFP-TgAtg8G124A mutant is equally well tolerated by the parasite 
[94]. This may indicate that the GFP-TgAtg8 fusion protein is not capable of interacting 
with the same set of proteins as the endogenous TgAtg8 protein and is thus unable to 
act in a dominant-negative fashion. Although GFP-Atg8 fusion proteins are routinely 
used to monitor autophagy in many systems and are capable of being lipidated, it is 
possible that the addition of a 27 kD GFP tag to the 15 kD TgAtg8 protein could prevent 
a subset of protein-protein interactions from occurring. Future studies comparing the 
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interactomes of GFP-TgAtg8 and cMyc-TgAtg8 proteins may reveal differences that 
explain the lack of phenotype in these mutants. 
 While examining the localization for each of these GFP-TgAtg8 fusion proteins, 
we discovered that in addition to its localization at the apicoplast, GFP-TgAtg8 localizes 
to the daughter parasite pellicle during cell division (Figure 9). GPF-TgAtg8 was 
observed at daughter buds early during mitosis and remained associated with the 
pellicle through the completion of cytokinesis. In higher eukaryotes, the N-terminal 
alpha-helices of Atg8 proteins facilitate their direct interactions with membranes and 
microtubules [112]. The localization of TgAtg8 to the daughter buds could therefore be 
the result of its interaction with the membrane of the IMC or with the subpellicular 
microtubules. However, the subpellicular microtubules only extend along the apical two-
thirds of the parasite [10], and we observe GFP-TgAtg8 localization along the entire 
length of the parasite. This suggests that localization of GFP-TgAtg8 to the daughter 
buds is not due to interactions with the microtubules. Interestingly, the results of our 
TgAtg8 interactome studies revealed a potential role for TgAtg8 in vesicle trafficking 
through the Golgi (Figure 22). As the IMC is thought to be derived from the Golgi/ER, it 
is possible that TgAtg8 is present on vesicles trafficked from the Golgi to the nascent 
daughter IMC. In this capacity, TgAtg8 could be used to direct specific proteins to the 
IMC by recruiting cargo proteins to the appropriate vesicles. Alternatively, TgAtg8 could 
be used to facilitate the homotypic fusion events required to expand the membrane of 
the IMC during daughter parasite growth. Further studies are required to determine the 
functional significance of this novel localization for TgAtg8, and may provide insight into 
the proteins localized at the IMC and their route of delivery to this organelle during 
division. However, this novel localization was observed in all K23 mutants, suggesting 
that the association with the pellicle is not dependent on the K23 acetylation status. 
 Although we encountered difficulties in directly assessing the effects of K23 
mutations on TgAtg8 protein lipidation in the parasite, we were able to determine that 
ablation of K23 acetylation by endogenous mutation of K23 to arginine did not prevent 
lipidation or localization to the apicoplast (Figure 13). As lipidation of TgAtg8 requires its 
interaction with components of the Atg8 conjugation system, this suggests that K23 
acetylation is not required for interaction with TgAtg7 or TgAtg3. To confirm these 
results, we used a complementary approach to assess the ability of K23 mutant proteins 
to bind with a peptide containing the putative Atg3 AIM motif (Figure 18). Our results 
suggest that K23 acetylation status is unlikely to significantly alter the interaction 
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between TgAtg8 and TgAtg3, as all mutants were able to similarly bind to the TgAtg3 
AIM peptide. Additionally, assessment of the TgAtg3-Atg8 by co-immunoprecipitation 
from a dual-tagged parasite strain further confirmed that acetylation of K23 is not 
required for this interaction to occur (Figure 20). Together, these results suggest that 
any potential effect of K23 acetylation on TgAtg8 function is unlikely to be related to 
regulating its interaction with components of the Atg8 conjugation system. 
 Our studies using ectopic and endogenous K23 mutant proteins revealed two 
potential phenotypes associated with K23 acetylation. First, we observed that ectopically 
expressed K23Q mutant proteins from multiple, independently generated parasite strains 
had higher protein levels compared to K23K controls, as measured by immunoblotting 
(Figure 8). Additionally, both ectopic and endogenous K23R mutant proteins appeared 
to have slightly lower protein levels as compared to K23K controls (Figure 13). We 
hypothesized that this may indicate a role of K23 acetylation in promoting TgAtg8 protein 
stability. Our thermal shift assays suggested a minor effect of both K23Q and K23R 
mutations on TgAtg8 protein thermal stability that followed the trends observed at the 
protein level (Figure 19). However, the shift in thermal stability was small compared to 
other reports of mutations shown to alter protein stability [212], and therefore the 
biological significance of the observed thermal stability effects are likely minimal. This 
suggests that any stabilizing effects of K23 acetylation are not directly due to increased 
intrinsic protein stabilization. 
 In addition to directly stabilizing proteins, acetylation can promote protein stability 
by protecting lysine residues from ubiquitination and subsequent degradation 
[197,201,249]. Although TgAtg8 was found to be ubiquitinated at two lysine residues in a 
global assessment of ubiquitination in Toxoplasma, K23 was not identified in this study 
[250]. In contrast, the analogous lysine in HsGABARAPL2/GATE-16 (K24) that was 
reported to be acetylated is also ubiquitinylated [194,251,252]. It is possible that 
although it wasn’t detected in the global assessment of ubiquitination in Toxoplasma, 
TgAtg8 K23 may also be the target of ubiquitinylation, and acetylation of K23 protects 
TgAtg8 from being targeted for degradation by the proteasome. However, protection 
from ubiquitination is unlikely to be the major reason behind the observed stabilizing 
effect in K23Q mutants, as mutation to arginine (K23R) would similarly protect against 
ubiquitnation, and yet we do not observe the same increase in protein levels with the 
K23 mutation. Together, these results led us to hypothesize that the differences in 
stability observed in K23 mutants may be due to altered protein-protein interactions.  
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 The second and more significant phenotype that we observed in our K23 
mutational analyses was the severe impairment of replication and spontaneous 
differentiation to bradyzoite tissue cysts following endogenous mutation of K23 to 
arginine (Figure 15). This phenotype was particularly remarkable given that the mutation 
was introduced into an RH type I backgrounds strain that is generally regarded to have 
lost its ability to form tissue cysts [29], and that the K23R parasites differentiated in the 
absence of exogenous stressors typically required for in vitro differentiation. The 
molecular mechanism behind the observed conversion of K23R parasites to bradyzoites 
remains unclear. Attempts at further studies to address this question were prevented by 
adaptation of these parasites during passage in tissue culture. However, the 
differentiation from tachyzoites to bradyzoites is known to be closely associated with 
progression through the cell cycle [41,253,254]. For example, the conversion of 
tachyzoites to bradyzoites has previously been shown to be preceded by a lengthening 
of the parasite doubling time, followed by upregulation of BAG1 [255]. It is therefore 
possible that the severe slow-growth phenotype we observed in the K23R mutant 
parasites “pre-disposed” these parasites to enter into a differentiation program that is 
cell-cycle regulated. However, other parasite strains generated in our lab that exhibit 
similar slow growth rates do not similarly undergo conversion to bradyzoites. Therefore, 
it is not clear how the K23R mutation promotes the parasites to enter into the 
differentiation process. It is possible that the observed phenotype could be directly 
caused by the K23R mutation. It also could have been the result of an adaptation made 
by the parasite to tolerate the K23R mutation. Given the difficulty in obtaining 
independent K23R mutant clones, confirmation and characterization of this phenotype 
will likely require the use of an inducible system to regulate the expression of the 
endogenous and K23R mutant proteins. Preliminary work has been done to establish 
these reagents and will be discussed in the Future Directions section below.  
Aim 2: Characterize the TgAtg8 interactome to identify novel TgAtg8 interacting 
proteins 
 With our second aim, we sought to expand the current knowledge regarding the 
function of TgAtg8 in parasite biology by performing the first proteomic characterization 
of Atg8 interacting proteins in Toxoplasma. We took advantage of the cMyc-TgAtg8 
endogenously-tagged parasite strain developed in our first aim to immunoprecipitate 
TgAtg8 from parasite lysate for the identification of interacting proteins. In addition to 
identifying homologues of components of the Atg8 conjugation system (TgAtg7), our 
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study revealed a novel role of TgAtg8 in vesicle trafficking through the Golgi (Figure 22). 
Our list of TgAtg8 interacting proteins was enriched for proteins known to specifically 
interact with the GABARAP/GATE-16 family of Atg8 proteins (NSF/Sec18p, 
SNAP/Sec17p), building confidence in the validity of our data set and supporting a role 
of TgAtg8 in GATE-16 like processes.  
 In addition to homologues of NSF and SNAP proteins, we also identified 
parasite-specific “hypothetical proteins” that may represent novel proteins involved in 
Golgi trafficking in Toxoplasma. For example, we identified proteins with predicted 
function as clathrin adaptors (TgGAT, (TGGT1_268430)) and in transport of vesicles 
along microtubules (TgARP, (TGGT1_247300)). Proteins containing the GGA1/GAT 
domain found in TgGAT have structural homology to SNARE proteins and are implicated 
in membrane fusion [218,256]. Additionally, the GAT domain can bind directly to 
ubiquitin. Although an interaction between the GAT domain and Atg8 family proteins has 
not been reported, it is possible that the GAT domain could bind to the ubiquitin-like fold 
present in Atg8 proteins. We also identified a protein with predicted structural homology 
to kinesin-associated protein 3 (KAP3) (TgARP), which further suggests a connection 
between TgAtg8 and vesicle trafficking. KAP3 associates with kinesin motor proteins 
and facilitates the transportation of cargo along microtubules [257]. It is possible that 
TgAtg8-decorated vesicles, representing either autophagosomes or vesicles transiting 
the Golgi network, could interact with KAP3 to direct their movement along microtubules. 
Further studies assessing these proteins are required to determine their function in 
Toxoplasma and to determine the regions responsible for interaction with TgAtg8. 
 In addition to TgGAT and TgARP, we were particularly interested in the dynamin-
like protein TgDrpC, which was the most significantly enriched protein in all three of our 
immunoprecipitations (Figure 22). Characterization of the dynamin-like proteins TgDrpA 
and TgDrpB revealed that these proteins are required for division of the apicoplast and 
biogenesis of the secretory organelles, respectively [223,224]. Given the known role of 
TgAtg8 in apicoplast division, as well as the novel role in Golgi-trafficking identified by 
our interactome studies, we hypothesized that TgDrpC participates with TgAtg8 to 
coordinate either or both of these processes. We therefore sought to characterize this 
novel dynamin-like protein to determine its localization and function in Toxoplasma. 
 Characterization of TgDrpC revealed that it localizes to cytoplasmic punctae in 
interphase tachyzoites. However, TgDrpC undergoes a dramatic relocalization following 
the initiation of daughter parasite formation, where it co-localizes to the MORN1 ring 
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structure at the leading edge of the forming daughter pellicle (Figure 28). The functional 
importance of this localization is unclear. MORN1 localizes to this ring structure where it 
is required for the constriction of the daughter pellicle to facilitate the pinching-off of 
daughter parasites at the completion of cytokinesis [231]. Dynamin and dynamin-like 
proteins are known to oligomerize and form contractile rings, providing GTPase activity 
for membrane fission during endocytosis or during organelle fission [225]. However, the 
oligomerization and stimulation of the GTPase activity typically require interaction 
between the GTPase and GED domains, of which TgDrpC only contains the GTPase 
domain (Figure 26). Therefore, it is unclear whether TgDrpC is capable of performing its 
canonical function in membrane fission, and as such its function at the MORN1 ring 
remains unknown.  
 This data suggests that the relocalization of TgDrpC to the daughter pellicle may 
represent a function in the trafficking of membrane material or proteins to the IMC during 
replication. This was particularly intriguing given our discovery that TgAtg8 also localizes 
to the daughter pellicle during division (Figure 9). However, the loss of TgDrpC following 
conditional knock-down did not appear to alter the formation of the IMC as visualized by 
IFA for IMC3 (Figure 32). Additionally, conditional knock-down of TgDrpC did not result 
in parasites that failed to complete cytokinesis, as was observed upon loss of MORN1 
[231]. Also, whereas TgAtg8 localized to the entire daughter pellicle, TgDrpC 
demonstrated a specific localization at the MORN1 contractile ring. Therefore, while the 
localization of TgDrpC and TgAtg8 to the daughter parasite during division is intriguing, 
further work is required to determine the function each of these proteins has at this 
location. 
 Although no defects in IMC formation or cytokinesis were observed in TgDrpC 
knock-down parasites, we did observe that loss of TgDrpC blocked parasite replication 
and progression through the lytic cycle (Figure 31). Assessment of various organelles 
revealed defects in the formation of rhoptries (Figure 35), disruption of the Golgi (Figure 
34) and fragmentation of the mitochondrion (Figure 33) following loss of TgDrpC. 
Additionally, we observed an increase in vacuoles containing parasites lacking 
apicoplasts. However, we note that the disruption of apicoplast division and biogenesis 
was not as penetrant as was observed following knock-down of TgDrpA, TgAtg8 or 
members of the Atg8 conjugation system [94,103,223]. In addition to these defects, we 
also observed an apparent defect in the secretion of the dense granules, which were 
found to accumulate in cytoplasmic vesicles within the parasites upon loss of TgDrpC 
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(Figure 36). Together, these phenotypes suggest that TgDrpC, and potentially TgAtg8, 
may be required for vesicle trafficking through the Golgi required for secretory organelle 
biogenesis and maturation.  
 A potential role for TgDrpC and/or TgAtg8 in vesicle trafficking related to the 
formation of the secretory organelles is particularly intriguing. Formation of the secretory 
organelles, including the rhoptries, micronemes and dense granules, is dependent on 
the coordinated function of proteins involved in sorting and trafficking of proteins from 
the ER to the appropriate vesicles that ultimately form the mature secretory organelles. 
For example, TgSORTLR contains an N-terminal lumenal domain that directly interacts 
with rhoptry and microneme proteins to recruit them to specific vesicles for transit 
through the Golgi and endosome like compartment [236]. Similarly, the Toxoplasma AP-
1 adaptin complex recognizes specific sequence motifs in rhoptry proteins and facilitates 
their transit from post-Golgi vesicles to mature rhoptries [258]. Disruption of both 
TgSORTLR and AP-1 resulted in accumulation of rhoptry and microneme proteins in 
endosomal compartment and a failure to form mature secretory organelles. Additionally, 
chemical disruption of the Golgi network by Brefeldin A resulted in the inhibition of dense 
granule secretion [235]. Therefore, the defects observed upon TgDrpC, namely the 
disruption of the Golgi network, could explain the downstream defects observed in 
rhoptry biogenesis and dense granule secretion. Additional studies defining which region 
of the Golgi/endosome like compartment TgDrpC and TgAtg8 localize to, as well as 
determining whether conditional knock-down of TgAtg8 also results in similar 
phenotypes, will clarify the function of both of these proteins on Golgi trafficking and 
organelle biogenesis in Toxoplasma. 
 One of the most striking phenotypes we observed following TgDrpC knock-down 
is fragmentation of the single parasite mitochondrion. Dynamin-like proteins are known 
to be involved in mitochondrial fission and division in other species [226–228]. However, 
this activity requires contractile function of dynamin-like proteins. The ability of TgDrpC 
to act in this manner is questionable given the absence of functional domains. Despite 
these missing domains, we do observe occasional localization of TgDrpC near the 
mitochondrion in regions of mitochondrial membrane constriction (Figure 25). It is 
possible that TgDrpC exerts its constrictive force through interactions with other proteins. 
Characterization of TgDrpC interacting proteins may shed light on potential proteins that 
could participate in this function, but remain unknown at this time.  
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 While the identification of proteins involved in Golgi trafficking agreed with known 
functions of Atg8 family proteins, the interaction of TgAtg8 with multiple members of the 
BCKDH complex in of TgAtg8 interactome is not as readily explained. All components of 
the BCKDH complex identified in our study were found to localize to the mitochondrion 
(Figure 24). As in higher eukaryotes, Toxoplasma mitochondrial proteins are 
posttranslationally imported into the mitochondrion through the recognition of a 
conserved, N-terminal targeting sequence [259]. Two of the identified BCKDH complex 
proteins in our interactome contain targeting sequences. Thus, it is unlikely that their 
interaction with TgAtg8 is the result of TgAtg8-mediated trafficking of these proteins to 
the mitochondrion. One possibility is that the identification of these complex members is 
due to their targeted degradation by mitophagy. Mitophagy is known to be induced in 
response to misfolding of proteins in the mitochondrial matrix [260]. The BCKDH is a 
particularly large complex, made up of over 40 subunits with a total size of ~10 million 
Daltons [261] (for comparison, the mammalian ATP synthase complex is ~ 650 kD 
[262]). As a result, the BCKDH complex may be more susceptible to errors in folding or 
complex formation and may be targeted for degradation by mitophagy. If this is the case, 
the mechanism by which these proteins are specifically targeted for degradation, as well 
as the adaptor protein at the outer mitochondrial membrane that interacts with TgAtg8 
(i.e., functional homologue of p62/SQSTM1) to target specific regions of the 
mitochondrion for degradation are of great interest and should be the subject of future 
studies.  
 Another point of interest regarding the BCKDH is the identification of both 
subunits of the mitochondrial trifunctional protein complex (HADHA and HADHB) in 
multiple, independent proteomic studies characterizing Atg8 protein interactions in 
mammalian systems [263,264]. The functional connection between Atg8 proteins and 
HADHA/B in mammalian cells remains poorly characterized, however they have been 
found to co-localize in cytoplasmic punctae following induction of autophagy by 
treatment with palmitic acid [263]. This complex typically localizes to the inner 
mitochondrial membrane and is used for beta-oxidation of long-chain fatty acids to 
generate acetyl-CoA in the mitochondrial matrix [265]. This is similar to the activity of the 
BCKDH identified in our interactome, which catabolizes short-chain alpha-ketoacids and 
pyruvate to generate acetyl-CoA in the mitochondrion [214]. Therefore, there appears to 
be a conserved connection between Atg8 and complexes involved in generation of 
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mitochondrial acetyl-CoA, and this connection deserves further exploration in 
Toxoplasma. 
  In summary, our characterization of the TgAtg8 revealed previously unreported 
functions of TgAtg8 in vesicle trafficking through the Golgi network. Characterization of 
the TgAtg8 interacting protein TgDrpC revealed that this divergent dynamin-like protein 
is essential for Toxoplasma tachyzoite viability. Conditional knock-down revealed that 
loss of TgDrpC impairs the biogenesis and maintenance of numerous organelles, 
including the Golgi apparatus, rhoptries and mitochondrion. Whether the loss of TgAtg8 
results in similar organelle defects remains to be seen and will be the subject of future 
experiments. Additionally, the characterization of TgAtg8 interacting proteins provides a 
reference dataset that can be used in future studies assessing the effects of TgAtg8 
mutations or small molecule inhibitors for the targeted disruption of TgAtg8 protein-
protein interactions.  
 Our interactome data shows that TgAtg8 interacts with a variety of proteins and 
likely has functions in multiple, distinct protein complexes with important roles in 
numerous aspects of Toxoplasma biology. Accordingly, it is possible that disruption of 
TgAtg8 protein interactions by small molecules targeting a single region of TgAtg8 could 
disrupt numerous pathways and processes in the parasite. Whether these interactions 
are facilitated through a common binding site on TgAtg8, such as the W- and L-site 
pockets, remains to be determined and requires further study. 
Aim 3: Determine whether TgAtg8 lipidation could be pharmacologically inhibited 
by treatment with Atg3-Atg8 interaction inhibitors recently identified in 
Plasmodium 
 In our third aim we assessed three inhibitors of the interaction between Atg3 and 
Atg8 in P. falciparum to determine whether they acted in a similar manner in 
Toxoplasma gondii. Our results show that despite high levels of conservation of the 
proposed binding sites for these compounds on TgAtg8, these compounds do not block 
TgAtg8 lipidation. Despite the lack of a conserved mechanism of action, all three 
compounds were found to inhibit Toxoplasma growth in a dose-dependent manner, with 
EC50 values in the sub-micromolar range. We have identified that two of these 
compounds (MMV001246 (MMV2) and MMV665909 (MMV3)) inhibit Toxoplasma 
replication by disrupting daughter bud formation and cytokinesis during parasite 
replication. Additionally, we found that treatment with the third compound (MMV007907 
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(MMV1)) results in the release of calcium from the intracellular stores resulting in 
parasite egress from the host cell. 
 Numerous inhibitors of the PfAtg3-Atg8 interaction have been identified using 
biophysical approaches [107,162,163], however we chose to focus on MMV1-3 for the 
following reasons. First, MMV1 is one of the few PfAtg3-Atg8 inhibitors that has been 
found to alter PfAtg8 lipidation status when parasites were treated in culture [162]. 
Second, all three of the compounds tested herein were identified from the Medicines for 
Malaria Venture Malaria Box, a collection of 200 drug-like and 200 probe-like molecules 
that is available for researchers free of charge. Importantly, MMV1-3 are also active 
against other important human pathogens including Cryptosporidium spp., Babesia spp., 
Trypanosoma spp., and Leishmania spp. (Table 4). Collectively, these pathogens 
represent a significant disease burden in humans, and treatment of these infections is 
threatened by the development of drug resistance to the limited number of therapeutics 
currently available. Therefore, the activity of MMV1-3 against multiple protozoans 
suggested that disruption of the Atg3-Atg8 interaction in these parasites may represent a 
potential avenue for development of novel broad-spectrum antiparasitics. 
 To address the possibility for a conserved mechanism of action for MMV1-3 
outside of Plasmodium, we evaluated these compounds for their ability to similarly 
disrupt the Atg3-Atg8 interaction in the closely related apicomplexan Toxoplasma. We 
hypothesized that the similarity between P. falciparum and Toxoplasma Atg8 proteins 
may allow for the mechanism of action to be conserved between the two species. 
However, our in silico docking experiments suggest that MMV2 and MMV3 are unlikely 
to bind to TgAtg8 in a similar fashion as described in P. falciparum (Figure 37). Although 
the residues that comprise the W- and L-site binding pockets are highly conserved 
between PfAtg8 and TgAtg8, it is possible that amino acid substitutions in the residues 
proximal to these binding pockets could prevent the binding of these compounds to 
TgAtg8, as shown for P. yoelli Atg8 [162]. The PfAtg8 W- and L-site pockets were 
proposed as ideal targets for small molecule inhibitors due to their differences in 
structure and electrostatic potential from human Atg8 homologues [107]. However, an 
additional set of compounds has recently been identified that inhibits the PfAtg3-Atg8 
interaction by binding to the apicomplexan-loop [163]. As this structure is unique to 
apicomplexan Atg8 proteins, it also provides an additional avenue for targeted disruption 
of the parasite Atg3-Atg8 interaction while avoiding effects on the host. Whether any of 
the compounds that target the PfAtg8 apicomplexan loop have activity against 
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Toxoplasma or other apicomplexans remains untested. However, given the differences 
in amino acid sequence present in this loop in Toxoplasma (Figure 37), identification of 
bona fide TgAtg3-Atg8 inhibitors may require structural resolution of the TgAtg3-Atg8 
interaction and/or development of biophysical screening approaches such as those used 
in P. falciparum. 
 Our characterization of MMV1-3 showed that all three compounds inhibited 
Toxoplasma at sub-micromolar concentrations. This is in contrast to a previous high-
throughput screen that failed to identify any of the three MMVs as having activity against 
Toxoplasma [237]. However, as noted by the authors in [237], the EC50 values they 
observed for certain 2,4-diamino-quinazoline-based compounds were significantly higher 
than values reported in a separate study in Toxoplasma [266]. The authors attribute 
these differences to their use of the TS-4 mutant derived from the standard RH strain, 
which could also explain the differences between their study and our observed activities 
for MMV1-3. Additionally, as shown in Table 4, EC50 values obtained from high-
throughput screens are highly variable, likely due to differences in the methods used to 
assess compound efficacy between studies. In contrast, our study characterized the 
effects of MMV1-3 on multiple aspects of Toxoplasma biology using standard 
Toxoplasma strains and assays. Our findings illustrate the importance of using multiple, 
independent methodologies for screening and validating the activity of the Malaria Box 
compounds across species. 
 Our studies revealed that the effects of MMV2 and MMV3 on Toxoplasma 
replication involve impairments of daughter parasite formation and cytokinesis (Figure 
43). Additionally, at higher concentrations, MMV2 and MMV3 induce fragmentation of 
the mitochondrion and increased lipidation of TgAtg8 (Figure 39, Figure 42), similar to 
the effects of monensin treatment and starvation [93,94,154]. However, unlike monensin 
and starvation, the autophagy inhibitor 3-MA does not block the effects of MMV2 and 
MMV3 on the mitochondrion. One possible explanation for this observation is that the 
induction of autophagy may occur downstream of mitochondrial fragmentation. In this 
scenario, mitochondrial disruption could be induced by several stimuli, including some 
that are blocked by 3-MA’s inhibition of phosphoinositide 3-kinase (PI3K) (including 
starvation and monensin), as well as others that target the mitochondrial through 
alternative, PI3k-independent mechanisms (like MMV2 and MMV3). We propose that in 
the case of MMV2 and MMV3, autophagy is likely induced following mitochondrial 
fragmentation, and the subsequent induction of TgAtg8 lipidation may represent cell 
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death with autophagy rather than cell death by autophagy [267]. In either case, given 
that the effects of MMV2 and MMV3 on the mitochondrion and TgAtg8 lipidation are only 
observed at concentrations significantly higher than the identified EC50 values, these 
effects are likely an indirect response occurring down stream of MMV2-3’s effects on cell 
cycle inhibition, or are off target effects resulting from use of such high concentrations.   
 In addition to novel mechanisms of action identified for MMV2 and MMV3, we 
also found that MMV1 can induce parasite egress from the host cells. This effect is 
comparable to the activity of the calcium ionophore A23187. Like A23187, MMV1-
induced egress is dependent on signaling through TgCDPK3. As shown in (Figure 45), 
MMV1 triggers the release of calcium from intracellular stores; however, the exact 
mechanism by which this occurs remains unclear. The chemical structure of MMV1 
precludes it from coordinating with calcium ions and transporting them across 
membranes in a manner similar to A23187. Instead, MMV1 my bind directly to receptors 
or ion channels to trigger calcium release, although such receptors and channels remain 
to be identified in Toxoplasma. Alternatively, MMV1 may act similar to other small 
molecules that stimulate calcium release and parasite egress through activation of the 
cGMP-dependent protein kinase PKG signaling pathway [268,269]. Further studies are 
needed to determine whether the effects of MMV1 are dependent on PKG signaling, and 
to determine which intracellular stores release calcium in response to MMV1 treatment. 
 Together, our studies revealed that MMV1-3 inhibit Toxoplasma at 
therapeutically relevant concentrations. The EC50 values we observe in vitro are well 
below concentrations reported to have cytotoxic effects in mammalian cells [238]. 
However, preliminary pharmacokinetic studies in mice suggest that MMV1-3 are highly 
bound to plasma proteins (>95%) [238]. Additionally, mice given an oral dose of 140 
µg/kg failed to show plasma concentrations greater than 1 µM within 9 hours of 
administration, suggesting that the efficacy of these compounds in vivo may be limited 
due to poor bioavailability [238]. Whether these compounds can be administered at 
dosages that are efficacious in an in vivo model of toxoplasmosis remains untested. 
While MMV1-3 may currently be limited to use in vitro towards target identification, future 
structure-activity relationship studies may lead to the development of derivatives of these 
compounds with better pharmacological properties. As MMV1-3 already display activity 
against a variety of protozoan pathogens, further characterization of their mechanisms of 
action holds promise towards the development of compounds with broad-spectrum use 
as antiparasitics. 
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Chapter 5: Future Directions and Closing Remarks 
Future directions for Aim 1: 
 Given our inability to generate endogenous K23 mutants, and the lack of a 
phenotype in ectopically expressed K23 mutants, further dissection of the role of K23 
mutations will require development of additional methods to express these proteins in a 
conditional system. We have designed constructs expressing TgAtg8 under the 
constitutive tubulin promoter and containing an N-terminal HA-epitope tag. These 
constructs integrate by double homologous recombination at the non-essential uracil 
phosphoribosyltransferase (UPRT) gene locus, and include a chloramphenicol 
acetyltransferase minigene selection cassette. These have been designed to be 
transfected into a parasite background in which the endogenous TgAtg8 gene is under 
the regulation of a Tetracycline-regulatable (TET-Off) promoter [103]. In this system, 
parasites harboring the HA-TgAtg8 ectopic protein could be isolated in the absence of 
tetracycline. After isolating these clones, the endogenous TgAtg8 gene could be 
conditionally repressed using anhydrous tetracycline treatment. This would allow for 
assessment of the phenotypes observed in various TgAtg8 mutant proteins in a 
conditional system that would avoid the limitations encountered by our previous two 
approaches; namely the lack of a dominant-negative phenotype in ectopically expressed 
GFP-Atg8 mutants, and the inability to recover certain TgAtg8 mutants potentially due to 
their negative effects on parasite viability.  
 This system would not only be useful for assessing the effects of K23 acetylation 
mutants, but could be used to introduce various mutations in TgAtg8 to identify specific 
residues required for lipidation or localization at the apicoplast, and to characterize their 
impacts on parasite fitness. This approach would also allow for confirmation of the K23R 
phenotype observed in the endogenous K23R mutant parasites. To compliment these 
studies, we have generated various mutations of TgAtg8 residues shown to facilitate the 
Atg3-Atg8 interaction in Plasmodium and have introduced these mutations in both the 
conditional expression constructs described above, as well as in pET19b plasmids for 
the purification of recombinant proteins harboring these mutations. This would allow 
these mutations to be studied side-by-side, assessing their effects on protein 
localization, lipidation and parasite fitness, as well as using the thermal shift assays 
developed in this thesis to monitor interaction with TgAtg3 AIM peptide. Together, these 
approaches would allow for identification of residues required for TgAtg3-TgAtg8 
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interaction and would allow for the assessment of the effects of their mutation and loss 
of interaction on parasite biological processes. 
 The thermal shift assays developed in this thesis may also be of utility for the 
screening of putative AIM motifs identified in TgAtg8 interacting proteins. Although 
TgAtg3 contained a single putative AIM sequence, many of the TgAtg8 interacting 
proteins identified in our proteomics analysis contain multiple potential AIMs that could 
facilitate their interaction with TgAtg8. The thermal shift assay could be a useful method 
to screen potential AIM motifs in vitro to identify candidates for additional mutational 
studies in the parasite.  
 Additionally, the recombinant TgAtg8 protein generated in these studies could be 
used to resolve the crystal structure of TgAtg8. This would provide important information 
regarding the exact structure of the W- and L-site binding pockets and may allow for 
more accurate in silico docking studies to identify potential inhibitors targeting this 
binding pocket. Alternatively, the recombinant TgAtg8 could be used for high-throughput 
screening of compounds using techniques similar to those used to identify PfAtg3-Atg8 
inhibitors, including surface plasmon resonance. Lastly, recombinant TgAtg8 could be 
used as a substrate for in vitro KAT assays using acetyltransferases purified from 
Toxoplasma to identify which KAT(s) are capable of acetylating TgAtg8 at K23. These 
approaches could all be undertaken using the reagents developed in this thesis, and 
could provide valuable information for the development of novel therapeutics targeting 
the TgAtg8 interactome.  
Future directions for Aim 2: 
 Our results from Aim 2 suggest that TgAtg8 interacts with components of the 
Golgi trafficking machinery. We also identified potential new Toxoplasma proteins 
involved in vesicle trafficking, including TgDrpC. Initial follow up studies based on the 
findings in Aim 2 should focus on confirmation of the role of TgAtg8 in the phenotypes 
associated with TgDrpC knock-down. For example, we plan to assess the effects of loss 
of TgAtg8 on the Golgi and secretory organelles using the TET-Off TgAtg8 parasite 
strain described above. These experiments will help delineate which phenotypes are 
associated with both TgAtg8 and TgDrpC, and which may be due solely to the function 
of each protein individually. Additional studies examining the co-localization of these 
proteins are also needed to determine the conditions that promote the interaction 
between TgAtg8 and TgDrpC, as we only observe their co-localization in extracellular 
parasites. We are currently in the process of conducting immuno-electron microscopy 
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studies using the dual-tagged TgDrpC-HA/cMycTgAtg8 parasite strain to determine 
where TgDrpC and TgAtg8 localize in the parasite in both intracellular and extracellular 
conditions. Previous studies examining TgAtg8 localization by immuno-EM were 
conducted only in parasites that had been subjected to extracellular HBSS starvation, 
and were done using the GFP-TgAtg8 parasite strain. Thus, the localization of TgAtg8 in 
intracellular or non-stressed parasites remains unknown. Additionally, none of the 
studies examining TgAtg8 localization have reported its localization at the Golgi or at the 
daughter parasite pellicle, two places that our studies suggest TgAtg8 localizes to. 
Therefore, our immuno-EM studies will allow us to examine TgAtg8 localization to 
confirm its localization in vesicles near the Golgi or associated with the daughter pellicle 
and to determine whether TgDrpC is found at these locations. 
 Another important question that could be addressed using the techniques 
developed in our second aim is the identification of proteins connecting TgAtg8 to the 
centrosomes during division. The TgARP protein identified in the interactome is a 
potential candidate connecting TgAtg8 to centrosome division. Although the armadillo 
repeat domain has homology to kinesin-associated protein 3 and thus may have function 
in vesicle trafficking on microtubules, it was also predicted by HHpred to have homology 
to beta-catenin. As introduced previously, beta-catenin is a multifunctional protein that 
localizes to centrosomes during mitosis and coordinates their separation during division. 
Accordingly, TgARP may be the link between TgAtg8 at the apicoplast and the 
centrosomes. As TgARP remains completely uncharacterized, future studies tagging this 
protein and characterizing its localization through the cell cycle will provide insight into 
whether TgARP has similar functions in centrosome duplication.  
 An additional future direction would be to optimize the immunoprecipitation 
methods to allow for characterization of TgAtg8 interactome following autophagy 
induction. Our studies revealed that induction of autophagy by extracellular starvation 
prevented TgAtg8 from being liberated from the membrane into the soluble fraction. 
Although harsher lysis buffer conditions may allow for solublization of TgAtg8 following 
autophagy starvation, these conditions will also likely disrupt protein-protein interactions. 
This could be prevented by the use of a cell-permeable cross-linking reagent such as 
dithiobis(succcinimidyl propionate) (DSP), an amine-reactive crosslinker containing a 
cleavable disulfide bond in the spacer arm to allow for reversal of crosslinking following 
immunoprecipitation. In addition to allowing the characterization of TgAtg8 interacting 
proteins following starvation, this approach may also allow for the identification of 
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TgAtg8 interactors that were missed in our initial study due to their presence at the 
membrane. For example, our TgAtg8 interactome did not identify any known apicoplast 
localized proteins, and none of the hypothetical proteins that we have since localized 
were found at the apicoplast. This is despite the fact that TgAtg8 localizes predominantly 
to the apicoplast in both intracellular and extracellular parasites. Therefore, development 
of these additional methods may also allow for a more thorough investigation of the 
TgAtg8 interactome even under non-autophagy inducing conditions. 
 Our characterization of TgDrpC has revealed an exciting potential function for 
this protein in organelle biogenesis, specifically related to the ER/Golgi and the Golgi-
derived secretory organelles. Further studies are required to ensure that the defects that 
we observe upon loss of TgDrpC are not indirect effects due to parasite death. Although 
we do not observe depletion of TgDrpC within the first 24 hours following removal of 
Shield-1, we have not done a thorough time-course experiment to assess TgDrpC 
regulation between 24 and 48 hours. These experiments will help inform the kinetics of 
TgDrpC loss with greater resolution and will provide insight into the time-points that we 
could assess the organelle phenotypes at in future studies. These additional 
experiments may allow us to observe the defects in organelles prior to the 48 hour time-
point, when the parasites may simply be displaying the organelle defects due to parasite 
death. 
 In addition to these proposed studies, it would be interesting to conditionally 
express a dominant-negative TgDrpC in which the conserved lysine residue in the 
GTPase domain has been mutated to alanine to ablate GTPase activity. Similar 
approaches were taken to characterize the functions of TgDrpA and TgDrpB, and would 
be informative to determine whether the GTPase activity of TgDrpC is required for its 
function in Toxoplasma. Other studies could be used to determine which regions of 
TgDrpC are required for function, and potentially to determine the region of TgDrpC that 
interacts with TgAtg8. These studies could be performed by Shield-1 regulatable 
expression of a series of TgDrpC trunctation proteins harboring the DD tag and 
examining the phenotypes following stabilization of these proteins by addition of Shield-
1. Alternatively, these conditional mutants could be ectopically expressed in the TgDrpC-
HA-DD parasite background to assess their ability to rescue the loss of full-length 
TgDrpC protein following the removal of Shield-1. These experiments would allow for 
determination of which portions of TgDrpC are required for proper localization and 
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function in the parasite, and may identify functionally important regions of the TgDrpC C-
terminus that lacks predicted functional domains. 
Future directions for Aim 3: 
 Our studies on MMV1-3 revealed that all three of these compounds are active 
against Toxoplasma. The initial characterization of these compounds revealed that 
MMV2-3 block parasite replication, and result in impairments of cytokinesis. Additionally, 
MMV1 is a potent inducer of parasite egress from the host cell. Despite these novel 
findings, the molecular target for each of these compounds is still unknown and requires 
further studies. For all three of these compounds, identification of their targets could be 
assessed using a forward genetics approach to mutagenize a population of parasites 
with ethylnitrosourea (ENU) followed by selection with each MMV compound to isolate 
resistant mutant parasites. Our group has extensive experience preforming these types 
of assays and has used this approach to identify targets of multiple compounds 
[245,270]. These studies would likely provide insight into the target of these molecules or 
the pathways that these compounds target to elicit their effects on the parasite. 
 In addition to taking a forward genetics approach, the mechanism of action for 
each drug could be further explored to expand upon our initial observations reported in 
this thesis. For example, parasites treated with MMV2 or MMV3 could be analyzed by 
flow cytometry to determine whether these compounds result in inhibition of parasite 
replication at a specific stage of the cell cycle. Additionally, the effects of each 
compound on cell division and cytokinesis could be further examined by IFA for 
additional markers of cell division, such as those used to characterize the defects in cell-
cycle upon loss of alpha-tubulin acetylation [200]. These could provide insight into which 
specific step of division is impaired by treatment with these compounds. 
 The mechanism of action for MMV1 could also be better defined by further 
characterization of the signaling pathways involved in its induction of egress. For 
example, given that MMV1 is unlikely to act as an ionophore to transport ions across 
membranes, it is possible that MMV1 is activating signaling pathways known to be 
involved with parasite egress, such as the PKG pathway. Parasite egress can be 
triggered by PKG activation, while treatment with PKG inhibitors can block the induction 
of egress in response to calcium ionophores [173]. Therefore, the ability for MMV1 to 
induce egress could be assessed in the presence and absence of inhibition of PKG by 
Compound 1 [173,271]. In addition, characterization of the effects of MMV1 on host cell 
calcium levels would help determine whether MMV1 stimulates egress by acting directly 
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upon the parasite or if this effect is mediated at least in part by the host cell. Completion 
of these assays will help determine whether MMV1 induces parasite egress through 
established signaling pathways, or may reveal that MMV1 acts through alternative 
signaling pathways that have not previously been implicated in parasite egress. 
 Additionally, the effects of MMV1 on calcium release could be further 
characterized by identification of the specific intracellular store that MMV1 treatment 
releases calcium from, as well as by quantitatively measuring calcium levels with the 
indicator Fura-2 AM. Determining the source of the calcium liberated by MMV1 treatment 
could be examined by assessing calcium fluxes before and after treatment with 
compounds known to liberate calcium from specific intracellular stores. For example, 
calcium stored in neutral compartments can be specifically mobilized by treatment with 
ionomycin, while calcium in acidic compartments can be mobilized by treatment with 
glycyl-L-phenylalanine-napthylamide (GPN). Treatment with thapsigargin, an inhibitor of 
the ER-localized SERCA pumps, inhibits reuptake of calcium into the ER and can be 
used to assess the role of ER-derived calcium in cytosolic calcium fluxes following drug 
treatment [269]. These compounds could be used to identify which compartment MMV1 
releases calcium from, providing additional insight into the mechanism of action for 
MMV1 and potential subcellular location of the target of MMV1. 
 Lastly, each of the three MMV compounds could be used for preliminary 
experiments to determine their in vivo efficacy using a mouse model for acute 
toxoplasmosis. Preliminary PK/PD studies suggest that these compounds are highly 
bound to plasma proteins, and they may have poor availability. However, we have also 
observed that they display EC50 values in the sub-micromolar range, and do not appear 
to have cytotoxic effects in cell culture at concentrations as high as 30 µM [238]. 
Therefore, it is possible that despite the poor bioavailability these compounds may be 
able to reach concentrations in vivo that have therapeutic effects. These preliminary 
studies would provide a baseline with which future studies using structural derivatives of 
these compounds could be tested against and could provide proof-of-concept for the 
potential of these compounds for future development as therapeutics. 
Future questions for the field: 
 In addition to the future studies mentioned above, there are a number of broader 
questions regarding the function of autophagy proteins in Toxoplasma and other 
apicomplexans that are of interest to the field. Although these questions do not directly 
relate to the studies presented herein, we have developed a number of reagents and 
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techniques that could be applied to address these following questions relating to 
autophagy in Toxoplasma: 
Is there a functional Atg5-Atg12 E3-like complex in Toxoplasma? 
 Homologues to the E1-like (Atg7), E2-like (Atg3) and Atg4 peptidase have been 
identified and characterized in Toxoplasma. However, there have been no studies 
exploring the putative homologues of the E3-like Atg5-Atg12 complex, and therefore 
whether these proteins are functional homologues remains unclear. Bioinformatics 
analysis casts doubt on their ability to function as canonical Atg5 or Atg12 proteins, due 
to the absence of conserved residues and sequence features that are found in higher 
eukaryotes (see Section 1.4). Therefore, it is likely that these proteins do not have a 
function in coordinating TgAtg8 lipidation to PE. If this is the case, does TgAtg8 undergo 
conjugation to PE in the absence of an E3 complex? To date there are no reports of 
Atg8 proteins undergoing lipidation in the absence of an E3 complex. Therefore it is 
possible that Toxoplasma may rely on the function of an uncharacterized protein to 
coordinate this activity. Although not discussed in this thesis, we have generated 
parasites in which both TgAtg5 and TgAtg12 are endogenously tagged. These reagents 
will be useful for determining whether these proteins form a complex similar to that 
observed in other systems, and to determine whether genetic disruption of these genes 
impacts TgAtg8 lipidation.  
Is autophagy a general cell death response in the parasite? 
 The autophagy pathway has been proposed to have numerous functions in 
Toxoplasma. In addition to its proposed role in response to starvation and drug 
treatment, autophagy has been suggested as a potential cell death mechanism in 
Toxoplasma. This is further supported by the lack of homologues to canonical apoptosis 
genes in the Toxoplasma genome. In higher eukaryotes, autophagy is recognized as a 
form of regulated cell death, however it is generally thought that autophagy plays both 
cytoprotective roles as well as cytotoxic roles. Indeed, in Toxoplasma it is possible that 
autophagy is induced in an attempt to alleviate stress caused by nutrient deprivation or 
drug treatment, and that prolonged autophagy can ultimately result in parasite death. 
This makes autophagy a particularly attractive drug target, as either inhibition or 
activation of the parasite autophagy pathway may result in parasite death. Recent 
studies showing that the autophagy pathway is active and essential for bradyzoites [272] 
suggests that this pathway may be a viable target for both acute and chronic stages of 
toxoplasmosis. However, it remains unclear how general of a response autophagy 
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induction is in Toxoplasma. Preliminary data collected during the completion of this 
thesis revealed that TgAtg8 lipidation was induced by treatment with EC50 
concentrations of multiple antiparasitics with diverse mechanisms of action 
(pyrimethamine, folate synthesis inhibitor; trichostatin A and apicidin, HDAC inhibitors). 
Importantly the ability of these compounds to induce TgAtg8 lipidation did not correlate 
with their ability to cause mitochondrial fragmentation. Previous methods to induce 
autophagy have also resulted in mitochondrial fragmentation, and as a result, it was 
unclear whether induction of autophagy was the cause or effect of mitochondrial 
fragmentation. Our observation suggests that numerous stresses can induce autophagy 
in the parasite, and that the induction of TgAtg8 can occur in the absence of 
mitochondrial fragmentation. The cMycTgAtg8 parasite strain should be a useful reagent 
to assess in TgAtg8 lipidation status in response to a wider variety of stressors or 
treatments, and will provide further insight into the potential role of autophagy as a 
general stress response in Toxoplasma. 
If canonical autophagy occurs in the parasite, to what organelle or location are 
autophagosomes trafficked and fused to for degradation of cargo? 
 One of the major outstanding questions relating to Toxoplasma autophagy is the 
identity of the lysosome or vacuole-like organelle that putative autophagosomes are 
trafficked to for degradation. Toxoplasma lacks a definitive lysosomal vacuole, however 
does contain an acidic vaucuolar compartment (VAC, also referred to as the plant-like 
vacuole (PLV)). This compartment contains cathepsin proteases that were first 
implicated in maturation of micronemal proteins in the endosomal compartment but have 
more recently been shown to degrade ingested material acquired through endocytosis 
[273]. Inhibition of proteases localized to the VAC/PLV blocked the degradation of 
TgAtg8-containing autophagosomes, providing the first support for the VAC/PLV as the 
site for autophagosome fusion and autophagic degradation [272]. However, the fusion of 
autophagosomes with the VAC/PLV has only been observed in bradyzoite stage 
parasites. Further studies are required to identify whether the VAC/PLV is also utilized 
by tachyzoites for autophagy, or, alternatively, whether TgAtg8 is utilized by the parasite 
in distinct, stage-specific functions. Additionally, identification of specific cargo proteins 
targeted for clearance by autophagy will provide powerful tools to monitor autophagic 
flux in Toxoplasma and confirm the role of this pathway in canonical autophagy 
processes. 
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Does Toxoplasma have functional homologues of ATG proteins outside of the 
Atg8 conjugation system? 
 The majority of studies of autophagy in Toxoplasma have focused on the 
components of the Atg8 conjugation system. A recent study has characterized the 
Toxoplasma homologue of Atg9, and found that the loss of this protein resulted in a 
decreased ability of the parasite to survive extracellular stress and a decreased 
virulence in mice [95]. However, this study did not definitively show that it was a 
functional homologue of Atg9 with respect to its role in delivery of membrane to the 
nascent autophagosomes. Additionally, other putative Toxoplasma ATG homologues 
including TgAtg1, TgAtg5, TgAtg6, TgAtg7, TgVps34, TgVps15, or TgAtg12 have not 
been characterized. We have endogenously tagged a number of these putative 
autophagy genes (including TgAtg5, TgAtg6, TgAtg7 and TgAtg12) and have begun to 
characterize their localization and expression levels under basal and autophagy-inducing 
conditions. Studies are now underway to characterize their interactomes using the 
methods developed for TgAtg8, and should provide insight into the biological functions of 
these putative ATG homologues in Toxoplasma. 
Closing Remarks: 
 In this thesis work we explored the Atg8 conjugation system in Toxoplasma to 
gain insight into how TgAtg8 function was regulated in the hopes of identifying potential 
avenues for therapeutic intervention. We hypothesized that in addition to interacting with 
homologues of the canonical eukaryotic Atg8 conjugation machinery, TgAtg8 interacts 
with novel proteins to facilitate its functions in parasite-specific processes. Additionally, 
we hypothesized that these protein interactions were subject to regulation by post-
translational modifications, and that they could be pharmacologically disrupted by the 
recently identified PfAtg3-Atg8 interaction inhibitors.  
 Our studies were motivated by our previous findings that TgAtg8 was acetylated 
in extracellular parasites, and that autophagy/TgAtg8 lipidation was induced by 
treatment with the ionophore drug monensin. As acetylation of ATG proteins is emerging 
as a major mechanism by which autophagy is regulated in other eukaryotes, we 
examined whether acetylation of TgAtg8 could provide a similar regulatory function in 
Toxoplasma. Our first aim sought to characterize the effects of this PTM on TgAtg8’s 
ability to interact with TgAtg3, and thus its ability to undergo lipidation and localization to 
the apicoplast. Our results show that acetylation of TgAtg8 at lysine-23 is not required 
for the TgAtg3-Atg8 interaction or its lipidation and apicoplast localization. Additionally, 
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these experiments revealed a new localization for TgAtg8 at the daughter parasite 
pellicle during division that could represent a novel function of this protein during 
daughter parasite formation. 
 We next characterized the TgAtg8 interactome to identify proteins that might 
coordinate TgAtg8’s functions in canonical autophagy and parasite-specific biological 
processes. While conducting these experiments, we discovered that TgAtg8 is 
significantly upregulated at the mRNA and protein levels following egress from the host 
cell. Our proteomics studies also identified a potential role for TgAtg8 in Golgi trafficking, 
suggesting that TgAtg8 may have similar biological functions as the GABARAP/GATE-
16 family of Atg8 proteins in addition to its previously characterized LC3-like function in 
autophagosome formation in Toxoplasma. These studies identified numerous proteins 
that are unique to Toxoplasma and may assist TgAtg8 in parasite-specific functions, 
such as apicoplast division. Our characterization of one of the TgAtg8 interacting 
proteins, TgDrpC, provides additional evidence for TgAtg8 involvement in trafficking 
through the Golgi and the biogenesis of post-Golgi secretory organelles. These 
preliminary findings set the stage for future studies exploring the role of TgAtg8 in these 
processes that may identify specific protein-protein interactions that could be the targets 
of future therapeutics. 
 In our third aim, we examined three Atg3-Atg8 interaction inhibitors recently 
identified in Plasmodium falciparum to determine their utility as therapeutics and as tools 
to study the autophagy pathway in Toxoplasma. Our studies are the first to show that 
these three compounds have activity against Toxoplasma, and revealed that the 
conservation of activity is not likely due to a conserved mechanism of action for these 
compounds in Toxoplasma. Although these compounds do not inhibit the TgAtg3-
TgAtg8 interaction, they do represent three novel compounds with potential for future 
development as antiparasitics. Future studies identifying their targets and mechanisms 
of action in Toxoplasma may provide valuable insight into the rationale behind their 
activity against other protozoan parasites, and could aid in the development of novel, 
broad spectrum antiparasitics. 
 Collectively, this work addresses previously unexplored aspects of TgAtg8 
function, and the results will help guide future studies of autophagy and TgAtg8 function 
both in our laboratories and in the field. We believe that characterization of TgAtg8 and 
other components of the Toxoplasma autophagy pathway will identify potential new drug 
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targets, and will uncover new and exciting aspects of Toxoplasma biology relating to 
autophagy and beyond. 
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Appendices 
Appendix 1: Primers used in this study 
Primer Name Sequence (5' - 3') Use 
Atg8 CDS Fw CCATCGATTCGCGACGAAGTG 
Amplification of Atg8 CDS 
Atg8 CDS Rev TTACCCCAGAGTGTTCTCTGAAGAGTATTCC 
Atg8 CDS Add cMyc Fw AAAATGGAGCAGAAGCTCATCTCCGAGGAGGACCTGCCATCGATTCGCGACGAAGT Add N-terminal cMyc tag to amplified Atg8 CDS 
Atg8 3' Amp EcoRV-GS Fw CGCGCCGGCGCCGATATCGGGAGTGTCGCGGCC Amplification of Atg8 3' homology 
arm for homologous recombination Atg8 3' Amp EcoRV-GS Rev GAGCTCCCCGGGGATATCGCATACCACACTGGGACGC 
Atg8 5' Amp ApaI-GS Fw GCGAATTGGGTACCGGGCCCGTAGGGGACCACCGAACAGC Amplification of Atg8 5' homology 
arm for homologous recombination Atg8 5' Amp ApaI-GS Rev TCCATTTTGTTTTTCAAGACGGCGAATATCTGGT 
cMyc-Atg8 XbaI-GS Fw GAAAAACAAAATGGAGCAGAAGCTCATCTCC Add Infusion cloning 15bp homology 
to Atg8 CDS cMyc-Atg8 XbaI-GS Rev GCAGCTCGAGTCTAGATTACCCCAGAGTGTTCTCTGAAGAGT 
Atg8 Intron 2 Rev TCCCAGGGCACCTATGGAAGA 
Screening of endogenous Atg8 
locus for replacement Atg8 5' HR Upstream Fw GCGTCTTTGGAGCCATTCGG 
Atg8 3'HR Downstream Rev TGCGAATGGCTAATGGGACATTATTCG 
Atg8 CDS pET19b Fw ACGACGACAAGCATATGCCATCGATTCGCGACG Infusion cloning of Atg8 CDS into 
pET19b for recombinant protein 
expression Atg8 CDS pET19b Rev CAGCCGGATCCTCGAGTTACCCCAGAGTGTTCTCTGAAGAGTATTCC 
TgAtg3 GT1 Infusion 600bp 
Fw TACTTCCAATCCAATTTAATTAAGAGACTTCCTCAATACATGCAAGTACACAT 
Amplification of 3' end of genes for 
cloning into pLIC vectors for 
endogenous tagging, all cloning into 
PacI site that allows for use in pLIC-
3xHA-DHFR, pLIC-HA-DD and 
pLIC-StrepTY-HXGPRT vectors 
TgAtg3 GT1 Infusion 600bp 
Rev CCTCCACTTCCAATTTTAATTAACTTCTCGTTTTTTGTACTGCGGT 
TgAtg6 GT1 Fw Infusion TACTTCCAATCCAATTTAATTAATGGGTGTTGTGCGTGGG 
TgAtg6 GT1 Rev Infusion CCTCCACTTCCAATTTTAATTAAGGAGGCAGGCGGGC 
TgAtg9 gDNA Infusion Fw TTCCAATCCAATTTAATTAAAGGGTCCTTTTCTTCCAAGAAGC 
TgAtg9 gDNA Infusion Rev CCACTTCCAATTTTAATTAAGTTGACGTCTCCTCGAGTCAC 
TgULK1 gDNA Infusion Fw TTCCAATCCAATTTAATTAAGAGCGAGCAGAGGCGAG 
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TgULK1 gDNA Infusion Rev CCACTTCCAATTTTAATTAACACTCCCATCCAAAATGAGGG 
TgTOR Infusion PacI Fw TTCCAATCCAATTTAATTAAGGTCTATGTGGCTTTGTGCGA 
TgTOR Infusion PacI Rev CCACTTCCAATTTTAATTAATCACCAAAACGGGCACCAG 
pLIC-Atg12 StrepTY Infusion 
Fw TTCCAATCCAATTTAATTAAGTACTGTGTAACGAATTTCATTACACTTCATGC 
pLIC-Atg12 StrepTY Infusion 
Rev CCACTTCCAATTTTAATTAAATAAGCGGGAGTGTAGCAGTACG 
pLIC-Atg4 StrepTY Infusion 
Fw TTCCAATCCAATTTAATTAAACGGTGTGCTGCAGATGG 
pLIC-Atg4 StrepTY Infusion 
Fw TTCCAATCCAATTTAATTAAACGGTGTGCTGCAGATGG 
pLIC-Atg4 StrepTY Infusion 
Rev CCACTTCCAATTTTAATTAACCGGTCTGTGCCGC 
pLIC-Atg7 StrepTY Infusion 
Fw TTCCAATCCAATTTAATTAAATGGGAGCCACGCCT 
pLIC-Atg7 StrepTY Infusion 
Rev CCACTTCCAATTTTAATTAACTTGGTCTCTGCTGCATCCT 
pLIC-Atg5 StrepTY Infusion 
Fw CCACTTCCAATTTTAATTAAAGTGCGGTTGCCGC 
pLIC-Atg5 StrepTY Infusion 
Rev TTCCAATCCAATTTAATTAACGGTCTTCGCGGAGACG 
TGGT1_318510 LIC-HA-DD 
Fw TTCCAATCCAATTTAATTAAGTCTGCGAGTCTGGCAAGG 
TGGT1_318510 LIC-HA-DD 
Rev CCACTTCCAATTTTAATTAAGAAGGGCATTGGGTCATAACT 
TGGT1_218760 LIC-HA-DD 
Fw TTCCAATCCAATTTAATTAACTCCAAATAAGCATTTGGCCATT 
TGGT1_218760 LIC-HA-DD 
Rev CCACTTCCAATTTTAATTAAAGAGAGGTCGACTTCTCCGT 
TGGT1_319920 LIC-HA Fw TTCCAATCCAATTTAATTAAGGTAAGAACAACGACCGACG 
TGGT1_319920 LIC-HA Rev CCACTTCCAATTTTAATTAATCGGAGATGAAGCAGCATCAT 
TGGT1_215250 LIC-HA Fw TTCCAATCCAATTTAATTAAGGATATCCGTACGTTCACACAGTCAAG 
TGGT1_215250 LIC-HA Rev CCACTTCCAATTTTAATTAAAGACTCATGCGACTTTTCAAGAGG 
TGGT1_314400 LIC-HA Fw TTCCAATCCAATTTAATTAACGTAAACAAGACCTCCCGCT 
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TGGT1_314400 LIC-HA Rev CCACTTCCAATTTTAATTAACGCCTGCTTCAGTTCACG 
pLIC-DrpC-HA Fw TTCCAATCCAATTTAATTAATGTCTGGCGCGGAGAAAC 
pLIC-DrpC-HA Rev CCACTTCCAATTTTAATTAAAGCCCCATTCAACGGTGAC 
StrepTY Tag sequencing Rev CCACTTCTCGTACTATGGCCGGTC 
Sequencing primer used to confirm 
insertion of gene fragment into the 
pLIC-StrepTY vector 
HA-Lic-DHFR 
Sequencing.REV GACAGAACAATACCGGCACCACTT 
Sequencing primer used to confirm 
insertion of gene fragment into the 
pLIC-3xHA-DHFR vector 
HA-Atg8 G124A Q5 Fw GAACACTCTGGCATAAGATATCCTAGGG 
Site-directed mutagenesis primers 
used to mutate residues in Atg8. 
Primers used for mutation of 
residues in both pET19b-Atg8 CDS 
vector to make mutant recombinant 
Atg8 proteins, as well as to mutate 
residues in pTub-HA-Atg8-CAT-
UPRT vector for mutating Atg8 
residues used for targeted 
expression of Atg8 mutants in 
conditional knock-down approaches 
HA-Atg8 G124A Q5 Rev TCTGAAGAGTATTCCACG 
HA-Atg8 R27E Fw Q5 GTATCCCAACGAAATTCCGGTCATCTGC 
HA-Atg8 R27E Rev Q5 TTTGCCCGAATGCGGTGT 
HA-Atg8 K47E Fw Q5 TGACAAGAAGGAATTCCTCGTGC 
HA-Atg8 K47E Rev Q5 ATCACTGGCAGGTCCGAC 
HA-Atg8 R19Q Fw Q5 GGAGGCACACCAGATTCGGGCAA 
HA-Atg8 R19Q Rev Q5 GCTGTCCTCTTTTCGAAGG 
HA-Atg8 R19A Fw Q5 GGAGGCACACGCAATTCGGGCAAAG 
HA-Atg8 R19A Rev Q5 GCTGTCCTCTTTTCGAAG 
GFP-Atg8 G/A Q5 Fw GAACACTCTGGCATAATTAATTAATCACCG Site-directed mutagenesis primers 
used to mutate G124 to alanine in 
pTUB-GFP-cMyc-Atg8 plasmid used 
for ectopic overexpression. 
GFP-Atg8 G/A Q5 Rev TCTGAAGAGTATTCCACG 
5' Flank UPRT Fw CCCTGGTACACTCGGAAATG Amplification of UPRT 5' homology 
for targeting of pTUB-HA-Atg8-CAT 
constructs to UPRT locus 5' Flank UPRT Rev CCAATGGCATCACTTGACAG 
3' Flank UPRT Fw GCCACGGGGTATATCTTTGG Amplification of UPRT 3' homology 
for targeting of pTUB-HA-Atg8-CAT 
constructs to UPRT locus 3' Flank UPRT Rev CAGACAGTTTTTCGGCAACC 
5' UPRT Infusion PciI Fw CCTTTTGCTCACATGTGGATCCCCCTGGTACACTCGGAAATG Addition of Infusion overhangs for 
cloning of 5'UPRT 5' UPRT Infusion PciI Rev GCAGGAAAGAACATGTCCAATGGCATCACTTGACAGCG 
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3' UPRT Infusion NotI Fw AGTTCTAGAGCGGCCGCGCCACGGGGTATATCTTTGGT Addition of Infusion overhangs for 
cloning of 3'UPRT 3' UPRT Infusion NotI Rev ACCGCGGTGGCGGCCGCGGATCCCAGACAGTTTTTCGGCAACC 
UPRT Screen US Fw GCGAAAATGGTGGGAGCAGC 
Primer for screening for disruption of 
UPRT locus by targeting of GOI; Fw 
primer upstream of 5'UPRT 
homology sequence used for 
targeting 
UPRT Screen CTRL Rev CAACAGGCAGAGTCACGGAAAGC 
Reverse primer for screening of 
UPRT locus; will only amplify if 
UPRT locus is intact. If GOI has 
been inserted, will not amplify 
pTUB Screen Rev GCAGGAACACATTCCTGCACC 
Reverse primer in tubulin promoter 
used to drive GOI targeted to UPRT 
locus. Will only amplify if 
recombination occurs, no 
amplification with UPRT screen US 
Fw primer if GOI at UPRT locus 
CAT SAG1 3'UTR int screen 
Fw GGAGTGTTTCGCAGCAAGCAG 
Fw primer in heterologous Sag1 
3'UTR used for Chloramphenicol 
selection cassette used in pTUB-HA 
targeting to the UPRT locus. Primer 
used with UPRT 3'DS Rev will only 
amplify if recombination occurred 
UPRT 3' DS Screen Rev TTCGATCGACCGAAGCAACACTGG 
Reverse primer downstream of 
UPRT 3' region used for targeting 
GOI to UPRT locus. 
PCR Lin UPRT Fw AGGATGGAATTCCTGCAGCCC Primers to linearize pTUB-HA-Atg8-
DHFR vector to replace DHFR 
selection cassette with 
Chloramphenicol selection cassette 
PCR Lin UPRT Rev CGCGGCTTATCTAGTTAAGGGAGC 
CAT UPRT Infusion Fw CAGGAATTCCATCCTCCCCTCGGGGGGGC Infusion cloning of Chloramphenicol 
selection cassette into linearized 
pTUB-HA-Atg8-DHFR CAT UPRT Infusion Rev TTGGCACGTGCATATCGCGATC 
pTUB-HA-CAT-UPRT EcoRV 
Del Fw TTGGCACGTGcATATCGCGATC 
Used to delete EcoRV site in UPRT 
5' Flank to allow for digestion with 
EcoRV to remove CDS and be able 
to clone in GOI into EcoRV site for 
targeted expression at UPRT locus 
under pTUB-HA 
pTUB-HA-CAT-UPRT EcoRV 
Del Rev CGTGCAGAAAATCAGTCAC 
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ML1771 CTGCTTTCGTCTGTCTTC Primers from Bestiero et al, used to 
confirm TATi-Atg8 parasite strain 
used for conditional knock-down of 
Atg8 and rescue with WT or mutant 
Atg8s at UPRT locus 
ML1772 CAAATGGCTATGTTCGCC 
ML1773 CCAAACCAGATATTCGCC 
ML1774 TACGACTCACTATAGGGC 
Atg1 qPCR Fw CT TCTTCTCCTCTGCCTTCTGC 
qRT-PCR Primers 
Atg1 qPCR Rev CT CGAAAAGTCACTCCAGCACA 
Atg3 qPCR Fw CT AGAAGGTGGTGGACAGTTGG 
Atg3 qPCR Rev CT CCATGGTGAAGTCGTACTCG 
Atg4 qPCR Fw CT ACGGAGAAGAGGCTGAGACA 
Atg4 qPCR Rev CT TGAGGTCCTTCTCCACAACC 
Atg5 qPCR Fw CT CTGGAAGCGAAGAAGCTGAT 
Atg5 qPCR Rev CT GCGACGATCTCTCTCGTTGT 
Atg6 qPCR CT Fw CGTCTCCAGGTGTCCAGACT 
Atg6 qPCR CT Rev CAGCCACTTCAGATCGATGA 
Atg7 qPCR Fw CT GGAGACAAGACCAAGCGAAG 
Atg7 qPCR Rev CT GCTTCTCTCCGACACCAAAG 
Atg8 qPCR FW CT TTGTTTGTTGAAAATACGGCACCGAAG 
Atg8 qPCR Rev CT TTACCCCAGAGTGTTCTCTGAAGAGTATTC 
Atg9 qPCR Fw CT AGACGAAGAAGAGCGAGACG 
Atg9 qPCR Rev CT GTCTCCCTCGACTGATCGAA 
Atg12 qPCR CT Fw ACATTTCCCTGTCGAACGTC 
Atg12 qPCR CT Rev TACGAAACCATGAGGCTTCC 
qGFP Fw GAGGGATACGTGCAGGAGAG 
qGFP Rev ATCCTGTTGACGAGGGTGTC 
qTubA1 Ct Fw GCATGATCAGCAACAGCACT 
qTubA1 Ct Rev GAGAGCAGCCAAATCCTCAC 
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Appendix 2: Primary antibodies used in this study 
Antibody Species Reference/Supplier 
Tg  β-tubulin Rabbit Morrissette & Sibley, 2002 JCS 
TgCentrin-1 Rabbit Sanders & Salisbury, 1994, JCB 
TgMORN1 Rabbit Gubbels & Striepen, 2006, JCS 
TgAtrx1 (apicoplast) Mouse DeRocher & Parsons, 2008, Eukaryotic Cell 
TgNHE3 (PLV) Guinea Pig Arrizabalaga et al 2011, Exp Cell Research 
TgSAG1 Mouse Genway (GWB-9894D) 
TgROP1 (Tg49) Mouse Ossorio & Boothroyd, 1992, MBP 
TgGRA7 Mouse Peter Bradley (unpublished) 
TgMIC5 Rabbit Carruthers et al, 2000, MBP 
TgIMC3 Rat Gubbels & Striepen, 2004, MBP 
TgF1β-ATPase Mouse Peter Bradley (unpublished) 
anti-acetyl-tubulin Mouse Sigma (6-11-B-1) 
anti-cMyc Mouse CST (9B11) 
anti-HA Rabbit CST (C29F4) 
anti-HA Rat Roche (3F10) 
anti-GFP Rabbit Sigma (G1544) 
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Appendix 3: TgAtg8 Interactome SAINTExpress Results (FC-B > 2, detected in at least 2 of 3 IPs) 
[Product Description] GENE ID MYC_FC_A MYC_FC_B MYC_SP cMyc IP 1 
cMyc 
IP 2 
cMyc 
IP 3 
IgG IP 
1 
IgG IP 
2 
IgG IP 
3 
arginyl-tRNA synthetase TGGT1_270690 233.28 214.21 1 77 84 92 0 0 0 
2-oxo acid dehydrogenases 
acyltransferase (catalytic 
domain) domain-containing 
protein 
TGGT1_319920 178.21 167.6 1 90 96 85 0 0 1 
putative autophagy-related 
protein 7 atg7 TGGT1_229690 132.5 126.27 1 59 62 33 0 0 0 
putative N-ethylmaleimide-
sensitive fusion protein TGGT1_318510 84.15 76.11 1 30 27 32 0 0 0 
hypothetical protein TGGT1_268430 35.76 32.49 1 7 17 16 0 0 0 
RNA pseudouridine synthase 
superfamily protein TGGT1_306660 25.78 25.19 1 17 23 10 0 1 1 
dehydrogenase E1 component 
family protein TGGT1_239490 32.03 21.95 0.85 12 59 2 0 0 1 
putative pyruvate 
dehydrogenase E1 
component, beta subunit 
TGGT1_314400 26.87 21.82 1 5 36 3 0 0 0 
thiamin pyrophosphokinase, 
catalytic domain-containing 
protein 
TGGT1_215250 21.28 20.79 1 5 19 5 0 0 0 
putative autophagy-related 
protein 8 atg8 TGGT1_254120 23.03 20.12 1 12 7 5 0 0 0 
putative SNAP protein (soluble 
N-ethylmaleimide-sensitive 
factor Attachment Protein) 
TGGT1_218760 20.31 15.98 1 3 6 11 0 0 0 
hypothetical protein TGGT1_247300 10.87 9.59 0.97 8 5 3 1 0 0 
transporter, major facilitator 
family protein TGGT1_297245 9.1 8.9 0.97 2 5 3 0 0 0 
acetyl-CoA acetyltransferase TGGT1_301120 14.15 7.06 0.66 9 0 3 0 0 0 
transmembrane protein TGGT1_313930 6.43 4.93 0.35 7 4 12 2 5 2 
putative gamma-soluble NSF 
attachment protein TGGT1_320690 6.74 4.44 0.63 2 0 3 0 0 0 
ATPase, AAA family protein TGGT1_234420 7.9 4.21 0.52 7 0 2 0 0 1 
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leucyl aminopeptidase LAP TGGT1_290670 4.35 4.06 0.33 4 14 2 1 0 5 
actin TGGT1_411760 4.4 4.04 0.01 7 11 12 3 6 7 
putative U1 snRNP-associated 
protein Usp106 TGGT1_262960 4.53 3.47 0 18 13 35 10 4 24 
heat shock protein HSP90 TGGT1_288380 3.64 3.45 0.26 4 21 5 0 0 13 
dense granule protein GRA1 TGGT1_270250 3.04 2.65 0.26 7 21 2 5 0 10 
glyceraldehyde-3-phosphate 
dehydrogenase GAPDH1 TGGT1_289690 2.99 2.65 0.16 10 27 3 4 0 18 
heat shock protein HSP70 TGGT1_273760 2.58 2.55 0 19 29 16 12 12 32 
actin ACT1 TGGT1_209030 2.47 2.43 0 9 24 6 8 3 18 
profilin PRF TGGT1_293690 3.67 2.34 0.42 3 8 0 1 0 2 
microneme protein MIC3 TGGT1_319560 2.69 2.25 0 16 15 3 10 14 5 
ribosomal-ubiquitin protein 
RPL40 TGGT1_289750 3.54 2.24 0.21 4 0 2 1 0 2 
serine-threonine phosophatase 
2C (PP2C) TGGT1_231850 3.8 2.08 0.42 6 12 0 4 0 2 
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Appendix 4: TgAtg3 Interactome SAINTExpress Results (FC-B > 2, detected in at least 2 of 3 IPs) 
[Product Description] GENE ATG3_FC_A ATG3_FC_B ATG3_SP Atg3 IP 1 Atg3 IP 2 Atg3 IP3 IgG 1 IgG 2 IgG 3 
putative autophagy-related 
protein 3 atg3 TGGT1_236110 221.81 187.86 1 91 59 58 0 0 0 
hypothetical protein TGGT1_305270 100.08 86.21 1 29 39 26 0 0 0 
putative autophagy-related 
protein 7 atg7 TGGT1_229690 78.34 67.65 1 26 27 20 0 0 0 
putative autophagy-related 
protein 8 atg8 TGGT1_254120 49.27 42.94 1 28 24 21 0 0 2 
hypothetical protein TGGT1_203280 20.04 16.16 0.97 11 12 6 1 0 1 
hypothetical protein TGGT1_311830 15.71 13.96 0.99 5 5 4 0 0 0 
S1 RNA binding domain-
containing protein TGGT1_211670 14.58 10.99 0.61 9 7 3 0 0 2 
hypothetical protein TGGT1_258850 13.84 10.73 0.46 7 11 4 0 0 3 
ribosomal-ubiquitin protein 
RPS27A TGGT1_245620 9.27 7.44 0.45 7 5 3 0 1 2 
hypothetical protein TGGT1_226050 12.58 6.92 0.66 5 4 0 0 0 0 
putative U1 snRNP-
associated protein Usp106 TGGT1_262960 5.31 4.66 0 38 52 38 26 29 15 
hypothetical protein TGGT1_241170 5.53 4.65 0 13 15 9 6 7 6 
peptidyl-prolyl cis-trans 
isomerase, cyclophilin-type 
domain-containing protein 
TGGT1_305940 7.52 4.3 0.33 4 1 0 0 0 0 
zinc knuckle domain-
containing protein TGGT1_244840 4.13 3.83 0.01 5 3 5 2 2 3 
hypothetical protein TGGT1_261620 6.17 3.71 0.17 8 9 1 4 2 2 
hypothetical protein TGGT1_249570 4.17 3.55 0 8 10 6 8 7 0 
putative rRNA-processing 
protein FCF1 TGGT1_319950 3.85 3.49 0 7 8 7 4 7 4 
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ribosomal protein RPL34 TGGT1_227600 4.81 3.48 0.22 1 2 0 0 0 0 
hypothetical protein TGGT1_230160 3.7 3.38 0 6 8 7 2 8 5 
ribosomal protein RPL38 TGGT1_231080 3.69 3.2 0 14 15 11 10 11 11 
ribosomal protein RPL44 TGGT1_203630 3.84 3.05 0 9 8 4 6 5 5 
hypothetical protein TGGT1_266470 3.34 3.03 0 6 7 6 5 6 4 
hypothetical protein TGGT1_315570 3.37 3.02 0 8 8 7 8 8 2 
ribosomal protein RPS25 TGGT1_231140 3.1 2.84 0 6 9 8 6 7 7 
ribosomal protein RPL27A TGGT1_310490 3.42 2.75 0 6 2 3 3 3 2 
ribosomal protein RPS18 TGGT1_225080 2.81 2.69 0 6 9 11 7 8 9 
ribosomal protein RPL37 TGGT1_239330 3.48 2.64 0 7 9 3 7 6 3 
ribosomal protein RPS17 TGGT1_207840 2.71 2.55 0 13 19 21 16 19 19 
mRNA turnover 4 (MRT4) 
family protein TGGT1_255320 3.01 2.54 0 5 5 3 5 3 4 
ribosomal protein RPL17 TGGT1_299050 2.72 2.45 0 16 13 14 14 17 15 
hypothetical protein TGGT1_311000 3.56 2.45 0.03 2 2 0 1 1 0 
ribosomal protein RPL37A TGGT1_300190 2.69 2.44 0 7 8 7 8 7 8 
ribosomal protein RPL26 TGGT1_248390 2.66 2.38 0 18 15 15 20 16 17 
hypothetical protein TGGT1_315610 2.74 2.37 0 8 11 7 7 12 9 
chaperonin protein BiP TGGT1_311720 2.54 2.35 0 38 37 42 41 52 40 
ribosomal protein RPL31 TGGT1_266070 2.53 2.32 0 7 7 7 8 8 7 
ribosomal protein RPL8 TGGT1_204020 2.31 2.29 0 4 6 13 5 4 15 
ribosomal protein RPL22 TGGT1_239760 2.43 2.29 0 5 5 6 6 7 4 
ribosomal protein RPS8 TGGT1_245460 2.61 2.27 0 16 15 12 17 15 18 
ribosomal protein RPL18 TGGT1_300000 2.42 2.2 0 3 8 8 6 7 7 
histone H2Ba TGGT1_305160 2.3 2.16 0 9 11 12 13 15 10 
ribosomal-ubiquitin protein 
RPL40 TGGT1_289750 2.19 2.14 0 2 2 3 2 4 1 
ribosomal protein RPL14 TGGT1_267060 2.22 2.13 0 3 3 4 4 4 3 
ribosomal protein RPL28 TGGT1_229250A 2.29 2.11 0 5 5 5 6 6 6 
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putative bud site selection 
protein TGGT1_226240 2.75 2.09 0 16 18 7 16 19 13 
3'5'-cyclic nucleotide 
phosphodiesterase domain-
containing protein 
TGGT1_280410 2.87 2.05 0.02 2 1 0 0 2 0 
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